

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 June 2006 (29.06.2006)

PCT

(10) International Publication Number
WO 2006/068928 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) **A61K 31/495** (2006.01)

(21) International Application Number:
PCT/US2005/045511

(22) International Filing Date:
16 December 2005 (16.12.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/637,556 20 December 2004 (20.12.2004) US

(71) Applicant (for all designated States except US): **WYETH**
[US/US]; Five Giralda Farms, Madison, New Jersey 07940
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SABATUCCI, Joseph, Peter** [US/US]; 84 Hunt Club Drive, Collegeville, Pennsylvania 19426 (US). **YE, Fei** [US/US]; 2502 Condor Drive, Audubon, Pennsylvania 19403 (US). **MAHANEY, Paige, Erin** [US/US]; 4 Freigh Lane, Pottstown, Pennsylvania 19465 (US).

(74) Agents: **LUCCI, Joseph** et al.; Woodcock Washburn LLP, One Liberty Place - 46th Floor, Philadelphia, Pennsylvania 19103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRROLO[1,2-A]QUINOXALIN-5-(4H)-YL)SULFONYLS AND CARBONYLS AND THEIR USE AS ESTROGENIC AGENTS



(57) Abstract: This invention provides estrogen receptor modulators having the structure: wherein R_1 to R_7 , R_9 and R_{10} X, Y, and Z are as defined in the specification; or a pharmaceutically acceptable salt thereof.

**PYRROLO[1,2-A]QUINOXALIN-5-(4H)-YL)SULFONYLS AND
CARBONYLS AND THEIR USE AS ESTROGENIC AGENTS**

RELATED APPLICATIONS

[0001] The present application claims benefit to U.S. Provisional Application Serial Number 60/637,556 filed December 20, 2004, which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

[0002] This invention relates to pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl and carbonyl compounds, to processes for their preparation, pharmaceutical compositions containing them and to their use as estrogenic agents.

BACKGROUND OF THE INVENTION

[0003] The ability of ligands for the estrogen receptor to inhibit inflammatory gene expression (causing a reduction of cytokines, chemokines,

adhesion molecules and inflammatory enzymes) provides a means to treat the inflammatory component of diseases such as atherosclerosis, myocardial infarction (MI), congestive heart failure (CHF), inflammatory bowel disease and arthritis. Other potential therapeutic indications for these type of molecules include type II diabetes (Cefalu, *J Womens Health & Gender-based Med.* **2001**, *10*, 241 & Yuan *et al.*, *Science*, **2001**, *293*, 1673), osteoarthritis (Pelletier *et al.*, *Arthr. & Rheum.*, **2001**, *44*:1237 and Felson *et al.*, *Curr Opinion Rheum*, **1998**, *10*, 269) asthma (Chin-Chi Lin *et. al.*, *Immunol. Lett.*, **2000**, *73*, 57), Alzheimer's disease (Roth, A. *et al.*, *J. Neurosci. Res.*, **1999**, *57*, 399) and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

[0004] A common component of these chronic inflammatory conditions is infiltration of polymorphonuclear leukocytes and monocytes into the site of damage through increased expression of cytokines and adhesion molecules responsible for their recruitment. Overproduction of the cytokine interleukin (IL-6) has been associated with states of chronic inflammation (Bauer M. A., Herrmann F., *Ann. Hematol.*, **1991**, *62*, 203). Synthesis of the IL-6 gene is induced by the transcription factor nuclear factor κ B (NF- κ B). Interference at this step in the inflammatory process is believed to effectively regulate the uncontrolled proliferative process that occurs in these chronic conditions.


[0005] In endothelial cells, 17 β -estradiol (E2) inhibits IL-1 β induced NF- κ B reporter activity and IL-6 expression in an estrogen receptor (ER)-dependent fashion (Kurebayashi S. *et. al.*, *J. Steroid Biochem. Molec. Biol.*, **1997**, *60*, 11). This has been said to correlate with anti-inflammatory action of E2 *in vivo* as confirmed in different animal models of inflammation. In models of atherosclerosis, E2 was shown to protect endothelial cell integrity and function, and to reduce leukocyte adhesion and intimal accumulation (Adams, M. R. *et al.*, *Arterio.*, **1990**, *1051*, Sullivan, T. R. *et al.*, *J. Clin. Invest.* **1995**, *96*, 2482, Nathan, L. *et. al.*, *Circ. Res.*, **1999**, *85*, 377). Similar effects of estrogen on the vascular wall have also been demonstrated in animal models of myocardial infarction (Delyani, J. A. *et al.*, *J. Molec. Cell. Cardiol.*, **1996**, *28*, 1001) and congestive heart failure. Clinically, estrogen replacement therapy (ERT) has been demonstrated to reduce the risk of mortality in patients with both CHF (Reis *et. al.*, *J. Am. Coll. Cardio.*, **2000**, *36*, 529) and MI (Grodstein, F. *et. al.*, *Ann. Int. Med.*, **2000**, *133*, 933, Alexander *et. al.*, *J. Am. Coll.*

Caraio., 2001, 30, 1 and Grodstein F. *et. al.*, *Ann. Int. Med.*, 2001, 135,1). In ERT, clinical studies demonstrated an influence of E2 on the decrease in the production of β -amyloid 1-42 ($A\beta$ 42), a peptide central for the formation of senile plaques in Alzheimer's disease (Schonknecht, P. *et. al.*, *Neurosci. Lett.*, 2001, 307, 122).

[0006] 17- β -Estradiol, however, also strongly stimulates creatine kinase expression. Thus, in ERT some potential unwanted side effects, such as an increase risk of cardiovascular events in the first year of use, have been demonstrated (Hulley, S. *et. al.*, *J. Am. Med. Assoc.*, 1998, 280, 605) as well as proliferative effects on uterine and breast tissue.

SUMMARY OF THE INVENTION

[0007] The present invention relates to compounds that are able to serve as ligands for the estrogen receptor. Preferred compounds of this type are pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls. In certain embodiments, these compounds are of the formula:



Formula I

wherein:

G is SO₂ or CO

R₁, R₄, R₈, and R₉ are each, independently, H, Cl, Br, F, I, NO₂, alkyl, alkoxy, phenyl, OCF₃, CF₃, CN;

R₂, R₃, R₅, and R₆ are each, independently, hydrogen, hydroxy, alkyl, alkoxy, or halogen; or R₂ and R₅ may together form a ring, said ring being a 4 to 8 membered cycloalkane, cycloalkene, cycloalkyne, or aromatic ring optionally containing one or more heteroatoms, e.g., 1-3 heteroatoms selected from O, N and S;

R₇ is hydrogen, alkyl, -(C=O)R₁₆, -S(O)₂R₁₇, -S(O)₂N(R₁₈)(R₁₉), or D-glucuronidate;

R₁₀ and R₁₁ are each, independently, H, alkyl, cycloalkyl, or phenyl;

R₁₆ is alkyl, alkoxy, arylalkyl or aryl;

R₁₇ is alkyl, aryl, heteroaryl, cycloalkyl, alkenyl, cycloalkenyl, or alkynyl;

R₁₈ and R₁₉ are, independently, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, monofluoroalkyl, perfluoroalkyl, aryl, arylalkyl, cycloalkenyl, heteroaryl, heteroarylalkyl, hydroxy-(C₂-C₆)alkyl, alkoxyalkyl, alkylthioalkyl, carbonyl, acyl, alkoxycarbonyl, -C(O)NH₂, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminoalkyl, or dialkylaminoalkyl;

or R₁₈ and R₁₉ are taken together with the nitrogen atom to which they are attached to form a saturated, unsaturated or partially saturated C₄-C₆ carbon ring;


X is H, alkyl, CN, CHO, F, Br, Cl, CONR_xR_y, COOH, CO₂R_z or cycloalkyl; and

R_x, R_y and R_z are each, independently, H or alkyl;

or a pharmaceutically acceptable salt thereof or a prodrug thereof.

[0008] In some embodiments, R₂, R₅ and R₆ are hydrogen, halogen, hydroxy, or alkoxy. In some compositions, OR₇ is OH or O(C=O)R₁₆.

[0009] In certain embodiments, the compound is of the formula:



wherein:

G is SO₂ or CO;

R₁₀ and R₁₁ are each, independently, H, alkyl or cycloalkyl;

Z is H, alkyl, Cl, F, Br, CF₃, OH, or OMe; and

X is H, alkyl, CN, CHO, F, Br, Cl, CONR_xR_y, COOH, CO₂R_z or cycloalkyl.

[0010] In some embodiments, R₅ or R₆ is OH. In certain embodiments, R₂ is CH₃.

[0011] In certain embodiments, R₂ and Z are each OH. In other embodiments, R₂ is CH₃ and Z is OH. In some compositions, R₁₀ is CH₃ or C₂H₅ and R₁₁ is H. In certain compositions, R₉ is Br, F, Cl, or CF₃. In some of these compositions, R₉ is F.

[0012] In another aspect, the invention is drawn to pharmaceutical compositions that comprise one or more estrogen receptor ligands and a pharmaceutically acceptable carrier.

[0013] In yet other aspects, the invention concerns methods of treating or inhibiting chronic inflammatory disease in a mammal in need thereof, which comprise administering to said mammal an effective amount of a compound of the invention.

[0014] Such diseases include rheumatoid arthritis, spondyloarthropathies, osteoarthritis, psoriatic arthritis, juvenile arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, indeterminate colitis, psoriasis, asthma and chronic obstructive pulmonary disease.

[0015] The invention is also directed to methods of treating or inhibiting stroke, ischemia, or reperfusion injury in a mammal in need thereof, which comprise administering to said mammal an effective amount of a compound of the invention. In other embodiments, the invention concerns methods of lowering cholesterol, triglycerides, Lp(a), and LDL levels; inhibiting or treating hypercholesteremia, hyperlipidemia, cardiovascular disease, atherosclerosis, acute coronary syndrome, peripheral vascular disease, restenosis, or vasospasm in a mammal.

[0016] In yet other aspects, the compounds of the invention can be used for treating or inhibiting Alzheimer's disease, cognitive decline, senile dementia, or type II diabetes in a mammal.

DETAILED DESCRIPTION OF THE INVENTION

[0017] Preferred compounds of the present invention block interleukin-1 β (IL-1 β) induced nuclear factor κ B (NF- κ B) luciferase reporter activity or interleukin-6 (IL-6) expression in an ER dependent fashion in human endothelial cells. These compounds show little or no proliferative effects on uterine and breast tissue that is associated with estrogen *in vivo*. A lack of estrogen side effects can be confirmed *in vitro* by the lack of expression of creatine kinase (CK); a classic estrogen responsive

gene. The compounds described herein are expected to prove useful for the treatment and prevention of chronic inflammatory diseases without stimulating uterine and breast cell proliferation as found with classic estrogens.

[0018] Compounds of the present invention include pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls of formula I as defined above.

[0019] Some preferred compounds of this invention are:

4-[(4-ethyl-7,8-difluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
4-[(4-ethyl-7,8-difluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-[(7,8-difluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
(S)-4-ethyl-7,8-difluoro-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
4-ethyl-7,8-difluoro-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
4-[(1,7,8-trifluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-{[(S)-1,7,8-trifluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl}phenol,
4-{[(R)-1,7,8-trifluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl}phenol,
4-[(7,8-difluoro-4,4-dimethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-[(4-ethyl-1,7-difluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-[(4-ethyl-1,7-difluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
4-[(1-bromo-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
2-chloro-4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,

4-ethyl-7-fluoro-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
4-ethyl-7-fluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2,6-dimethylphenol,
4-[(7-bromo-4,4-dimethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-[(7-bromo-4-ethyl-1-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
4-[(7-fluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-[(7-fluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
4-[(7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-{[4-ethyl-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl}phenol,
4-{[4-ethyl-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl}-2-methylphenol,
4-ethyl-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-7-(trifluoromethyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
2-chloro-4-{[4-ethyl-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl}phenol,
4-[(4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
4-[(7-chloro-4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
4-[(8-chloro-4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-ethyl-7-fluoro-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxalin-8-ol,
4-[(4-ethyl-7-fluoro-8-methoxypyrrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-{[(4S)-7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl}phenol,

4-{[(4*R*)-7-bromo-4-ethylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}phenol,
7-bromo-4-ethyl-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-*a*]quinoxaline-1-carbonitrile,
3-[(7-bromo-4-ethylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl)sulfonyl]phenol,
4-ethyl-7,8-difluoro-5-[(3-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-*a*]quinoxaline-1-carbonitrile,
3-[(4-ethyl-7-fluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl)sulfonyl]phenol,
(4*S*)-7-bromo-4-ethyl-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-*a*]quinoxaline-1-carbonitrile,
(4*R*)-7-bromo-4-ethyl-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-*a*]quinoxaline-1-carbonitrile,
4-ethyl-7,8-difluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-*a*]quinoxaline-1-carbonitrile,
4-{[(4*R*)-4-ethyl-7,8,9-trifluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}phenol,
4-{[(4*S*)-4-ethyl-7,8,9-trifluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}phenol,
4-[(4-ethyl-7,8,9-trifluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl)sulfonyl]phenol,
3-[(4-ethyl-7,8,9-trifluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl)sulfonyl]phenol,
(4*S*)-4-ethyl-7,8-difluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-*a*]quinoxaline-1-carbonitrile,
4-{[(4*S*)-4-ethyl-7,8-difluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}-2-methylphenol,
4-{[(4*R*)-4-ethyl-7,8-difluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}-2-methylphenol,
4-{[(4*S*)-1-cyano-4-ethyl-7,8-difluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}-2-methylphenyl sulfamate,
4-{[(4*S*)-1-cyano-4-ethyl-7,8-difluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}phenyl sulfamate,
4-{4-ethyl-7,8-difluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}phenyl sulfamate,
3-[(7-bromo-4-methylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl)carbonyl]phenol,

3-{[(4S)-7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
3-{[(4R)-7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
4-[(7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol,
4-[(7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]benzene-1,3-diol,
4-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol,
4-{[(4S)-7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
4-{[(4R)-7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
3-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol,
4-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]benzene-1,3-diol,
3-[(7-bromo-4-*tert*-butylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol,
3-{[(4S)-7-bromo-4-*tert*-butylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
3-{[(4R)-7-bromo-4-*tert*-butylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
4-[(7-bromo-4-*tert*-butylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol,
4-[(7-bromo-4-*tert*-butylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]benzene-1,3-diol,
4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol,
4-{[(4S)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
4-{[(4R)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
4-{[(4R)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}benzene-1,3-diol,
4-{[(4S)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}benzene-1,3-diol,
4-{[(4R)-7-fluoro-4-methylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
4-{[(4S)-7-fluoro-4-methylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,

4-{[(4*R*)-7-chloro-4-ethylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl} benzene-1,3-diol,
 4-{[(4*S*)-7-chloro-4-ethylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl} benzene-1,3-diol,
 3-{[(4*R*)-4-ethyl-7-fluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl} phenol,
 3-{[(4*S*)-4-ethyl-7-fluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl} phenol,
 (4*R*)-4-ethyl-7-fluoro-5-(4-hydroxybenzoyl)-4,5-dihydropyrrolo[1,2-*a*]quinoxaline-1-carbonitrile,
 (4*S*)-4-ethyl-7-fluoro-5-(4-hydroxybenzoyl)-4,5-dihydropyrrolo[1,2-*a*]quinoxaline-1-carbonitrile,
 3-{[(4*R*)-4-methyl-7-fluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl} phenol, and
 3-{[(4*S*)-4-methyl-7-fluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl} phenol.

[0020] The term “alkyl”, employed alone, is defined herein as, unless otherwise stated, a C₁-C₂₀ monovalent saturated hydrocarbon moiety, eg either a (C₁-C₂₀) straight chain or (C₃-C₂₀) branched-chain. Examples of saturated hydrocarbon alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, *tert*-butyl, isobutyl, *sec*-butyl; higher homologs such as *n*-pentyl, *n*-hexyl, *n*-heptyl, *n*-octyl, and the like. It is preferred that straight chain alkyl moieties have 1-6 carbon atoms, and branched alkyl moieties have 3-8 carbon atoms.

[0021] The term “alkenyl”, employed alone, is defined herein as, unless otherwise stated, a C₂-C₂₀ monovalent hydrocarbon moiety containing at least one double bond, eg either a (C₂-C₂₀) straight chain or (C₃-C₂₀) branched-chain. Such hydrocarbon alkenyl moieties may be mono or polyunsaturated, and may exist in the E or Z configurations. The compounds of this invention are meant to include all possible E and Z configurations. Examples of mono or polyunsaturated hydrocarbon alkenyl moieties include, but are not limited to, chemical groups such as vinyl, 2-propenyl, isopropenyl, crotyl, 2-isopentenyl, butadienyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), and higher homologs, isomers, and the like. It is preferred that straight chain alkenyl moieties have 2-7 carbon atoms, and branched alkenyl moieties have 3-8 carbon atoms.

[0022] The term "alkynyl", employed alone, is defined herein as, unless otherwise stated, a C₂-C₂₀ monovalent hydrocarbon moiety containing at least one triple bond, eg either a (C₂-C₂₀) straight chain or (C₃-C₂₀) branched-chain. Examples of alkynyl moieties include, but are not limited to, chemical groups such as ethynyl, 1-propynyl, 1-(2-propynyl), 3-butynyl, and higher homologs, isomers, and the like. It is preferred that straight chain alkynyl moieties have 2-7 carbon atoms, and branched alkynyl moieties have 3-8 carbon atoms.

[0023] The term "alkylene", employed alone or in combination with other terms, is defined herein as, unless otherwise stated, either a (C₁-C₂₀) straight chain or (C₂-C₂₀) branched-chain bivalent hydrocarbon moiety derived from an alkane; or a (C₂-C₂₀) straight chain or branched-chain bivalent hydrocarbon moiety derived from an alkene. Such hydrocarbon alkylene moieties may be fully saturated, or mono or polyunsaturated, and may exist in the E or Z configurations. The compounds of this invention are meant to include all possible E and Z configurations. Examples of saturated and unsaturated hydrocarbon alkylene moieties include, but are not limited to, bivalent chemical groups such as -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH₂CH₂CH₂CH₂-, -CH=CH-, -CH=CHCH=CH-, vinylidene, and higher homologs, isomers, and the like. Preferred alkylene chains have 2-7 carbon atoms.

[0024] The term "cycloalkyl", employed alone or in combination with other terms, is defined herein as, unless otherwise stated, a monocyclic, bicyclic, tricyclic, fused, bridged, or spiro monovalent saturated hydrocarbon moiety of 3-10 carbon atoms, wherein the carbon atoms are located inside or outside of the ring system. Any suitable ring position of the cycloalkyl moiety may be covalently linked to the defined chemical structure. Examples of C₃-C₁₀ cycloalkyl moieties include, but are not limited to, chemical groups such as cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cycloheptyl, norbornyl, adamantyl, spiro[4.5]decanyl, and homologs, isomers, and the like.

[0025] The term "cycloalkenyl", employed alone or in combination with other terms, is defined herein as, unless otherwise stated, a monocyclic, bicyclic, tricyclic, fused, bridged, or spiro monovalent unsaturated hydrocarbon moiety of 3-10 carbon atoms containing at least one double bond, wherein the carbon atoms are located inside or outside of the ring system. Any suitable ring position of the cycloalkenyl moiety may be covalently linked to the defined chemical structure.

Examples of C₃-C₁₀ cycloalkenyl moieties include, but are not limited to, chemical groups such as cyclopropenyl, cyclopropenylmethyl cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexenylmethyl, cyclohexenylethyl, cycloheptenyl, norbornenyl, and homologs, isomers, and the like.

[0026] The term “cycloalkylene”, employed alone, is defined herein as, unless otherwise stated, a bivalent moiety of 3-10 carbon atoms derived from a monocyclic, bicyclic, tricyclic, fused, bridged, or spiro hydrocarbon. Such hydrocarbon cycloalkylene moieties may be fully saturated, or mono or polyunsaturated, and may exist in the E or Z configurations. The compounds of this invention are meant to include all possible E and Z configurations. Any suitable ring position of the cycloalkylene moiety may be covalently linked to the defined chemical structure. Examples of saturated and unsaturated hydrocarbon cycloalkylene moieties include, but are not limited to, bivalent chemical groups such as cyclopropylene, cyclopentylene, cyclohexylene, cyclohexenylene, *trans*-decahydronaphthalenylene, spiro[3.3]heptenylene, and higher homologs, isomers, and the like.

[0027] The terms “halo” or “halogen”, employed alone or in combination with other terms, is defined herein as, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.

[0028] The term “monofluoroalkyl”, employed alone, is defined herein as, unless otherwise stated, a C₁-C₁₀ monovalent saturated hydrocarbon moiety containing only one fluorine atom, eg, either a (C₁-C₁₀) straight chain or (C₃-C₁₀) branched-chain. Examples of monofluoroalkyl moieties include, but are not limited to, chemical groups such as -CH₂F, -CH₂CH₂F, -CH(CH₃)CH₂CH₂F, and higher homologs, isomers, and the like. Preferred chain lengths are from 1-6 carbon atoms for straight chains and from 3-8 carbon atoms for branched chains.

[0029] The term “monofluoroalkenyl”, employed alone, is defined herein as, unless otherwise stated, a C₂-C₁₀ monovalent unsaturated hydrocarbon moiety, containing only one fluorine atom and at least one double bond, eg either a (C₂-C₁₀) straight chain or (C₃-C₁₀) branched-chain. Examples of monofluoroalkenyl moieties include, but are not limited to, chemical groups such as -CH=CH₂F, -CH₂CH=CH₂F, -CH=CHCH₂F, -C(CH₃)=CHF and higher homologs, isomers, and the like. Preferred chain lengths are from 2-7 carbon atoms for straight chains and from 3-8 carbon atoms for branched chains.

[0030] The term "perfluoroalkyl", employed alone or in combination with other terms, is defined herein as, unless otherwise stated, C₁-C₁₀ monovalent saturated hydrocarbon moiety containing two or more fluorine atoms, eg, either a (C₁-C₁₀) straight chain or (C₃-C₁₀) branched-chain. Examples of perfluoroalkyl moieties include, but are not limited to, chemical groups such as trifluoromethyl, -CH₂CF₃, -CF₂CF₃, and -CH(CF₃)₂, and homologs, isomers, and the like. Preferred chain lengths are from 1-7 carbon atoms for straight chains and from 3-8 carbon atoms for branched chains.

[0031] The term "aryl", employed alone or in combination with other terms, is defined herein as, unless otherwise stated, an aromatic carbocyclic moiety of up to 20 carbon atoms (e.g., 6-20 carbon atoms), which may be a single ring (monocyclic) or multiple rings (bicyclic, up to three rings) fused together or linked covalently. Any suitable ring position of the aryl moiety may be covalently linked to the defined chemical structure. Examples of aryl moieties include, but are not limited to, chemical groups such as phenyl, 1-naphthyl, 2-naphthyl, dihydronaphthyl, tetrahydronaphthyl, biphenyl, anthryl, phenanthryl, fluorenyl, indanyl, biphenylenyl, acenaphthenyl, acenaphthylenyl, and the like. It is preferred that the aryl moiety contain 6-14 carbon atoms.

[0032] The term "arylalkyl", employed alone or in combination with other terms, is defined herein as, unless otherwise stated, an aryl group, as herein before defined eg C₆-C₂₀ aryl, suitably substituted on any open ring position with an alkyl moiety wherein the alkyl chain is either a (C₁-C₇) straight or (C₂-C₇) branched-chain saturated hydrocarbon moiety. Examples of aryl(C₁-C₇)alkyl moieties include, but are not limited to, chemical groups such as benzyl, 1-phenylethyl, 2-phenylethyl, diphenylmethyl, 3-phenylpropyl, 2-phenylpropyl, fluorenylmethyl, and homologs, isomers, and the like.

[0033] The term "heteroaryl", employed alone or in combination with other terms, is defined herein as, unless otherwise stated, an aromatic heterocyclic ring system, which may be a single ring (monocyclic) or multiple rings (bicyclic, up to three rings) fused together or linked covalently and having for example five to twenty ring atoms. The rings may contain from one to four hetero atoms selected from nitrogen (N), oxygen (O), or sulfur (S), wherein the nitrogen or sulfur atom(s) are optionally oxidized, or the nitrogen atom(s) are optionally substituted or

quarternized. Any suitable ring position of the heteroaryl moiety may be covalently linked to the defined chemical structure. Examples of heteroaryl moieties include, but are not limited to, heterocycles such as furan, thiophene, pyrrole, N-methylpyrrole, pyrazole, N-methylpyrazole, imidazole, N-methylimidazole, oxazole, isoxazole, thiazole, isothiazole, 1H-tetrazole, 1-methyltetrazole, 1,3,4-oxadiazole, 1H-1,2,4-triazole, 1-methyl-1,2,4-triazole, 1,3,4-triazole, 1-methyl-1,3,4-triazole, pyridine, pyrimidine, pyrazine, pyridazine, benzoxazole, benzisoxazole, benzothiazole, benzofuran, benzothiophene, thianthrene, dibenzo[b,d]furan, dibenzo[b,d]thiophene, benzimidazole, N-methylbenzimidazole, indole, indazole, quinoline, isoquinoline, quinazoline, quinoxaline, purine, pteridine, 9H-carbazole, β -carboline, and the like.

[0034] The term “heteroarylalkyl”, employed alone or in combination with other terms, is defined herein as, unless otherwise stated, a heteroaryl group, as herein defined, suitably substituted on any open ring position with a C₁-C₇ alkyl moiety, e.g., wherein the alkyl chain is either a (C₁-C₆) straight or (C₂-C₇) branched-chain saturated hydrocarbon moiety. Examples of heteroarylalkyl moieties include, but are not limited to, chemical groups such as furanylmethyl, thienylethyl, indolylmethyl, and the like.

[0035] Heteroaryl chemical groups, as herein before defined, also include saturated or partially saturated heterocyclic rings. Examples of saturated or partially saturated heteroaryl moieties include, but are not limited to, chemical groups having 4-20 ring atoms such as azetidiny, 1,4-dioxany, hexahydroazepiny, piperaziny, piperidiny, pyrrolidiny, morpholiny, thiomorpholiny, dihydrobenzimidazolyl, dihydrobenzofurany, dihydrobenzothienyl, dihydrobenzoxazolyl, dihydrofurany, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrraziny, dihydropyrazolyl, dihydropyridiny, dihydropyrimidiny, dihydropyrroly, dihydroquinoliny, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidiny, dihydro-1,4-dioxany, tetrahydrofurany, tetrahydrothienyl, tetrahydroquinoliny, tetrahydroisoquinoliny, and the like.

[0036] The term “acyl”, employed alone or in combination with other terms, is defined herein as, unless otherwise stated, either an alkyl, arylalkyl, heteroarylalkyl, (C₂-C₁₀) straight chain, or (C₄-C₁₁) branched-chain monovalent hydrocarbon moiety; wherein the carbon atom, covalently linked to the defined

chemical structure, is oxidized to the carbonyl oxidation state. Such hydrocarbon moieties may be mono or polyunsaturated, and may exist in the E or Z configurations. The compounds of this invention are meant to include all possible E and Z configurations. Examples of C₂-C₁₁acyl moieties include, but are not limited to, chemical groups such as acetyl, propionyl, butyryl, 3,3-dimethylbutyryl, trifluoroacetyl, pivaloyl, hexanoyl, hexenoyl, decanoyl, benzoyl, nicotinyl, isonicotinyl, and homologs, isomers, and the like.

[0037] The term “hydroxyalkyl”, employed alone or in combination with other terms, is defined herein as, unless otherwise stated, a (C₁-C₁₀) straight chain hydrocarbon, terminally substituted with a hydroxyl group. Examples of hydroxyalkyl moieties include chemical groups such as -CH₂OH, -CH₂CH₂OH, -CH₂CH₂CH₂OH, and higher homologs.

[0038] The term “alkoxy”, employed alone or in combination with other terms, is defined herein as, unless otherwise stated, either a (C₁-C₁₀) straight chain or (C₃-C₁₀) branched-chain hydrocarbon covalently bonded to an oxygen atom. Examples of C₁-C₁₀ alkoxy moieties include, but are not limited to, chemical groups such as methoxy, ethoxy, isopropoxy, *sec*-butoxy, *tert*-butoxy, decanoxo, and homologs, isomers, and the like.

[0039] The terms “aryloxy” or “heteroaryloxy”, employed alone or in combination with other terms, or unless otherwise stated, are aryl or heteroaryl groups, as herein before defined, which are further covalently bonded to an oxygen atom. Examples of aryloxy, or heteroaryloxy moieties include, but are not limited to, chemical groups such as C₆H₅O-, 4-pyridyl-O-, and homologs, isomers, and the like.

[0040] The term “carbonyl”, employed alone or in combination with other terms, is defined herein as, unless otherwise stated, a bivalent one-carbon moiety further bonded to an oxygen atom with a double bond. An example is $\left(\begin{array}{c} \diagup \text{C} \diagdown \\ \parallel \\ \text{O} \end{array} \right)$.

[0041] The term “alkoxycarbonyl”, employed alone or in combination with other terms, is defined herein as, unless otherwise stated, an alkoxy group, as herein before defined, which is further bonded to a carbonyl group to form an ester moiety. Examples of alkoxycarbonyl moieties include, but are not limited to, chemical groups such as methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, *sec*-

butyloxycarbonyl, *tert*-butoxycarbonyl, decanoxycarbonyl, and homologs, isomers, and the like.

[0042] The term “alkylthio”, employed alone or in combination with other terms, is defined herein as, unless otherwise stated, is an alkyl group as previously defined covalently bonded to a sulfur atom. Examples of alkylthio moieties include, but are not limited to, chemical groups such as methylthio, ethylthio, isopropylthio, *sec*-butylthio, *tert*-butylthio, decanylthio, and homologs, isomers, and the like. It is preferred that straight chain alkylthio moieties have 1-6 carbon atoms, and branched alkylthio moieties have 3-8 carbon atoms.


[0043] The terms “arylthio” or “heteroarylthio”, employed alone or in combination with other terms, or unless otherwise stated, are aryl or heteroaryl groups, as herein before defined, which are further covalently bonded to a sulfur atom. Examples of arylthio or heteroarylthio moieties include, but are not limited to, chemical groups such as C₆H₅S-, 4-pyridyl-S-, and homologs, isomers, and the like.

[0044] The terms “alkoxyalkyl” or “alkylthioalkyl”, employed alone or in combination with other terms, are an alkoxy or alkylthio group, as herein before defined, which is further covalently bonded to an unsubstituted (C₁-C₁₀) straight chain or unsubstituted (C₂-C₁₀) branched-chain hydrocarbon. Examples of alkoxyalkyl or alkylthioalkyl moieties include, but are not limited to, chemical groups such as , methoxymethyl, methylthioethyl, ethylthioethyl, isopropylthiomethyl, *sec*-butylthioethyl, -CH₂CH(CH₃)OCH₂CH₃, and homologs, isomers, and the like. It is preferred that straight chain alkoxyalkyl or alkylthioalkyl moieties have 1-6 carbon atoms, and branched alkoxyalkyl or alkylthioalkyl moieties have 3-8 carbon atoms.

[0045] The terms “aryloxyalkyl”, “heteroaryloxyalkyl”, “arylthioalkyl”, or “heteroarylthioalkyl”, employed alone or in combination with other terms, or unless otherwise stated, are aryloxy, heteroaryloxy, arylthio, or heteroarylthio groups, as herein before defined, which are further covalently bonded to an unsubstituted (C₁-C₁₀) straight chain or unsubstituted (C₂-C₁₀) branched-chain hydrocarbon. Examples of aryloxyalkyl, heteroaryloxyalkyl, arylthioalkyl, or heteroarylthioalkyl moieties include, but are not limited to, chemical groups such as C₆H₅OCH₂-, C₆H₅OCH(CH₃)-, 4-pyridyl-O-CH₂CH₂-, C₆H₅SCH₂-, C₆H₅SCH(CH₃)-, 4-pyridyl-S-CH₂CH₂-, and homologs, isomers, and the like. It is preferred that straight chain aryloxyalkyl, heteroaryloxyalkyl, arylthioalkyl, or heteroarylthioalkyl moieties have 1-6 carbon

atoms, and branched aryloxyalkyl, neteroaryloxyalkyl, arylthioalkyl, or heteroarylthioalkyl moieties have 3-8 carbon atoms.

[0046] The term “alkylamino”, employed alone or in combination with other terms, or unless otherwise stated, is a moiety with one alkyl group, wherein the alkyl group is an unsubstituted (C₁-C₈) straight chain hereunto before defined alkyl group or an unsubstituted (C₃-C₈) hereunto before defined cycloalkyl group. Examples of alkylamino moieties include, but are not limited to, chemical groups such as -NH(CH₃), -NH(CH₂CH₃), -NH-cyclopentyl, and homologs, and the like.

[0047] The term “dialkylamino”, employed alone or in combination with other terms, or unless otherwise stated, is a moiety with two independent alkyl (including cycloalkyl) groups, wherein the alkyl groups are unsubstituted (C₁-C₆) straight chain hereunto before defined alkyl groups or unsubstituted (C₃-C₈) hereunto before defined cycloalkyl groups. Two groups may be linked to form an unsubstituted (C₂-C₆) -alkylene- group. Examples of dialkylamino moieties include, but are not limited to, chemical groups such as -N(CH₃)₂, -N(CH₂CH₃)₂, -NCH₃(CH₂CH₃), , and homologs, and the like.

[0048] The term “alkylaminoalkyl” employed alone or in combination with other terms, or unless otherwise stated, is an alkylamino moiety, as herein before defined, which is further covalently bonded to a straight chain alkyl group of 1-6 carbon atoms. Examples of alkylaminoalkyl moieties include, but are not limited to, chemical groups such as -CH₂NH(CH₃), -CH₂CH₂NH(CH₂CH₃), -CH₂CH₂CH₂NH(CH₂CH₃), and homologs, and the like.

[0049] The term “dialkylaminoalkyl” employed alone or in combination with other terms, or unless otherwise stated, is a dialkylamino moiety, as herein before defined, which is further covalently bonded to a straight chain alkyl group of 1-6 carbon atoms. Examples of dialkylaminoalkyl moieties include, but are not limited to, chemical groups such as -CH₂N(CH₃)₂, -CH₂CH₂N(CH₂CH₃)₂, -CH₂CH₂CH₂NCH₃(CH₂CH₃), and homologs, and the like.

[0050] The terms “alkylaminocarbonyl” or “dialkylaminocarbonyl”, employed alone, or unless otherwise stated, are alkylamino or dialkylamino moieties, as herein before defined, which are further bonded to a carbonyl group. Examples of alkylaminocarbonyl or dialkylaminocarbonyl moieties include, but are not limited to,

chemical groups such as $-\text{C}(\text{O})\text{N}(\text{CH}_2\text{CH}_3)_2$, $-\text{C}(\text{O})\text{N}(\text{CH}_2\text{CH}_3)_2$, $-\text{C}(\text{O})\text{NCH}_3(\text{CH}_2\text{CH}_3)$, and homologs, and the like.

[0051] Each of the above terms (e.g., alkyl, aryl, heteroaryl) includes unsubstituted, monosubstituted, and polysubstituted forms of the indicated radical or moiety. Substituents for each type of moiety are provided below.

[0052] Substituents for alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, alkylene, cycloalkylene, the alkyl portion of arylalkyl and heteroarylalkyl, saturated or partially saturated heterocyclic rings, and acyl or carbonyl moieties are, employed alone or in combination with other terms, selected from the group consisting of $-\text{R}'$, OR' , $=\text{O}$, $=\text{NR}'$, $=\text{N}-\text{OR}'$, $-\text{NR}'\text{R}''$, $-\text{SR}'$, halo, trifluoromethyl, trifluoromethoxy, $-\text{OC}(\text{O})\text{R}'$, $-\text{CO}_2\text{R}'$, $-\text{C}(\text{O})\text{NR}'\text{R}''$, $-\text{OC}(\text{O})\text{NR}'\text{R}''$, $-\text{NR}''\text{C}(\text{O})\text{R}'$, $-\text{NR}''\text{CO}_2\text{R}'$, $-\text{NR}'\text{C}(\text{O})\text{NR}'\text{R}''$, $-\text{NH}-\text{C}(\text{NH}_2)=\text{NH}$, $-\text{NR}'\text{C}(\text{NH}_2)=\text{NH}$, $-\text{NH}-\text{C}(\text{NH}_2)=\text{NR}'$, $-\text{S}(\text{O})\text{R}'$, $-\text{S}(\text{O})_2\text{R}'$, $-\text{S}(\text{O})_2\text{NR}'\text{R}''$, cyano, and nitro; wherein, R' or R'' are each, independently, hydrogen, unsubstituted (C_1-C_6) alkyl, unsubstituted (C_3-C_7) cycloalkyl, aryl, aryl- (C_1-C_3) alkyl, aryloxy- (C_1-C_3) alkyl, arylthio- (C_1-C_3) alkyl, heteroaryl, heteroaryl- (C_1-C_3) alkyl, heteroaryloxy- (C_1-C_3) alkyl, or heteroarylthio- (C_1-C_3) alkyl groups; or if optionally taken together may be linked as an $-\text{alkylene}-$ group, e.g., 2-6 carbon atoms, to form a ring.

[0053] The aryl or heteroaryl moieties, employed alone or in combination with other terms, may be optionally mono-, di- or tri-substituted with substituents selected from the group consisting of $-\text{R}'$, $-\text{OR}'$, $-\text{SR}'$, $-\text{C}(\text{O})\text{R}'$, $-\text{CO}_2\text{R}'$, $-\text{alkoxyalkyl}$, alkoxyalkyloxy , cyano, halogen, nitro, trifluoromethyl, trifluoromethoxy, $-\text{NR}'\text{R}''$, alkylaminoalkyl , dialkylaminoalkyl , hydroxyalkyl , $-\text{S}(\text{O})\text{R}'$, $-\text{S}(\text{O})_2\text{R}'$, $-\text{SO}_3\text{R}'$, $-\text{S}(\text{O})_2\text{NR}'\text{R}''$, $-\text{CO}_2\text{R}'$, $-\text{C}(\text{O})\text{NR}'\text{R}''$, $-\text{OC}(\text{O})\text{NR}'\text{R}''$, $-\text{NR}''\text{C}(\text{O})\text{R}'$, $-\text{NR}''\text{CO}_2\text{R}'$, $-\text{NR}'\text{C}(\text{O})\text{NR}'\text{R}''$, $-\text{NH}-\text{C}(\text{NH}_2)=\text{NH}$, $-\text{NR}'\text{C}(\text{NH}_2)=\text{NH}$, $-\text{NH}-\text{C}(\text{NH}_2)=\text{NR}'$, $-\text{S}(\text{O})\text{R}'$, and $-\text{S}(\text{O})_2\text{R}'$; wherein, R' or R'' are each, independently, hydrogen, (C_1-C_6) alkyl, (C_3-C_7) cycloalkyl, aryl, aryl- (C_1-C_3) alkyl, aryloxy- (C_1-C_3) alkyl, arylthio- (C_1-C_3) alkyl, heteroaryl, heteroaryl- (C_1-C_3) alkyl, heteroaryloxy- (C_1-C_3) alkyl, or heteroarylthio- (C_1-C_3) alkyl groups; or if optionally taken together may be linked as an $-\text{alkylene}-$ group, e.g., 2-6 carbon atoms, to form a ring.

[0054] A pro-drug is defined as a compound which is convertible by *in vivo* enzymatic or non-enzymatic metabolism (e.g. hydrolysis) to a compound of Formula (I) wherein, R_7 is a hydrogen atom.

[0055] The compounds of the present invention may contain an asymmetric atom, and some of the compounds may contain one or more asymmetric atoms or centers, which may thus give rise to optical isomers (enantiomers) and diastereomers. While shown without respect to the stereochemistry in Formula (I) or (II), the present invention includes such optical isomers (enantiomers) and diastereomers (geometric isomers); as well as the racemic and resolved, enantiomerically pure *R* and *S* stereoisomers; as well as other mixtures of the *R* and *S* stereoisomers and pharmaceutically acceptable salts thereof. Optical isomers may be obtained in pure form by standard procedures known to those skilled in the art, and include, but are not limited to, diastereomeric salt formation, kinetic resolution, and asymmetric synthesis. It is also understood that this invention encompasses all possible regioisomers, and mixtures thereof, which may be obtained in pure form by standard separation procedures known to those skilled in the art, and include, but are not limited to, column chromatography, thin-layer chromatography, and high-performance liquid chromatography.

[0056] The compounds of the present invention may contain isotopes of atoms for diagnostic, therapeutic, or metabolic purposes. Such isotopes may or may not be radioactive.

[0057] The compounds of this invention include racemates, enantiomers, geometric isomers, or pro-drugs of the compounds shown herein.


[0058] Pharmaceutically acceptable salts of the compounds of compounds of the instant invention with an acidic moiety can be formed from organic and inorganic bases. Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, or magnesium salts; or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, where 'lower' includes 1-6 carbon atoms for example ethyl-tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethylpropylamine, or a mono-, di-, or trihydroxy lower alkylamine, for example mono-, di- or triethanolamine. Internal salts may furthermore be formed. Similarly, when a compound of the present invention contains a basic moiety, salts can be formed from organic and inorganic acids. For example salts can be formed from acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric,

methanesulfonic, naphthalenesulfonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known pharmaceutically acceptable acids.

[0059] As used in accordance with this invention, the term "providing," with respect to providing a compound or substance covered by this invention, means either directly administering such a compound or substance, or administering a pro-drug, derivative, or analog which will form the effective amount of the compound or substance within the body. This invention also covers providing the compounds of this invention to treat the disease states disclosed herein that the compounds are useful for treating.

[0060] Solvates (*e.g.*, hydrates) of the compounds of the present invention are also within the scope of the present invention. Methods of solvation are generally known in the art. Accordingly, the compounds of the instant invention can be in the free or hydrate form, and can be obtained by methods exemplified by the following schemes below.

[0061] It is another object of this invention to provide a process for the production of the compounds of the instant invention. These compounds may be synthesized according to methods illustrated in Scheme I.



[0062] THE SYNTHESIS OF THE COMPOUNDS OF THE INSTANT INVENTION IS DEPICTED IN Scheme I. Nitro anilines of formula **I** may be reacted with 2,5-dimethoxy tetrahydrofuran to give the pyrrolo anilines of formula **II**. Reduction of the nitro group with iron in acetic acid yields the pyrrolo anilines of formula **III**. The latter reactions proceed with methods known in the art. These intermediates can be cyclized to dihydroquinoline type compounds of formula **IV** with the appropriate aldehyde in methanol with a catalytic amount of camphorsulfonic acid. The resulting product may be reacted with the appropriate sulfonyl or carbonyl chloride to give the coupled product **V**. The protecting group may be removed by methods known in the art to give title products of formula **VII**. Alternatively, the intermediate **V** can be reacted with an appropriate electrophile to give substituted product **VI**. Removal of protecting groups as stated above give title products of formula **VIII**.

[0063] According to the present invention there is also provided a method of treating inflammatory diseases. Such diseases include atherosclerosis, myocardial infarction, congestive heart failure, arthritis and inflammatory bowel disease in humans or other mammals which comprises administering to a human or other mammal an antiinflammatory effective amount of a compound of the present invention.

[0064] It is understood that the effective dosage of the active compounds of this invention may vary depending upon the particular compound utilized, the mode of administration, the condition, and severity thereof, of the condition being treated, as well as the various physical factors related to the individual being treated. For treating atherosclerosis, myocardial infarction, congestive heart failure, arthritis and/or inflammatory bowel disease, generally satisfactory results may be obtained when the compounds of this invention are administered to the individual in need at a daily dosage of from about 0.1 mg to about 1 mg per kilogram of body weight, preferably administered in divided doses two to six times per day, or in a sustained release form. For most large mammals, the total daily dosage is from about 3.5 mg to about 140 mg, preferably from about 3.5 to about 5 mg. In the case of a 70 kg human adult, the total daily dose will generally be from about 7 mg to about 70 mg and may be adjusted to provide the optimal therapeutic result.

[0065] The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredients, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

[0066] The compounds of the invention may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0067] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. The formulation should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

[0068] The present invention also concerns processes for producing the compounds of the present invention.

EXAMPLES

[0069] The present invention is illustrated by the following examples which are not intended to limit the scope of the invention.

EXAMPLE 1

Preparation of 1-(4,5-difluoro-2-nitrophenyl)-H-pyrrole

[0070] A 250 ml round bottom flask was charged with 5.0 g (0.028 mol) of 4,5 -difluoro- 2-nitroaniline, 4.0 ml (0.030 mol) of 2,5- dimethoxy -tetrahydrofuran and 30 ml of acetic acid. The mixture was heated to 100 °C for 3 hours, after which time the reaction was complete. The solution was concentrated and the residue diluted with 10 ml saturated sodium bicarbonate solution and extracted 3 times with 20 ml of ethyl acetate. The organic layers were combined , dried (MgSO₄) and concentrated. The crude solid was filtered through a plug of silica gel eluting with 20% ethyl acetate:hexane and the filtrate concentrated to afford 5.9 g (92%) of product as a dark oil which slowly solidified.

¹H NMR (DMSO-d₆): δ 8.43 (m, 1H, ArH), 7.94 (m, 1H, ArH), 6.96 (s, 2H, ArH), 6.29 (s, 2H, ArH);

MS (ESI) m/z 223 ([M-H]⁻);

Anal. calcd for C₁₀H₆F₂N₂O₂: C:53.58 H:2.70 N:12.50 Found: C:53.53 H:2.77 N:12.32.

EXAMPLE 2

Preparation of 4,5-difluoro-2-(H-pyrrol-1-yl)aniline

[0071] A 250 ml round bottom flask was charged with 5.0 g (0.026 mol) of the product from Example 1, 5.0 g (0.19 mol) of iron granules, 15 ml of acetic acid and 15 ml of ethanol. The solution was heated to 80 °C with reflux condenser for 16 hr. At the end of this time the solution was filtered through Celite and the filtrate concentrated. The residue was filtered through a plug of silica gel eluting with 20% ethyl acetate:hexane and the filtrate concentrated. The solid was azeotroped on the

rotovap with neptane to afford 4.3 g (85%) of product as a dark yellow solid, which was used in the next step without further purification.

^1H NMR (DMSO- d_6): δ 7.20 (m, 1H, ArH), 6.85 (s, 2H, ArH), 6.88 (m, 1H, ArH), 6.23 (s, 2H, ArH), 4.96 (bs, 2H, NH_2);

MS (ESI) m/z 193 ($[\text{M}-\text{H}]^-$);

Anal. calcd for $\text{C}_{10}\text{H}_8\text{F}_2\text{N}_2$: C:61.85 H:4.15 N:14.43 Found: C:61.87 H:4.16 N:14.32.

EXAMPLE 3

Preparation of 4-ethyl-7,8-difluoro-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0072] A 250 ml round bottom flask was charged with 1.94 g (0.01 mol) of the product from Example 2 and dissolved in 30 ml of methanol. The solution was degassed for 10 minutes by nitrogen purge whereupon 0.86 ml (0.012 mol) of propionaldehyde was introduced via syringe. A few crystals of camphorsulphonic acid were added to this mixture which was then stirred for 18 hr at room temperature. At the end of this time the solution was concentrated, and the residue purified by filtration through a plug of silica gel eluting with 20% ethyl acetate:hexane. The filtrate was concentrated, and the yellow oil induced to solidify with the addition of hexane. The solid could be recrystallized from ethyl acetate: hexane to afford 1.82 g (77%) of product, mp 67-69 °C;

^1H NMR (DMSO- d_6): δ 7.61 (m, 1H, ArH), 7.38 (s, 1H, H1), 6.79 (m, 1H ArH), 6.24 (m, 2H, NH and H3), 5.91 (s, 1H, H2), 4.31 (m, 1H CH), 1.77 (m, 1H, CH) 1.65 (m, 1H, CH), 0.92 (t, 3H, CH_3);

MS (ESI) m/z 235.1 ($\text{M}+\text{H}$);

Anal. calcd for $\text{C}_{13}\text{H}_{12}\text{F}_2\text{N}_2$: C:66.66 H:5.16 N:11.96 Found: C:66.56 H:5.11 N:11.86.

EXAMPLE 4

Preparation of 4-ethyl-7,8-difluoro-5-[(4-methoxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0073] 1.35 g (5.0 mmol) of the product from Example 3 was dissolved in 40 ml of methylene chloride and 1 ml of pyridine added. To this solution was added 1.20 g (5.4 mmol) of 4-methoxy-3-methyl benzenesulfonyl chloride. The solution was stirred at room temperature for 6 hours, after which it was concentrated, then diluted with 5 ml of 2N HCl. The residue was extracted 2 times with ethyl acetate, dried (MgSO₄) and concentrated. The crude solid so obtained was chromatographed on silica gel, eluting with 20% ethyl acetate:hexane to afford a light yellow solid, which can be recrystallized from ethyl acetate:hexane to yield 1.52 g (72%) of product.

¹H NMR (DMSO-d₆) δ 7.74 (m, 1H, ArH), 7.65 (m, 1H, ArH), 6.98 (m, 1H, H1), 6.95 (m, 1H, ArH), 6.93 (m, 1H, ArH), 6.73 (d, 1H, ArH), 6.03 (m, 1H, H2), 5.96 (m, 1H, H3), 5.16 (t, 1H, CH), 3.71 (s, 3H, OCH₃), 1.91 (s, 3H, CH₃), 1.35 (m, 2H, CH₂), 0.88 (t, 3H, CH₃).

MS (ESI) *m/z* 419 ([M+H]⁺);

Anal. calcd for C₂₁H₂₀F₂N₂O₃S: C:60.28 H:4.82 N:6.69 Found: C:60.49 H:4.83 N:6.63.

EXAMPLE 5

Preparation of 4-[(4-ethyl-7,8-difluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol

[0074] To a 50 ml round bottom flask charged with 25 ml of methylene chloride was added 0.60 g (1.43 mmol) of the product from Example 4 and 1.05 g (2.86 mmol) of Tetrabutylammonium iodide. After the solution was homogeneous, it was cooled to -78 °C and 4.30 ml (4.30 mmol) of a 1M solution of boron trichloride introduced via syringe. The cooling bath was removed and the solution allowed to warm to room temperature to induce reaction. The solution was stirred for 1 hr at room temperature where upon it was judged complete. The reaction was quenched with saturated ammonium chloride solution and the organic phase separated. The organic phase was diluted with more methylene chloride and washed twice with

saturated sodium bicarbonate. The aqueous layers were combined and extracted once more with methylene chloride. The organic phases were combined, dried (MgSO₄) and concentrated. The crude solid so obtained was chromatographed on silica gel, eluting with 40% ethyl acetate:hexane. The fractions were combined and residue triturated with hexane: methylene chloride to induce solidification. The product was recrystallized from ethyl acetate:hexane to yield 0.47 (71%)g of product, mp 191-193 °C.

¹H NMR (DMSO-d₆): δ 10.32 (bs, 1H, OH), 7.72 (m, 1H, ArH), 7.63 (m, 1H, ArH), 7.01 (m, 1H, H1), 6.85 (m, 1H, ArH), 6.80 (d, 1H, ArH), 6.50 (d, 1H, ArH), 6.04 (m, 1H, H2), 5.94 (m, 1H, H3), 5.17 (t, 1H, CH), 1.88 (s, 3H, CH₃), 1.37 (m, 2H, CH₂), 0.86 (t, 3H, CH₃);

MS (ESI) *m/z* 403 ([M-H]⁻);

Anal. calcd for C₂₀H₁₈F₂N₂O₃S: C:59.40 H:4.49 N:6.93 Found: C:59.13 H:4.38 N:6.63.

EXAMPLE 6

Preparation of ethyl 4-[(4-ethyl-7,8-difluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenyl carbonate

[0075] 1.35 g (5.0 mmol) of the product from Example 3 was dissolved in 40 ml of methylene chloride and 1 ml of pyridine added. To this solution was added 1.43 g (5.4 mmol) of ethyl -(4- chlorosulfonyl) phenylcarbonate. The solution was stirred at room temperature for 6 hours, after which it was concentrated, then diluted with 5 ml of 2N HCl. The residue was extracted 2 times with ethyl acetate, dried (MgSO₄) and concentrated. The crude solid so obtained was chromatographed on silica gel, eluting with 20% ethyl acetate:hexane. The fractions were combined and concentrated and the product triturated with hexane to induce solidification. The solid was recrystallized from ethyl acetate:hexane to yield 1.91 g (83%) of product, mp 105-107 °C.

¹H NMR (DMSO-d₆): δ 7.80 (m, 1H, ArH), 7.77 (m, 1H, ArH), 7.28 (d, 2H, ArH), 7.16 (d, 2H, ArH), 6.87 (m, 1H, H1), 5.97 (m, 1H, H2), 5.91 (m, 1H, H3), 5.19 (t, 1H, CH), 4.21 (q, 2H, OCH₃), 1.39 (m, 2H, CH₂), 1.26 (t, 3H, CH₃), 0.88 (t, 3H, CH₃);

MS (ESI) *m/z* 463 ([M+H]⁺);

Anal. calcd for C₂₂H₂₀F₂N₂O₅S: C:57.14 H:4.36 N:6.06 Found: C:57.22 H:4.23 N:5.93.

EXAMPLE 7

Preparation of 4-[(4-ethyl-7,8-difluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol

[0076] To 50 ml round bottom flask charged with 30 ml of methanol was added 0.67 g (1.4 mmol) of the product from Example 6, then 2 ml of 2N NaOH. The solution was stirred for 0.5 hr to completion then concentrated. The residue was neutralized with 2N HCl and extracted with ethyl acetate (2 X 10 ml), dried (MgSO₄) and concentrated. The solid was passed through a plug of silica gel eluting with 40% ethyl acetate:hexane. The product so obtained was triturated with hexane to induce solidification, then crystallized from ethyl acetate:hexane to afford 0.47 g (86%) of product as colorless crystals, mp 177-179 °C.

¹H NMR (DMSO-d₆): δ 10.62 (bs, 1H, OH), 7.76 (m, 1H, ArH), 7.64 (m, 1H, ArH), 7.06 (m, 1H, H1), 7.02 (d, 2H, ArH), 6.51 (d, 2H, ArH), 6.03 (m, 1H, H2), 5.93 (m, 1H, H3), 5.17 (t, 1H, CH), 1.37 (m, 2H, CH₂), 0.84 (t, 3H, CH₃);

MS (ESI) *m/z* 391 ([M+H]⁺);

Anal. calcd for C₁₉H₁₆F₂N₂O₃S: C:58.45 H:4.13 N:7.18 Found: C:58.38 H:4.07 N:6.91.

EXAMPLE 8

Preparation of 7,8-difluoro-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0071] The title compound was prepared from the product of Example 2 and acetaldehyde according to the procedure of Example 3, and isolated as a light yellow solid, mp 93-95 °C.

¹H NMR (DMSO-d₆): δ 7.61 (m, 1H, ArH), 7.38 (s, 1H, H1), 6.79 (m, 1H ArH), 6.23 (s, 1H, NH), 6.18 (m, 1H, H1), 5.91 (s, 1H, H2), 4.42 (m, 1H CH), 1.40 (d, 3H, CH₃);

MS (EI) *m/z* 220;

Anal. calcd for C₁₂H₁₀F₂N₂: C:65.45 H:4.58 N:12.72 Found: C:65.48 H:4.49 N:12.63.

EXAMPLE 9

Preparation of 4-[(7,8-difluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenyl ethyl carbonate

[0078] The title compound was prepared from the product of Example 8 and ethyl -(4- chlorosulfonyl) phenylcarbonate according to the procedure of Example 6 and isolated as colorless crystals, mp 89-91 °C.

¹H NMR (DMSO-d₆): δ 7.81 (m, 1H, ArH), 7.75 (m, 1H, ArH), 7.27 (d, 2H, ArH), 7.20 (d, 2H, ArH) 6.91 (m, 1H, H1), 5.97 (m, 1H, H2), 5.91 (m, 1H, H3), 5.58 (q, 1H, CH), 4.22 (q, 2H, OCH₂), 1.27 (t, 3H, CH₃), 1.18 (d, 3H, CH₃);

MS (ESI) *m/z* 449 ([M+H]⁺);

Anal. calcd for C₂₁H₁₈F₂N₂O₅S: C:56.25 H:4.05 N:6.25 Found: C:56.18 H:3.94 N:6.26.

EXAMPLE 10

Preparation of 4-[(7,8-difluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol

[0079] The title compound was prepared from the product of Example 9 according to the procedure of Example 7 and isolated as colorless crystals mp 208-209 °C.

^1H NMR (DMSO- d_6): δ 10.74 (bs, 1H, OH) 7.80 (m, 1H, ArH), 7.65 (m, 1H, ArH), 7.06 (m, 1H, H1), 7.02 (d, 2H, ArH), 6.53 (d, 2H, ArH), 6.02 (m, 1H, H2), 5.94 (m, 1H, H3), 5.50 (q, 1H, CH), 1.17 (d, 3H, CH₃);

MS (ESI) m/z 375 ([M-H]⁻);

Anal. calcd for C₁₈H₁₄F₂N₂O₃S: C:57.44 H:3.75 N:7.44 Found: C:57.29 H:3.61 N:7.27.

EXAMPLE 11

Preparation of 4-ethyl-7,8-difluoro-5-[(4-methoxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0080] To a 250 ml round bottom flask with addition funnel was added 2g (4.8 mmol) of the product from Example 4 and 50 ml of THF. The solution was cooled to -78°C and 0.50 ml (5.76 mmol) of chlorosulfonyl isocyanate in 20 ml of THF added dropwise via the addition funnel. After the addition was complete the solution was stirred at this temperature for 3 hr until all of the product had disappeared by TLC. Added 1 ml of DMF and allowed the solution to warm to room temperature, whereupon product begins to form. After stirring overnight the reaction was quenched with saturated sodium bicarbonate solution, then extracted 3 times with ethyl acetate. The organic layers were combined, dried (MgSO₄) and concentrated to afford an oil, which was chromatographed on silica gel eluting with 30% ethyl acetate:hexane to afford 1.81 g (83%) of product as a solid, which was recrystallized from ethyl acetate hexane, mp $176-178^\circ\text{C}$.

^1H NMR (DMSO- d_6): δ 7.84 (m, 1H, ArH), 7.76 (m, 1H, ArH), 7.03 (m, 1H, H2), 6.96(s, 1H, ArH), 6.92 (d, 1H, ArH), 6.79 (d, 1H, ArH), 6.22 (m, 1H, H3), 5.96 (m, 1H, H3), 5.28 (t, 1H, CH), 3.61 (s, 3H, OCH₃), 1.96 (s, 3H, CH₃), 1.28-1.45 (m, 2H, CH₂), 0.80 (t, 3H, CH₃);

MS (ESI) m/z 444 ([M+H]⁺);

Anal. calcd for C₂₂H₁₉F₂N₃O₃S: C:59.59 H:4.32 N:9.48 Found: C:59.21 H:4.26 N:9.19.

EXAMPLE 11A**Separation of the Enantiomeric Mixture of Example 11**

[0081] The enantiomeric mixture obtained from Example 11 was separated on a Chiracel OJ column eluting with 9:1 hexane:isopropanol at 0.8 ml/min..

(R)-4-ethyl-7,8-difluoro-5-[(4-methoxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

mp 153-155 °C;

$[\alpha]_D^{25} = -48.5^\circ$ (c = 1% SOLUTION, DMSO);

^1H NMR (DMSO- d_6): Identical to Example 11;

MS (ESI) m/z 444 ($[\text{M}+\text{H}]^+$);

Anal. calcd for $\text{C}_{22}\text{H}_{19}\text{F}_2\text{N}_3\text{O}_3\text{S}$: C:59.59 H:4.32 N:9.48 Found: C:59.31 H:4.33 N:9.29.

(S)-4-ethyl-7,8-difluoro-5-[(4-methoxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

mp 153-155 °C;

$[\alpha]_D^{25} = +53.0^\circ$ (c = 1% SOLUTION, DMSO);

^1H NMR (DMSO- d_6): Identical to Example 11;

MS (ESI) m/z 444 ($[\text{M}+\text{H}]^+$);

Anal. calcd for $\text{C}_{22}\text{H}_{19}\text{F}_2\text{N}_3\text{O}_3\text{S}$: C:59.59 H:4.32 N:9.48 Found: C:59.17 H:4.38 N:9.04.

EXAMPLE 11B

Preparation of (S)-4-ethyl-7,8-difluoro-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0082] The (+)-(S) enantiomer of Example 11A was demethylated according to the procedure of Example 5 to yield the title compound mp 208-210 °C.

$[\alpha]_D^{25} = +45.2^\circ$ (c = 1% SOLUTION, DMSO);

¹H NMR (DMSO-d₆): δ 10.53 (bs, 1H, OH), 7.81 (m, 2H, ArH), 7.01 (d, 1H, H₂), 6.84 (s, 1H, ArH), 6.81 (d, 1H, ArH), 6.58 (d, 1H, ArH), 6.21 (d, 1H, H₃), 5.23 (t, 1H, CH), 1.93 (s, 3H, CH₃), 1.28-1.45 (m, 2H, CH₂), 0.85 (t, 3H, CH₃);

MS (ESI) *m/z* 428 ([M-H]⁻);

Anal. calcd for C₂₁H₁₇F₂N₃O₃S: C:58.73 H:3.99 N:9.78 Found: C:58.37 H:4.07 N:9.56.

EXAMPLE 12

4-ethyl-7,8-difluoro-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0083] The title compound was prepared from the product of Example 11 according to the procedure of Example 5 and isolated as colorless crystals, mp 201-203 °C.

¹H NMR (DMSO-d₆): δ 10.40 (s, 1H, OH), 7.74-7.85 (m, 2H, ArH), 7.02 (m, 1H, H₂), 6.84 (s, 1H, ArH), 6.81 (d, 1H, ArH), 6.58 (d, 1H, ArH), 6.22 (m, 1H, H₃), 5.23 (t, 1H, CH), 1.95 (s, 3H, CH₃), 1.28-1.45 (m, 2H, CH₂), 0.84 (t, 3H, CH₃);

MS (ESI) *m/z* 428 ([M-H]⁻);

Anal. calcd for C₂₁H₁₇F₂N₃O₃S: C:58.73 H:3.99 N:9.78 Found: C:58.44 H:4.00 N:9.46.

EXAMPLE 13

Preparation of 4-[(1,7,8-trifluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol

[0084] To a 250 ml round bottom flask equipped with condenser was added 3.2 g (7.2 mmol) of the product from Example 9, 3.5 g (10.8 mmol) of N-fluorobenzenesulfonimide and 100 ml of acetonitrile. The solution was heated to reflux for 4 hours. At the end of this time the solution was concentrated and the residue washed with saturated potassium carbonate solution and extracted with ethyl acetate (3 X 50 ml). The organic layers were combined dried (MgSO₄) and

concentrated and the resulting crude material chromatographed with 20% ethyl acetate:hexane to yield 1.5 g of material. The enantiomers can be separated (see below) or this material can be hydrolyzed by dissolving in 50 ml of MeOH and 2 ml of 2N NaOH added. After 0.5 hr the solution was concentrated and neutralized with 2N HCL then extracted with ethyl acetate (3 X 50 ml). The organic layers were combined dried (MgSO₄) and concentrated and the solid once again chromatographed with 40% ethyl acetate:hexane. The solid so obtained was recrystallized from ethyl acetate:hexane to yield 0.45 g of product, mp 184-186 °C.

¹H NMR (DMSO-d₆) δ 7.76 (m, 1H, ArH), 7.57 (m, 1H, ArH), 7.01 (d, 2H, ArH), 6.57 (d, 2H, ArH), 5.79 (m, 1H, H₂), 5.49 (m, 1H, H₃), 5.40 (q, 1H, CH), 1.17 (d, 3H, CH₃);

MS (ESI) *m/z* 393 ([M-H]⁻);

Anal. calcd for C₁₈H₁₃F₃N₂O₃S: C:54.82 H:3.32 N:7.10 Found: C:55.17 H:3.44 N:7.06.

EXAMPLE 13 A

Isolation of 4-[(*S*)-1,7,8-trifluoro-4-methylpyrrolo[1,2-*a*]quinoxalin-5-(4H)-yl]sulfonyl}phenol and 4-[(*R*)-1,7,8-trifluoro-4-methylpyrrolo[1,2-*a*]quinoxalin-5-(4H)-yl]sulfonyl}phenol

[0085] The enantiomeric mixture of carbonate intermediate from Example 13 was separated on a Chiracel OJ column eluting with 9:1 hexane:isopropanol at 0.8 ml/min. The resulting carbonates were hydrolyzed with 2N NaOH and crystallized as before to isolate the title products.

4-[(*S*)-1,7,8-trifluoro-4-methylpyrrolo[1,2-*a*]quinoxalin-5-(4H)-yl]sulfonyl}phenol
mp 197-200 °C;

[α]_D²⁵ = +106.8° (c = 1% SOLUTION, DMSO);

¹H NMR (DMSO-d₆): Identical to Example 13 NMR;

MS (ESI) *m/z* 393 ([M-H]⁻);

Anal. calcd for C₁₈H₁₃F₃N₂O₃S: C:54.82 H:3.32 N:7.10 Found: C:54.91 H:3.50 N:6.99.

4-{[(*R*)-1,7,8-trifluoro-4-methylpyrrolo[1,2-*a*]quinoxalin-5-(4*H*)-yl]sulfonyl}phenol
mp 184-189 °C;
[α]_D²⁵ = -90.2° (c = 1% SOLUTION, DMSO);
¹H NMR (DMSO-*d*₆): Identical to Example 13;
MS (ESI) *m/z* 393 ([*M*-H]⁻);
Anal. calcd for C₁₈H₁₃F₃N₂O₃S: C:54.82 H:3.32 N:7.10 Found: C:54.95 H:3.45
N:6.90.

EXAMPLE 14

Preparation of 7,8-difluoro-4,4-dimethyl-4,5-dihydropyrrolo[1,2-*a*]quinoxaline

[0086] To a 250 ml round bottom flask was added 1.94 g (10 mmol) of the product from Example 2 and 50 ml of methanol. Added 2 ml of dry acetone to this mixture along with a few crystals of camphorsulfonic acid. The reaction was stirred at room temperature overnight whereupon it was concentrated and the residue passed through a plug of silica gel with 20% ethyl acetate:hexane elution. After concentration, the solid was crystallized from ethyl acetate:hexane to yield 2.1 g (81%) of product as a light tan solid mp 123-125°C.

¹H NMR (DMSO-*d*₆): δ 7.64 (m, 1H, ArH), 7.35 (s, 1H, H1), 6.79 (m, 1H ArH), 6.18 (m, 2H, NH and H3), 5.93 (s, 1H, H2), 1.38 (t, 3H, CH₃);
MS (ESI) *m/z* 235 ([*M*+H]⁺);
Anal. calcd for C₁₃H₁₂F₂N₂: C:66.66 H:5.16 N:11.96 Found: C:66.69 H:5.14 N:11.84.

EXAMPLE 15

Preparation of 4-[(7,8-difluoro-4,4-dimethylpyrrolo[1,2-*a*]quinoxalin-5-(4*H*)-yl)sulfonyl]phenol

[0087] To a 100 ml round bottom flask was added 1.5 g (6.38 mmol) of the product from Example 14 and 15 ml of pyridine. Added 2.48 g (9.28 mmol) of ethyl – (4- chlorosulfonyl) phenylcarbonate and heated this mixture at 50°C for 4 hr. At the

end of this time another 2.48 g of ethyl –(4-chlorosulfonyl) phenylcarbonate was added, and the reaction heated an additional 24 hr. At the end of this time it was concentrated and diluted with 2N HCl. The residue was extracted with ethyl acetate (3 X 50 ml) and the organic layers combined, dried (MgSO₄) and concentrated to afford a dark oil, which was chromatographed on silica gel eluting with 15 % ethyl acetate:hexane. After the fractions containing product were combined and concentrated, the resulting solid was dissolved in 10 ml of methanol and 1 ml of 2N NaOH added. After stirring at room temperature for 0.5 hr, the reaction was complete and solution was concentrated. The residue was treated with 2N HCl and the residue extracted with ethyl acetate (3 X 25 ml) and the organic layers combined, dried (MgSO₄) and concentrated to afford an oil. Purification by column chromatography on silica gel eluting with 40% ethyl acetate:hexane yielded a light yellow solid, which was crystallized from ethyl acetate:hexane to give 0.32 g (12%) of product, mp 202-204 °C.

¹H NMR (DMSO-d₆): δ 10.32 (bs,1,OH), 7.82 (m,1H,ArH), 7.67 (m,1H,ArH), 7.03 (m,1H,H1), 6.95 (d,2H,ArH), 6.57 (d,2H,ArH), 5.91 (m,1H,H2), 5.79 (m,1H, H3), 1.56 (bs,6H,CH₃);

MS (ESI) *m/z* 391 ([M+H]⁺);

Anal. calcd for C₁₉H₁₆F₂N₂O₃S: C:58.45 H:4.13 N:7.18 Found: C:58.25 H:4.05 N:6.84.

EXAMPLE 16

Preparation of 5-fluoro-2-(*H*-pyrrol-1-yl)aniline

[0088] 5-Fluoro-2-(*H*-pyrrol-1-yl)aniline was prepared from 4-fluoro 2-nitro aniline according to the procedure of Example 1, and the isolated oil converted to the title product according to the procedure of Example 2. The product was isolated as a light yellow solid, mp 82-84 °C.

¹H NMR (DMSO-d₆): δ 7.03 (m,1H,ArH), 6.84 (m,2H,ArH), 6.59 (d,1H,ArH), 6.38 (t,1H,ArH), 6.22 (m,2H,ArH), 5.07 (bs, 2H,NH);

MS (ESI) m/z 177 ([M+H]⁺),

Anal. calcd for C₁₀H₉FN₂: C:68.17 H:5.15 N:15.90 Found: C:68.11 H:5.09 N:15.81.

EXAMPLE 17

Preparation of 4-ethyl-7-fluoro-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0089] The title compound was prepared from the product of Example 16 according to the procedure of Example 3, mp 49-51 °C.

¹H NMR (DMSO-d₆): δ 7.43 (m, 1H, ArH), 7.37 (s, 1H, H1), 6.61 (m, 1H, ArH), 6.44 (m, 1H, ArH), 6.38 (s, 1H, NH), 6.21 (m, 1H, H2), 5.92 (m, 1H, H3), 4.36 (t, 1H, CH), 1.60-1.8 (m, 2H, CH₂), 0.92 (t, 3H, CH₃);

MS (ESI) m/z 217 ([M+H]⁺);

Anal. calcd for C₁₃H₁₃FN₂: C:72.20 H:6.06 N:12.95 Found: C:72.12 H:6.13 N:13.01.

EXAMPLE 18

Preparation of 4-ethyl-7-fluoro-5-[(4-methoxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0090] The title compound was prepared from the product of Example 17 according to the procedure of Example 4 to yield light tan crystals, mp 164-166 °C.

¹H NMR (DMSO-d₆) δ 7.57 (m, 1H, ArH), 7.43 (m, 1H, ArH), 7.22 (m, 1H, ArH), 6.98 (m, 2H, H1 and ArH), 6.95 (m, 1H, ArH), 6.70 (d, 1H, ArH), 6.03 (m, 1H, H2), 5.96 (m, 1H, H3), 5.20 (t, 1H, CH), 3.71 (s, 3H, OCH₃), 1.91 (s, 3H, CH₃), 1.37 (m, 2H, CH₂), 0.87 (t, 3H, CH₃);

MS (ESI) m/z 401 ([M+H]⁺);

Anal. calcd for C₂₁H₂₁FN₂O₃S: C:62.98 H:5.29 N:7.00 Found: C:62.72 H:5.12 N:6.73.

EXAMPLE 19**Preparation of 4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol**

[0091] The title compound was prepared from the product of Example 19 using the procedure of Example 5 to yield light tan crystals, mp 175-177 °C.

¹H NMR (DMSO-d₆): δ 10.34 (s, 1H, OH) 7.55 (m, 1H, ArH), 7.42 (m, 1H, ArH), 7.22 (m, 1H, ArH), 6.98 (m, 2H, H1 and ArH), 6.95 (m, 1H, ArH), 6.52 (d, 1H, ArH), 6.03 (m, 1H, H2), 5.96 (m, 1H, H3), 5.20 (t, 1H, CH), 1.91 (s, 3H, CH₃), 1.37 (m, 2H, CH₂), 0.87 (t, 3H, CH₃);

MS (ESI) *m/z* 387 ([M+H]⁺);

Anal. calcd for C₂₀H₁₉FN₂O₃S: C:62.16 H:4.96 N:7.25 Found: C:62.25 H:4.97 N:6.96.

EXAMPLE 20**Preparation of ethyl 4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenyl carbonate**

[0092] The title compound was prepared from the product of Example 17 according to the procedure of Example 6 to yield light tan crystals mp 114-116 °C.

¹H NMR (DMSO-d₆): δ 7.57 (m, 1H, ArH), 7.43 (m, 1H, ArH), 7.25 (m, 1H, ArH), 7.22 (d, 2H, ArH), 7.15 (d, 2H, ArH), 6.93 (m, 1H, H1), 5.98 (m, 1H, H2), 5.91 (m, 1H, H3), 5.21 (t, 1H, CH), 4.21 (q, 2H, OCH₂), 1.38 (m, 2H, CH₂), 1.28 (t, 3H, CH₃), 0.86 (t, 3H, CH₃);

MS (ESI) *m/z* 445 ([M+H]⁺);

Anal. calcd for C₂₂H₂₁FN₂O₅S: C:59.45 H:4.76 N:6.30 Found: C:59.43 H:4.73 N:6.22.

[0093] The enantiomeric mixture so obtained can be separated on a Chiracel OJ column eluting with 9:1 hexane:isopropanol at 0.8 ml/min to yield a 50:50 mixture of the 2 enantiomers.

Ethyl 4-[(S)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl]sulfonyl}phenyl carbonate

mp 96-97 °C.

 $[\alpha]_D^{25} = +108.3^\circ$ (c = 5.32MG/.532ML, DMSO);

^1H NMR (DMSO- d_6): δ 7.57 (m,1H,ArH), 7.43 (m,1H,ArH), 7.25 (m,1H,ArH), 7.22 (d,2H,ArH), 7.15 (d,2H,ArH), 6.93 (m,1H, H1), 5.98 (m,1H,H2), 5.91 (m,1H, H3), 5.21 (t,1H, CH), 4.21 (q,2H,OCH₂), 1.38 (m,2H,CH₂), 1.28 (t,3H,CH₃), 0.86 (t,3H,CH₃); MS (ESI) m/z 445 ([M+H]⁺); Anal. calcd for C₂₂H₂₁FN₂O₅S: C:59.45 H:4.76 N:6.30 Found: C:59.16 H:4.61 N:6.19.

Ethyl 4-[(R)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl]sulfonyl}phenyl carbonate

mp 90-92 °C;

 $[\alpha]_D^{25} = -108.3^\circ$ (c = 1% SOLUTION, EtOH);

^1H NMR (DMSO- d_6): δ 7.57 (m,1H,ArH), 7.43 (m,1H,ArH), 7.25 (m,1H,ArH), 7.22 (d,2H,ArH), 7.15 (d,2H,ArH), 6.93 (m,1H, H1), 5.98 (m,1H,H2), 5.91 (m,1H, H3), 5.21 (t,1H, CH), 4.21 (q,2H,OCH₂), 1.38 (m,2H,CH₂), 1.28 (t,3H,CH₃), 0.86 (t,3H,CH₃);

MS (ESI) m/z 445 ([M+H]⁺);

Anal. calcd for C₂₂H₂₁FN₂O₅S: C:59.45 H:4.76 N:6.30 Found: C:59.32 H:4.43 N:6.21.

EXAMPLE 21**Preparation of 4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol**

[0094] The title compound was prepared from the product of Example 20 according to the procedure of Example 7 and isolated as crystals, mp 150-152 °C.

^1H NMR (DMSO- d_6): δ 10.34 (bs,1H,OH), 7.58 (m,1H,ArH), 7.42 (m,1H,ArH), 7.05

(m, 1H, H1), 1.04 (d, 2H, ArH), 0.51 (d, 2H, ArH), 6.03 (m, 1H, H2), 5.91 (m, 1H, H3), 5.18 (t, 1H, CH), 1.38 (m, 2H, CH₂), 0.86 (t, 3H, CH₃);

MS (ESI) *m/z* 373 ([M+H]⁺);

Anal. calcd for C₁₉H₁₇FN₂O₃S: C:61.28 H:4.60 N:7.52 Found: C:61.22 H:4.71

N:7.34.

EXAMPLE 22

Preparation of ethyl 4-[(4-ethyl-1,7-difluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenyl carbonate

[0095] The title compound was prepared from the product of Example 20 according to the procedure of Example 13 to yield light tan crystals mp 122-124 °C.

¹H NMR (DMSO-d₆): δ 7.57 (m, 1H, ArH), 7.45 (m, 1H, ArH), 7.35 (m, 1H, ArH), 7.24 (d, 2H, ArH), 7.17 (d, 2H, ArH), 5.79 (m, 1H, H2), 5.44 (m, 1H, H2), 5.12 (t, 1H, CH), 4.23 (q, 2H, OCH₂), 1.38 (m, 2H, CH₂), 1.24 (t, 3H, CH₃), 0.88 (t, 3H, CH₃);

MS (ESI) *m/z* 463 ([M+H]⁺);

Anal. calcd for C₂₂H₂₀F₂N₂O₅S: C:57.14 H:4.36 N:6.06 Found: C:57.25 H:4.29

N:5.82.

EXAMPLE 23

Preparation of 4-[(4-ethyl-1,7-difluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol

[0096] The title compound was prepared from the product of Example 22 according to the procedure of Example 7 to yield light yellow crystals, mp 169-171 °C.

¹H NMR (DMSO-d₆): δ 10.33 (bs, 1H, OH), 7.48 (m, 2H, ArH), 7.25 (m, 1H, ArH), 7.04 (d, 2H, ArH), 6.56 (d, 2H, ArH), 5.80 (m, 1H, H2), 5.50 (m, 1H, H2), 5.08 (t, 1H, CH), 1.38 (m, 2H, CH₂), 0.84 (t, 3H, CH₃);

MS (ESI) m/z 387 ([M+H]⁺),

Anal. calcd for C₁₉H₁₆F₂N₂O₃S: C:58.45 H:4.13 N:7.18 Found: C:58.02 H:4.15 N:7.00.

EXAMPLE 24

Preparation of 4-ethyl-7-fluoro-5-[(4-methoxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carboxaldehyde

[0097] To a 25 ml round bottom flask under nitrogen charged with 10 ml of methylene chloride was added 0.1 ml (1.25 mmol) of DMF and cooled to 0°C. Added 0.12 ml of phosphorous oxychloride and stirred for 15 minutes. 0.40 g (1 mmol) of the product from Example 18 was added and the mixture was stirred at room temperature for 16 hours. At the end of this time added 5 ml of water and stirred vigorously an additional 0.5 hr. The solution was diluted with methylene chloride and the layers separated. The aqueous phase was extracted with methylene chloride and combined with the previous layer. After drying (MgSO₄) and concentrating the crude solid was subjected to column chromatography on silica gel, eluting with 30% ethyl acetate:hexane. The product was collected and briefly characterized, then used in the next step without further purification.

¹H NMR (DMSO-d₆): δ 9.20 (s, 1H, CHO), 7.72 (m, 1H, ArH), 7.45 (m, 1H, ArH), 7.30 (m, 1H, ArH), 7.05 (d, 1H, H₂), 6.91 (m, 2H, ArH), 6.64 (d, 1H, H₃), 5.22 (t, 1H, CH), 3.68 (s, 3H, OCH₃), 1.85 (s, 3H, CH₃), 1.39 (m, 2H, CH₂), 0.88 (t, 3H, CH₃);

MS (ESI) m/z 429 ([M+H]⁺);

Anal. calcd for C₂₂H₂₁FN₂O₄S: C:61.67 H:4.94 N:6.54 Found: C:61.51 H:4.80 N:6.43.

EXAMPLE 25

Preparation of 4-ethyl-7-fluoro-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carboxaldehyde

[0098] The title compound was prepared from the product of Example 25 using the procedure of Example 5 to yield a light orange solid, mp 192-194 °C.

¹H NMR (DMSO-d₆): δ 9.23 (s, 1H, CHO), 7.80 (m, 1H, ArH), 7.42 (m, 1H, ArH), 7.28 (m, 1H, ArH), 7.07 (d, 1H, H1), 6.84 (m, 1H, H3), 6.81 (dd, 1H, ArH), 6.44 (d, 1H, ArH), 6.24 (d, 1H, H3), 5.21 (t, 1H, CH), 1.82 (s, 3H, CH₃), 1.24-1.43 (m, 2H, CH₂), 0.88 (t, 3H, CH₃);
MS (ESI) *m/z* 415 ([M+H]⁺);
Anal. calcd for C₂₁H₁₉FN₂O₄S: C:60.86 H:4.62 N:6.76 Found: C:60.25 H:4.70 N:6.49.

EXAMPLE 26

Preparation of ethyl 4-[(4-ethyl-7,8-difluoro-1-formylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenyl carbonate

[0099] The title compound was prepared from the product of Example 6 according to the procedure of Example 24 to yield light yellow crystals mp 124-126 °C.

¹H NMR (DMSO-d₆): 9.20 (s, 1H, CHO), 7.98 (m, 1H, ArH), 7.79 (m, 1H, ArH), 7.28 (d, 2H, ArH), 7.09 (d, 2H, ArH), 7.03 (d, 1H, H2), 6.29 (d, 1H, H3), 5.32 (t, 1H, CH), 4.21 (q, 2H, OCH₂), 1.21- 1.41 (m, 2H, CH₂), 1.22 (t, 3H, CH₃), 0.88 (t, 3H, CH₃);
MS (ESI) *m/z* 491 ([M+H]⁺);
Anal. calcd for C₂₃H₂₀F₂N₂O₆S: C:56.32 H:4.11 N:5.71 Found: C:56.19 H:4.02 N:5.61.

EXAMPLE 27

Preparation of 4-ethyl-7,8-difluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carboxaldehyde

[0100] The title compound was prepared from the product of Example 26 according to the procedure of Example 7 to yield light tan crystals, > 225 °C.

¹H NMR (DMSO-d₆): 9.20 (s, 1H, CHO), 7.98 (m, 1H, ArH), 7.65 (m, 1H, ArH), 7.10

(d,1H,H2), 7.04 (d,2H,ArH), 6.43 (d,2H, ArH), 6.28 (d,1H,H3), 5.25 (t,1H, CH), 1.21- 1.44 (m,2H,CH₂), 0.88 (t,3H,CH₃);

MS (ESI) *m/z* 417 ([M-H]⁻);

Anal. calcd for C₂₀H₁₆F₂N₂O₄S: C:57.41 H:3.85 N:6.70 Found: C:57.09 H:3.79 N:6.40.

EXAMPLE 28

Preparation of 4-[(4-ethyl-1,7-difluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol

[0101] The title compound was prepared from the product of Example 19 using the procedure of Example 13 to yield colorless crystals, mp 149-151 °C.

¹H NMR (DMSO-d₆): δ 10.31 (bs,1H,OH), 7.43 (m,1H,ArH), 7.25 (m,1H,ArH), 6.90 (s,1H,ArH), 6.80 (d,1H,ArH), 6.55 (d,1H, ArH), 5.80 (m,1H,H2), 5.49 (m,1H,H3), 5.12 (t,1H, CH), 1.34 (m,2H,CH₂), 0.86 (t,3H,CH₃);

MS (ESI) *m/z* 405 ([M+H]⁺);

Anal. calcd for C₂₀H₁₈F₂N₂O₃S: C:59.40 H:4.49 N:6.93 Found: C:59.44 H:4.34 N:6.91.

EXAMPLE 29

Preparation of 4-[(1-bromo-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol

[0102] To a 50 ml round bottom flask with addition funnel was added 30 ml of methylene chloride and 0.38g (1 mmol) of the product from Example 19. The flask was cooled to -78°C and a solution of 0.18g (1 mmol) of N-bromosuccinimide in 10 ml of methylene chloride was slowly added via addition funnel. After addition was complete, the reaction was allowed to stir at this temperature for 1 hr, then cooling removed. When the reaction had warmed to room temperature it was extracted with 20 ml of saturated sodium bicarbonate solution and separated. The aqueous layer was extracted twice with 10 ml of methylene chloride and the combined organic layers

were dried (MgSO_4) and concentrated. The crude solid was subjected to column chromatography eluting with 40% ethyl acetate:hexane to yield 0.32 g (69%) of solid which was crystallized from ethyl acetate:hexane to produce colorless crystals, mp 119 °C (dec).

^1H NMR (DMSO-d_6): δ 10.26 (bs, 1H, OH), 7.95 (m, 1H, ArH), 7.24 (m, 1H, ArH), 7.32 (m, 1H, ArH), 6.82 (m, 1H, ArH), 6.80 (s, 1H, ArH), 6.57 (d, 1H, ArH), 6.10 (d, 1H, H2), 6.05 (d, 1H, H3), 5.09 (t, 1H, CH), 1.20-1.36 (m, 2H, CH_2), 0.82 (t, 3H, CH_3);

MS (ESI) m/z 465 ($[\text{M}+\text{H}]^+$);

Anal. calcd for $\text{C}_{20}\text{H}_{18}\text{BrFN}_2\text{O}_3\text{S}$: C:51.62 H:3.90 N:6.02 Found: C:51.36 H:3.76 N:5.86.

EXAMPLE 30

Preparation of 5-[(3-chloro-4-methoxyphenyl)sulfonyl]-4-ethyl-7-fluoro-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0103] The title compound was prepared from the product of Example 17 and 3-chloro, 4-methoxy sulfonyl chloride according to the procedure of Example 4 to yield yellow crystals, mp 152-154 °C.

^1H NMR (DMSO-d_6): δ 7.59 (m, 1H, ArH), 7.44 (m, 1H, ArH), 7.32 (m, 1H, ArH), 7.16 (s, 1H, ArH), 7.08 (d, 1H, ArH), 6.98 (s, 1H, H1), 6.92 (d, 1H, ArH), 6.00 (m, 1H, H2), 5.97 (m, 1H, H3), 5.21 (t, 1H, CH), 3.80 (s, 3H, OCH_3), 1.28 (m, 2H, CH_2), 0.84 (t, 3H, CH_3);

MS (ESI) m/z 421 ($[\text{M}+\text{H}]^+$);

Anal. calcd for $\text{C}_{20}\text{H}_{18}\text{ClFN}_2\text{O}_3\text{S}$: C:57.07 H:4.31 N:6.66 Found: C:57.20 H:4.37 N:6.46.

EXAMPLE 31

Preparation of 2-chloro-4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol

[0104] The title compound was prepared from the product of Example 30 according to the procedure of Example 5 to yield yellow crystals, mp 180-184 °C.

¹H NMR (DMSO-d₆): δ 11.20 (bs, 1H, OH), 7.59 (m, 1H, ArH), 7.44 (m, 1H, ArH), 7.28 (m, 1H, ArH), 7.07 (s, 1H, ArH), 7.02 (d, 1H, ArH), 6.90 (s, 1H, ArH), 6.68 (d, 1H, ArH), 6.00 (m, 1H, H₂), 5.97 (m, 1H, H₃), 5.19 (t, 1H, CH), 1.28 (m, 2H, CH₂), 0.84 (t, 3H, CH₃);

MS (ESI) *m/z* 407 ([M+H]⁺);

Anal. calcd for C₁₉H₁₆ClFN₂O₃S: C:56.09 H:3.96 N:6.89 Found: C:56.26 H:4.22 N:5.80.

EXAMPLE 32

Preparation of 4-ethyl-7-fluoro-5-[(4-methoxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0105] The title compound was prepared from the product of Example 18 according to the procedure of Example 15 to yield colorless crystals, mp 196-199 °C.

¹H NMR (DMSO-d₆): δ 7.77 (m, 1H, ArH), 7.58 (m, 1H, ArH), 7.44 (m, 1H, ArH), 6.97 (s, 1H, H₂), 6.92 (d, 1H, ArH), 6.88 (d, 1H, ArH), 6.78 (d, 1H, ArH), 6.23 (d, 1H, H₃), 5.24 (t, 1H, CH), 1.42-1.28 (m, 2H, CH₂), 0.86 (t, 3H, CH₃);

MS (ESI) *m/z* 426 ([M+H]⁺);

Anal. calcd for C₂₂H₂₀FN₃O₃S: C:62.10 H:4.74 N:9.88 Found: C:62.48 H:4.55 N:9.52.

EXAMPLE 33

Preparation of 4-ethyl-7-fluoro-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0106] The title compound was prepared from the product of Example 32 according to the procedure of Example 6 to yield colorless crystals, mp 192-194 °C.

¹H NMR (DMSO-d₆): δ 10.40 (bs, 1H, OH), 7.80 (m, 1H, ArH), 7.57 (m, 1H, ArH), 7.44 (m, 1H, ArH), 6.97 (s, 1H, H₂), 6.84 (s, 1H, ArH), 6.81 (d, 1H, ArH), 6.68 (d, 1H, ArH), 6.20 (d, 1H, H₃), 5.23 (t, 1H, CH), 1.42-1.28 (m, 2H, CH₂), 0.86 (t, 3H, CH₃);
MS (ESI) *m/z* 410 ([M-H]⁻);
Anal. calcd for C₂₁H₁₈FN₃O₃S: C:61.30 H:4.41 N:10.21 Found: C:61.09 H:4.70 N:9.83.

EXAMPLE 34

Preparation of 4-[(1-cyano-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenyl ethyl carbonate

[0107] The title compound was prepared from the product of Example 20 according to the procedure of Example 11 to yield colorless crystals, mp 110-112°C.

¹H NMR (DMSO-d₆): δ 7.82 (m, 1H, ArH), 7.62 (m, 1H, ArH), 7.47 (m, 1H, ArH), 7.24 (d, 2H, ArH), 7.17 (d, 2H, ArH), 6.96 (d, 1H, H₂), 6.20 (d, 1H, H₃), 5.37 (t, 1H, CH), 4.23 (q, 2H, OCH₂), 1.42-1.28 (m, 2H, CH₂), 1.24 (t, 3H, CH₃), 0.86 (t, 3H, CH₃);
Anal. calcd for C₂₃H₂₀FN₃O₅S: C:58.84 H:4.29 N:8.95 Found: C:58.23 H:4.18 N:8.75.

EXAMPLE 35

Preparation of 4-ethyl-7-fluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0108] The title compound was prepared from the product of Example 34 using the procedure of Example 7 to yield light gray crystals, mp 169-171°C.

¹H NMR (DMSO-d₆): δ 10.50 (bs, 1H, OH), 7.82 (m, 1H, ArH), 7.57 (m, 1H, ArH), 7.42 (m, 1H, ArH), 6.99 (m, 2H, ArH and H₂), 6.57 (d, 2H, ArH), 6.20 (d, 1H, H₃), 5.28 (t, 1H, CH), 1.42-1.28 (m, 2H, CH₂), 0.86 (t, 3H, CH₃);

MS (ESI) m/z 390 ($[M-H]^-$);

Anal. calcd for $C_{20}H_{16}FN_3O_3S$: C:60.44 H:4.06 N:10.57 Found: C:59.94 H:3.82 N:10.37.

EXAMPLE 36

Preparation of 4-ethyl-7-fluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carboxamide

[0109] 0.25 g (0.53 mmol) of the product from Example 34 was dissolved in 15 ml of ethanol and 5 ml of 2N NaOH was added. The solution was heated to reflux for 3 hours, after which time it was concentrated then neutralized with 2N HCl. The mixture was extracted with ethyl acetate (2 X 20 ml) and the combined organic layers were dried ($MgSO_4$) and concentrated. The crude solid was subjected to column chromatography on silica gel eluting with chloroform:methanol (95:5). The fractions containing product were combined and concentrated to yield a light tan solid, which was crystallized from ethyl acetate:hexane to yield 32 mg (14%) of product, mp 168-170 °C (d).

^1H NMR ($DMSO-d_6$): ^1H NMR ($DMSO-d_6$): δ 10.50 (bs, 1H, OH), 7.49 (bs, 1H, NH), 7.37 (m, 2H, ArH), 7.12 (m, 1H, ArH), 7.14 (d, 2H, ArH), 6.99 (bs, 1H, NH), 6.56 (d, 1H, H2), 6.55 (d, 2H, ArH), 5.84 (t, 1H, CH), 1.42-1.28 (m, 2H, CH_2), 0.86 (t, 3H, CH_3); MS (ESI) m/z 414 ($[M-H]^-$);

Anal. calcd for $C_{20}H_{18}FN_3O_4S$: C:57.82 H:4.37 N:10.11 Found: C:57.22 H:4.28 N:9.75.

EXAMPLE 37

Preparation of 4-ethyl-7-fluoro-5-[(4-methoxy-3,5-dimethylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0110] The title compound was prepared from the product of Example 4 using 3,5 dimethyl-4-methoxy benzenesulfonyl chloride to yield crystals, mp 140-142 °C.

¹H NMR (DMSO-d₆): δ 7.56 (m,1H,ArH), 7.45 (m,1H,ArH), 7.24 (m,1H, ArH), 6.95 (m,1H,H1), 6.78 (s,2H,ArH), 5.97 (m,1H,H2), 5.91 (m,1H, H3), 5.16 (t,1H, CH), 3.51 (s,3H,OCH₃), 1.98 (s,6H,ArCH₃), 1.35 (m,2H,CH₂), 0.86 (t,3H,CH₃);

MS (ESI) *m/z* 415 ([M+H]⁺);

Anal. calcd for C₂₂H₂₃FN₂O₃S: C:63.75 H:5.59 N:6.76 Found: C:62.71 H:5.52

N:6.45.

EXAMPLE 38

Preparation of 4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2,6-dimethylphenol

[0111] The title product was prepared from the product of Example 37 using the procedure of Example 6 to yield a colorless solid, mp 216-218 °C.

¹H NMR (DMSO-d₆): δ 9.10 (m,1H,ArH), 7.45 (m,1H,ArH), 7.24 (m,1H, ArH), 7.02 (m,1H,H1), 6.81 (s,2H,ArH), 6.03 (m,1H,H2), 5.95 (m,1H, H3), 5.17 (t,1H, CH), 1.97 (s,6H,ArCH₃), 1.35 (m,2H,CH₂), 0.84 (t,3H,CH₃);

MS (ESI) *m/z* 401 ([M+H]⁺);

Anal. calcd for C₂₁H₂₁FN₂O₃S: C:62.98 H:5.29 N:7.00 Found: C:62.65 H:5.26

N:6.62.

EXAMPLE 39

Preparation of 5-bromo-2-(H-pyrrol-1-yl)aniline

[0112] The title compound was prepared from 4-bromo-2- nitro aniline according to the procedure of Example 1, and the resulting oil converted to the title

product according to the procedure of Example 2. The product was isolated as a light tan solid.

^1H NMR (DMSO- d_6): ^1H NMR (DMSO- d_6): δ 7.03 (m, 1H, ArH), 6.91 (1, 1H, ArH), 6.84 (m, 2H, ArH), 6.74 (m, 1H, ArH), 6.21 (m, 2H, ArH), 5.07 (bs, 2H, NH);

MS (ESI) m/z 261 ($[\text{M}+\text{H}]^+$);

Anal. calcd for $\text{C}_{10}\text{H}_9\text{BrN}_2$: C:50.66 H:3.83 N:11.81 Found: C:50.97 H:3.64 N:11.73.

EXAMPLE 40

Preparation of 7-bromo-4,4-dimethyl-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0113] The title compound was prepared from the product of Example 39 according to the procedure of Example 14 to yield yellow crystals, mp 89-91 °C.

^1H NMR (DMSO- d_6): δ 7.42 (d, 1H, ArH), 7.35 (s, 1H, H1), 6.91 (s, 1H ArH), 6.81 (d, 1H, ArH), 6.31 (2, 1H, NH), 6.19 (m, 1H, H3), 5.94 (s, 1H, H2) 1.39 (s, 6H, CH_3);

MS (ESI) m/z 277 ($[\text{M}+\text{H}]^+$);

Anal. calcd for $\text{C}_{13}\text{H}_{13}\text{BrN}_2$: C:56.34 H:4.73 N:10.11 Found: C:56.28 H:4.67 N:10.00.

EXAMPLE 41

Preparation of 4-[(7-bromo-4,4-dimethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol

[0114] The title compound was prepared the product of Example 40 according to the procedure of Example 15. The resulting carbonate intermediate was then isolated by hydrolysis according to the procedure of Example 7 to yield colorless crystals mp 227-229 °C.

^1H NMR (DMSO- d_6): δ 10.32 (bs, 1, OH), 7.70 (m, 1H, ArH), 7.63 (d, 1H, ArH), 7.52 (d, 1H, ArH), 7.05 (m, 1H, H1), 6.91 (d, 2H, ArH), 6.53 (d, 2H, ArH), 5.92 (t, 1H, H2), 5.78 (m, 1H, H3), 1.56 (bs, 6H, CH_3);

MS (ESI) m/z 431 ($[\text{M}-\text{H}]^-$);

Anal. calcd for C₁₉H₁₁BrN₂O₅S: C:52.67 H:3.95 N:6.46 Found: C:52.35 H:4.08 N:6.26.

EXAMPLE 42

Preparation of 7-bromo-4-ethyl-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0115] The title compound was prepared from the product of Example 39 according to the procedure of Example 3.

¹H NMR (DMSO-d₆): δ 7.39 (s, 1H, NH), 7.37 (s, 1H, H1), 6.99 (s, 1H, ArH), 6.76 (d, 1H ArH), 6.37 (s, 1H, ArH), 6.34 (s, 1H, H3), 6.20 (s, 1H, H2), 4.37 (m, 1H CH), 1.60-1.77 (m, 2H, CH₂), 0.92 (t, 3H, CH₃);

MS (ESI) *m/z* 275 ([M+H]⁺);

Anal. calcd for C₁₃H₁₃BrN₂: C:56.34 H:4.73 N:10.11 Found: C:56.11 H:4.57 N:10.09.

EXAMPLE 43

Preparation of 4-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenyl ethyl carbonate

[0116] The title compound was prepared from the product of Example 42 using the procedure of Example 6 to yield crystals mp 142-144 °C.

¹H NMR (DMSO-d₆): δ 7.80 (s, 1H, ArH), 7.61 (d, 1H, ArH), 7.52 (d, 1H, ArH), 7.23 (d, 2H, ArH), 7.20 (d, 2H, ArH), 6.97 (d, 1H, H1), 5.98 (m, 1H, H2), 5.93 (d, 1H, H3), 5.20 (t, 1H, CH), 4.21 (q, 2H, OCH₂), 1.37 (m, 2H, CH₂), 1.23 (t, 3H, CH₃), 0.86 (t, 3H, CH₃);

MS (ESI) *m/z* 505 ([M+H]⁺);

Anal. calcd for C₂₂H₂₁BrN₂O₅S: C:52.29 H:4.19 N:5.54 Found: C:52.49 H:4.21 N:5.42.

EXAMPLE 44

Preparation of 4-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol

[0117] The title compound was prepared from the product of Example 43 using the procedure of Example 7 to yield crystals, mp 206-208 °C.

¹H NMR (DMSO-d₆): δ 10.31 (bs, 1H, OH), 7.77 (s, 1H, ArH), 7.54 (d, 1H, ArH), 7.51 (d, 1H, ArH), 7.07 (m, 1H, H1), 7.00 (d, 2H, ArH), 6.51 (d, 2H, ArH), 6.02 (d, 1H, H3), 5.97 (m, 1H, H2), 5.18 (t, 1H, CH), 1.37 (m, 2H, CH₂), 0.86 (t, 3H, CH₃);

MS (ESI) *m/z* 431 ([M-H]⁻);

Anal. calcd for C₁₉H₁₇BrN₂O₃S: C:52.67 H:3.95 N:6.46 Found: C:52.65 H:3.79 N:6.32.

EXAMPLE 45

Preparation of 4-[(7-bromo-4-ethyl-1-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol

[0118] The title compound was prepared from the product of Example 43 using the procedure of Example 13. The resulting carbonate intermediate was then hydrolyzed according to the procedure of Example 7 to yield light yellow crystals, mp 160-162 °C.

¹H NMR (DMSO-d₆): δ 10.31 (bs, 1H, OH), 7.80 (s, 1H, ArH), 7.62 (d, 1H, ArH), 7.39 (d, 1H, ArH), 7.00 (d, 2H, ArH), 6.55 (d, 2H, ArH), 5.81 (t, 1H, H2), 5.52 (t, 1H, H2), 5.06 (t, 1H, CH), 1.38 (m, 2H, CH₂), 0.84 (t, 3H, CH₃);

MS (ESI) *m/z* 449 ([M-H]⁻);

Anal. calcd for C₁₉H₁₆BrFN₂O₃S: C:50.57 H:3.57 N:6.21 Found: C:50.19 H:3.47 N:6.10.

EXAMPLE 46

Preparation of 4-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol

[0119] The title compound was prepared from the product of Example 43 using the procedure of Example 4. The resulting intermediate was treated according to the procedure of Example 5 to yield the product, mp 191-193 °C.

¹H NMR (DMSO-d₆): δ 10.21 (bs, 1H, OH), 7.77 (s, 1H, ArH), 7.54 (d, 1H, ArH), 7.51 (d, 1H, ArH), 7.07 (m, 1H, H1), 6.88 (s, 1H, ArH), 6.81 (d, 1H, ArH), 6.51 (d, 1H, ArH), 6.01 (m, 1H, H2), 5.94 (m, 1H, H3), 5.18 (t, 1H, CH), 1.85 (s, 3H, CH₃), 1.37 (m, 2H, CH₂), 0.86 (t, 3H, CH₃); MS (ESI) *m/z* 445 ([M-H]⁻);

Anal. calcd for C₂₀H₁₉BrN₂O₃S: C:53.70 H:4.28 N:6.26 Found: C:53.39 H:4.22 N:5.84.

EXAMPLE 47

Preparation of 7-fluoro-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0120] The title compound was prepared from the product of Example 16 and acetaldehyde according to the procedure of Example 3, and isolated as a light yellow solid, mp 76-78 °C.

¹H NMR (DMSO-d₆): δ 7.43 (dd, 1H, ArH), 7.36 (s, 1H, H1), 6.58 (d, 1H, ArH), 6.44 (t, 1H, ArH), 6.18 (s, 1H, NH), 6.19 (m, 1H, H2), 5.91 (m, 1H, H3), 4.42 (q, 1H, CH), 1.41 (d, 3H, CH₃);

MS (ESI) *m/z* 203 ([M+H]⁺);

Anal. calcd for C₁₂H₁₁FN₂: C:71.27 H:5.48 N:13.85 Found: C:70.96 H:5.60 N:13.72.

EXAMPLE 48

Preparation of ethyl 4-[(7-fluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenyl carbonate

[0121] The title compound was prepared from the product of Example 47 using the procedure of Example 6 to yield a colorless solid.

¹H NMR (DMSO-d₆): δ 7.59 (m, 1H, ArH), 7.42 (m, 1H, ArH), 7.25 (m, 1H, ArH), 7.22 (d, 2H, ArH), 7.18 (d, 2H, ArH), 6.93 (m, 1H, H1), 5.98 (m, 1H, H2), 5.91 (m, 1H, H3), 5.57 (q, 1H, CH), 4.21 (q, 2H, OCH₂), 1.27 (t, 3H, CH₃), 1.19 (d, 3H, CH₃);
MS (ESI) *m/z* 431 ([M+H]⁺).

EXAMPLE 49

Preparation of 4-[(7-fluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol

[0122] The title compound was prepared from the product of Example 48 using the procedure of Example 7 to yield colorless crystals, mp 180-182 °C.

¹H NMR (DMSO-d₆): δ 10.35 (bs, 1H, OH), 7.58 (m, 1H, ArH), 7.44 (m, 1H, ArH), 7.25 (m, 1H, ArH), 7.22 (d, 2H, ArH), 7.18 (d, 2H, ArH), 6.93 (m, 1H, H1), 5.98 (m, 1H, H2), 5.91 (m, 1H, H3), 5.57 (q, 1H, CH), 1.19 (d, 3H, CH₃);

MS (ESI) *m/z* 359 ([M+H]⁺);

Anal. calcd for C₁₈H₁₅FN₂O₃S: C:60.32 H:4.22 N:7.82 Found: C:60.18 H:4.15 N:7.56.

EXAMPLE 50

Preparation of 7-fluoro-5-[(4-methoxy-3-methylphenyl)sulfonyl]-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0123] The title compound was prepared from the product of Example 47 using the procedure of Example 4 to yield colorless crystals mp 154-156 °C.

¹H NMR (DMSO-d₆) δ 7.57 (dd, 1H, ArH), 7.41 (dd, 1H, ArH), 7.23 (dt, 1H, ArH), 6.99 (m, 1H, H1), 6.98 (m, 1H, ArH), 6.92 (d, 1H, ArH), 6.71 (d, 1H, ArH), 5.98 (m, 1H, H2),

3.97 (m, 1H, H3), 3.55 (q, 1H, CH), 3.71 (s, 3H, OCH₃), 1.89 (s, 3H, CH₃), 1.18 (d, 3H, CH₃);

MS (ESI) *m/z* 387 ([M+H]⁺);

Anal. calcd for C₂₀H₁₉N₂O₃S: C:62.16 H:4.96 N:7.25 Found: C:62.50 H:4.91 N:7.24.

EXAMPLE 51

Preparation of 4-[(7-fluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol

[0124] The title compound was prepared from the product of Example 50 using the procedure of Example 5 to yield light brown crystals, mp 191-193 °C.

¹H NMR (DMSO-d₆) δ 10.23 (bs, 1H, OH), 7.57 (dd, 1H, ArH), 7.41 (dd, 1H, ArH), 7.23 (dt, 1H, ArH), 7.01 (m, 1H, H1), 6.85 (m, 1H, ArH), 6.82 (d, 1H, ArH), 6.51 (d, 1H, ArH), 6.01 (m, 1H, H2), 5.97 (m, 1H, H3), 5.54 (q, 1H, CH), 1.84 (s, 3H, CH₃), 1.18 (d, 3H, CH₃);

MS (ESI) *m/z* 373 ([M+H]⁺);

Anal. calcd for C₁₉H₁₇N₂O₃S: C:61.28 H:4.60 N:7.52 Found: C:61.00 H:4.59 N:7.21.

EXAMPLE 52

Preparation of 4-[(7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol

Step 1: Preparation of 7-bromo-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0125] The product of Example 39 was treated with acetaldehyde according to the procedure of Example 3 to yield the intermediate product, which was used in the next step without further purification.

Step 2: Preparation of 4-[(7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol

[0126] The product from Step 1 was treated according to the procedure of Example 6 to yield the carbonate intermediate, which was hydrolyzed according to the procedure of Example 7 to give the title product as colorless crystals, mp 204-206 °C.

¹H NMR (DMSO-d₆): δ 10.62 (bs, 1H, OH), 7.76 (s, 1H, ArH), 7.58 (d, 1H, ArH), 7.50 (d, 1H, ArH), 7.02 (s, 1H, H1), 7.00 (d, 2H, ArH), 6.56 (d, 2H, ArH), 6.03 (m, 1H, H2), 5.93 (m, 1H, H3), 5.52 (q, 1H, CH), 1.17 (d, 3H, CH₃);

MS (ESI) *m/z* 419 ([M+H]⁺);

Anal. calcd for C₁₈H₁₅BrN₂O₃S: C:51.56 H:3.61 N:6.68 Found: C:50.99 H:3.54 N:6.51.

EXAMPLE 53

Preparation of 4-ethyl-7-fluoro-5-[(4-methoxy-3-methylphenyl)sulfonyl]-1-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0127] To a 25 ml flask was added 0.45 g (1.0 mmol) of the product from Example 18 in 10 ml of ethanol, to which was added 0.21 g of paraformaldehyde and 2 ml of a 2.0 M solution of dimethylamine in methanol. 3 ml of acetic acid was added and the mixture was heated for 16 hr. The solution was concentrated and the residue washed with sodium bicarbonate solution and extracted twice with ethyl acetate. After drying (MgSO₄) and concentrating the crude oil was passed through a plug of silica eluting with 80 % ethyl acetate hexane to recover 0.46 g of an oil. The resulting oil was dissolved in 10 ml of methylene chloride and excess (~1 ml) methyl iodide was added and stirred for 10 hr. At the end of this time the solution was concentrated and the solid triturated with ether and hexane to yield 0.56 g of the methyl iodide salt as an orange solid. This solid was dissolved in 10 ml of methanol and heated to reflux with 186 mg (3 mmol) of sodium cyano borohydride for 15 hr. At the end of this time the solution was concentrated and quenched with 5 ml of 2N HCl. Extracted the mixture twice with 15 ml of ethyl acetate then dried (MgSO₄) and concentrated. The residue was passed through a plug of silica gel, eluting with 20% ethyl acetate:hexane

and the resulting solid crystallized from the same to yield 0.24 g (64%) of the title product.

¹H NMR (DMSO-d₆) δ 7.57 - 7.43 (m, 2H, ArH and ArH), 7.22 (dt, 1H, ArH), 6.84 (d, 1H, ArH), 6.82 (s, 1H, ArH), 6.72 (d, 1H, ArH), 5.81 (d, 1H, H₂), 5.64 (d, 1H, H₃), 5.02 (t, 1H, CH), 3.74 (s, 3H, OCH₃), 2.00 (s, 3H, CH₃), 1.92 (s, 3H, CH₃), 1.27 (m, 2H, CH₂), 0.83 (t, 3H, CH₃);
MS (ESI) *m/z* 415 ([M+H]⁺).

EXAMPLE 54

Preparation of 4-[(4-ethyl-7-fluoro-1-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol

[0128] The title compound was prepared from the product of Example 53 using the procedure of Example 5 to yield crystals, mp 199-201 °C.

¹H NMR (DMSO-d₆) δ 10.25 (bs, 1H, OH), 7.49 (dt, 1H, ArH), 7.21 (dd, 1H, ArH), 7.22 (t, 1H, ArH), 6.74 (s, 1H, ArH), 6.65 (d, 1H, ArH), 6.51 (d, 1H, ArH), 5.82 (d, 1H, H₂), 5.64 (d, 1H, H₃), 5.02 (t, 1H, CH), 2.02 (s, 3H, CH₃), 1.87 (s, 3H, CH₃), 1.27 (m, 2H, CH₂), 0.83 (t, 3H, CH₃);
MS (ESI) *m/z* 401 ([M+H]⁺);
Anal. calcd for C₂₁H₂₁FN₂O₃S: C:62.98 H:5.29 N:7.00 Found: C:63.16 H:5.40 N:6.78.

EXAMPLE 55

Preparation of ethyl 4-[[4-ethyl-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxalin-5-(4H)-yl]sulfonyl]phenyl carbonate

Step 1: Preparation of Preparation of 4-ethyl-7-trifluoromethyl -4,5-dihydropyrrolo[1,2-a]quinoxaline

[0129] 4-Ethyl-7-trifluoromethyl -4,5-dihydropyrrolo[1,2-a]quinoxaline was prepared from 4-trifluoromethyl-2-nitro aniline according to the sequence of Example

1 and 2, and the resulting oil treated with propionaldehyde according to the procedure of Example 3 to yield a light orange oil, which was used in the next step without further characterization.

Step 2: Preparation of the title compound

[0130] The product from Step 1 was treated according to the procedure of Example 4 to yield the title product as light tan crystals mp 88-90 °C.

¹H NMR (DMSO-d₆) δ 7.84 (s, 1H, ArH), 7.78 (m, 2H, ArH), 7.22 (d, 2H, ArH), 7.10 (d, 2H, ArH), 7.08 (s, 1H, H1), 6.03 (m, 1H, H2), 5.96 (m, 1H, H3), 5.22 (t, 1H, CH), 4.21 (q, 2H, OCH₂), 1.38 (m, 2H, CH₂), 1.23 (t, 3H, CH₃), 0.88 (t, 3H, CH₃);

MS (ESI) *m/z* 495 ([M+H]⁺);

Anal. calcd for C₂₃H₂₁F₃N₂O₅S: C:55.87 H:4.28 N:5.67 Found: C:55.37 H:4.02 N:5.47.

EXAMPLE 56

Preparation of 4-{[4-ethyl-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxalin-5-(4H)-yl]sulfonyl}phenol

[0131] The title compound was prepared from the product of Example 55 according to the procedure of Example 7 to yield off white crystals, mp 181-183 °C.

¹H NMR (DMSO-d₆) δ 10.39 (bs, 1H, OH), 7.84 (s, 1H, ArH), 7.78 (m, 2H, ArH), 7.18 (s, 1H, H1), 6.98 (d, 2H, ArH), 6.52 (d, 2H, ArH), 6.08 (m, 1H, H2), 5.98 (m, 1H, H3), 5.20 (t, 1H, CH), 1.38 (m, 2H, CH₂), 0.85 (t, 3H, CH₃);

MS (ESI) *m/z* 421 ([M-H]⁻);

Anal. calcd for C₂₀H₁₇F₃N₂O₃S: C:56.87 H:4.06 N:6.63 Found: C:56.53 H:3.91 N:6.47.

EXAMPLE 57

Preparation of 4-ethyl-5-[(4-methoxy-3-methylphenyl)sulfonyl]-7-(trifluoromethyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0132] The title compound was prepared from the product of Example 55, Step 1 according to the procedure of Example 4 to yield off white crystals, mp 151-154 °C.

¹H NMR (DMSO-d₆): ¹H NMR (DMSO-d₆): δ 7.84 (s,1H,ArH), 7.74 (s,2H,ArH), 7.11 (m,1H, H1), 6.92 (s,1H,ArH), 6.91 (d,1H,ArH), 6.73 (d,1H,ArH), 6.04 (m,1H,H2), 6.01 (m,1H, H3), 5.23 (t,1H, CH), 3.72 (s,3H,OCH₃), 1.88 (s,3H,CH₃), 1.37 (m,2H,CH₂), 0.86 (t,3H,CH₃);

MS (ESI) *m/z* 451 ([M+H]⁺);

Anal. calcd for C₂₂H₂₁F₃N₂O₃S: C:58.66 H:4.70 N:6.22 Found: C:58.92 H:4.77 N:6.15.

EXAMPLE 58

Preparation of 4-{[4-ethyl-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxalin-5-(4H)-yl]sulfonyl}-2-methylphenol

[0133] The title compound was prepared from the product of Example 57 according to the procedure of Example 5 to yield tan crystals mp 177-179 °C.

¹H NMR (DMSO-d₆): δ 10.26 (s,1H,OH), 7.84 (s,1H,ArH), 7.74 (dd,2H,ArH), 7.15 (m,1H, H1), 6.83 (s,1H,ArH), 6.78 (d,1H,ArH), 6.49 (d,1H,ArH), 6.08 (m,1H,H2), 6.01 (m,1H, H3), 5.23 (t,1H, CH), 1.83 (s,3H,CH₃), 1.37 (m,2H,CH₂), 0.86 (t,3H,CH₃);

MS (ESI) *m/z* 435 ([M-H]⁻);

Anal. calcd for C₂₁H₁₉F₃N₂O₃S: C:57.79 H:4.39 N:6.42 Found: C:57.30 H:4.29 N:6.24.

EXAMPLE 59

Preparation of 4-ethyl-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-7-(trifluoromethyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0134] The title compound was prepared from the product of Example 57 using the procedure of Example 11, then treatment of the resulting intermediate according to the procedure of Example 5 to yield colorless crystals mp 194-196 °C.

¹H NMR (DMSO-d₆): ¹H NMR (DMSO-d₆): δ 10.44 (s, 1H, OH), 7.88 (m, 3H, ArH), 7.07 (d, 1H, H₂), 6.83 (s, 1H, ArH), 6.78 (d, 1H, ArH), 6.57 (d, 1H, ArH), 6.23 (d, 1H, H₃), 5.30 (t, 1H, CH), 1.91 (s, 3H, CH₃), 1.37 (m, 2H, CH₂), 0.85 (t, 3H, CH₃);

MS (ESI) *m/z* 460 ([M-H]⁻);

Anal. calcd for C₂₂H₁₈F₃N₃O₃S: C:57.26 H:3.93 N:9.11 Found: C:57.65 H:4.17 N:8.61.

EXAMPLE 60

Preparation of 5-[(3-chloro-4-methoxyphenyl)sulfonyl]-4-ethyl-7-(trifluoromethyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0135] The title compound was prepared from the product of Example 55, step 1 and 4-methoxy-3-chloro benzenesulfonyl chloride according to the procedure of Example 4 to yield light brown crystals, mp 126-129 °C.

¹H NMR (DMSO-d₆): ¹H NMR (DMSO-d₆): δ 7.84 (s, 1H, ArH), 7.78 (m, 2H, ArH), 7.16 (m, 1H, H₁), 7.12 (s, 1H, ArH), 7.01 (d, 1H, ArH), 6.94 (d, 1H, ArH), 6.04 (m, 1H, H₂), 6.02 (m, 1H, H₃), 5.24 (t, 1H, CH), 3.79 (s, 3H, OCH₃), 1.38 (m, 2H, CH₂), 0.84 (t, 3H, CH₃);

MS (ESI) *m/z* 471 ([M+H]⁺);

Anal. calcd for C₂₁H₁₈ClF₃N₂O₃S: C:53.56 H:3.85 N:5.95 Found: C:53.25 H:3.63 N:5.73.

EXAMPLE 61

Preparation of 2-chloro-4-{[4-ethyl-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxalin-5-(4H)-yl]sulfonyl}phenol

[0136] The title compound was prepared from the product of Example 60 using the procedure of Example 5 to yield light tan crystals, mp 169-171 °C.

^1H NMR (DMSO- d_6): ^1H NMR (DMSO- d_6): δ 11.29 (bs, 1H, OH), 7.84 (s, 1H, ArH), 7.78 (m, 2H, ArH), 7.18 (m, 1H, H1), 7.13 (s, 1H, ArH), 6.84 (d, 1H, ArH), 6.64 (d, 1H, ArH), 6.04 (m, 1H, H2), 6.02 (m, 1H, H3), 5.22 (t, 1H, CH), 1.38 (m, 2H, CH₂), 0.84 (t, 3H, CH₃);
MS (ESI) m/z 455 ([M-H]⁻);
Anal. calcd for C₂₀H₁₆ClF₃N₂O₃S: C:52.58 H:3.53 N:6.13 Found: C:52.49 H:3.72 N:5.63.

EXAMPLE 62

Preparation of 4-ethyl-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0137] The title compound was prepared from 2-nitro aniline according to the sequence of Example 1 and 2, and the resulting oil treated with propionaldehyde according to the procedure of Example 3 to yield a light orange oil, which was used in the next step without further characterization.

^1H NMR (DMSO- d_6): δ 7.40 (d, 1H, ArH), 7.38 (s, 1H, H1), 6.87 (t, 1H, ArH), 6.83 (t, 1H, ArH), 6.19 (t, 1H, H3), 6.01 (s, 1H, NH), 5.91 (s, 1H, H2), 4.29 (m, 1H, CH), 1.61-1.88 (m, 1H, CH), 0.93 (t, 3H, CH₃);
MS (ESI) m/z 197 ([M-H]⁻);
Anal. calcd for C₁₃H₁₄N₂: C:78.75 H:7.12 N:14.13 Found: C:78.63 H:7.16 N:13.94.

EXAMPLE 63

Preparation of 4-ethyl-5-[(4-methoxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0138] The title compound was prepared from the product of Example 62 using the procedure of Example 4 to yield light tan crystals, mp 124-126 °C.

^1H NMR (DMSO- d_6) δ 7.61 (d, 1H, ArH), 7.44 (d, 1H, ArH), 7.34 (t, 1H, ArH), 7.22 (t, 1H, ArH), 6.98 (m, 1H, H1), 6.90 (d, 1H, ArH), 6.86 (s, 1H, ArH), 6.67 (d, 1H, ArH),

6.00 (m, 1H, H₂), 5.96 (m, 1H, H₃), 5.19 (t, 1H, CH), 3.71 (s, 3H, OCH₃), 1.87 (s, 3H, CH₃), 1.37 (m, 2H, CH₂), 0.87 (t, 3H, CH₃);

MS (ESI) *m/z* 383 ([M+H]⁺);

Anal. calcd for C₂₁H₂₂N₂O₃S: C:65.95 H:5.80 N:7.32 Found: C:65.69 H:5.87 N:7.24.

EXAMPLE 64

Preparation of 4-[(4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol

[0139] The title compound was prepared from the product of Example 63 using the procedure of Example 5 to yield light tan crystals, mp 171-173 °C.

¹H NMR (DMSO-d₆) δ 10.15 (bs, 1H, OH), 7.61 (d, 1H, ArH), 7.44 (d, 1H, ArH), 7.33 (t, 1H, ArH), 7.20 (t, 1H, ArH), 7.00 (m, 1H, H₁), 6.80 (s, 1H, ArH), 6.75 (d, 1H, ArH), 6.43 (d, 1H, ArH), 6.01 (m, 1H, H₂), 5.96 (m, 1H, H₃), 5.19 (t, 1H, CH), 1.83 (s, 3H, CH₃), 1.36 (m, 2H, CH₂), 0.87 (t, 3H, CH₃);

MS (ESI) *m/z* 369 ([M+H]⁺);

Anal. calcd for C₂₀H₂₀N₂O₃S: C:65.20 H:5.47 N:7.60 Found: C:65.13 H:5.49 N:7.52.

EXAMPLE 65

Preparation of 4-ethyl-6-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0140] The title compound was prepared from 3-methyl-2-nitro aniline according to the sequence of Examples 1 and 2, and the resulting oil treated with propionaldehyde according to the procedure of Example 3 to yield a brown solid, mp 65-68 °C.

¹H NMR (DMSO-d₆) δ 7.36 (s, 1H, H₁), 7.28 (d, 1H, ArH), 6.80 (d, 2H, ArH), 6.58 (t, 1H, ArH), 6.19 (t, 1H, H₂), 5.90 (m, 1H, H₃), 5.30 (s, 1H, NH), 4.39 (t, 1H, CH), 2.18 (s, 3H, CH₃), 1.66 (m, 2H, CH₂), 0.85 (t, 3H, CH₃);

MS (ESI) *m/z* 213 ([M+H]⁺);

Anal. calcd for C₁₄H₁₆N₂: C:79.21 H:7.60 N:13.20 Found: C:79.23 H:7.52 N:13.22.

EXAMPLE 66**Preparation of ethyl 4-[(4-ethyl-6-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenyl carbonate**

[0141] The title compound was prepared from the product of Example 65 using the procedure of Example 6 to yield colorless crystals, mp 103.5-104.5 °C.

¹H NMR (DMSO-d₆) δ 7.36 (t, 1H, ArH), 7.24 (d, 1H, ArH), 7.17 (d, 1H, ArH), 7.10 (d, 2H, ArH), 7.03 (d, 2H, ArH), 6.88 (s, 1H, H1), 5.83 (t, 1H, H2), 5.80 (s, 1H, H3), 5.05 (t, 1H, CH), 4.21 (q, 1H, CH₂), 2.52 (s, 3H, CH₃), 1.23 (m, 2H, CH₂), 1.22 (t, 3H, CH₃), 0.87 (t, 3H, CH₃);

MS (ESI) *m/z* 441 ([M+H]⁺);

Anal. calcd for C₂₃H₂₄N₂O₅S: C:62.71 H:5.49 N:6.36 Found: C:62.45 H:5.19 N:6.31.

EXAMPLE 67**Preparation of 4-[(4-ethyl-6-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol**

[0142] The title compound was prepared from the product of Example 66 using the procedure of Example 7 to yield colorless crystals, mp 165-167 °C.

¹H NMR (DMSO-d₆) δ 10.23 (bs, 1H, OH), 7.27 (m, 2H, ArH), 7.14 (t, 1H, ArH), 6.91 (d, 2H, ArH), 6.85 (s, 1H, H1), 6.44 (d, 2H, ArH), 5.90 (t, 1H, H2), 5.80 (s, 1H, H3), 5.00 (s, 1H, H3), 2.48 (s, 3H, CH₃), 1.23 (m, 2H, CH₂), 0.91 (t, 3H, CH₃);

MS (ESI) *m/z* 369 ([M+H]⁺);

Anal. calcd for C₂₀H₂₀N₂O₃S: C:65.20 H:5.47 N:7.60 Found: C:65.10 H:5.27 N:7.52.

EXAMPLE 68**Preparation of 5-chloro-2-(*H*-pyrrol-1-yl)aniline**

[0143] The title compound was prepared from 4-chloro-2-nitro aniline according to the procedures of Example 1 and 2 to yield a dark yellow solid.

MS (ESI) m/z 193;

Anal. Calcd for $C_{10}H_9ClN_2$: C, 62.35; H, 4.71; N, 14.54. Found: C, 62.77; H, 4.80; N, 14.21.

EXAMPLE 68A

Preparation of 4-[(7-chloro-4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol

[0144] The title compound was prepared from the product of Example 68 according to the procedure of Example 3 and the resulting intermediate converted according to the procedure of Example 4. This intermediate was then converted following the procedure of Example 5 to yield colorless crystals, mp 170-172 °C.

^1H NMR ($DMSO-d_6$) δ 10.22 (bs, 1H, OH) 7.60 (s, 1H, ArH), 7.56 (d, 1H, ArH), 7.41 (d, 2H, ArH), 7.03 (s, 1H, H1), 6.83 (s, 1H, ArH), 6.81 (d, 1H, ArH), 6.50 (d, 1H, ArH), 6.02 (t, 1H, H2), 5.97 (s, 1H, H3), 5.19 (s, 1H, H3), 1.84 (s, 3H, CH_3), 1.37 (m, 2H, CH_2), 0.84 (t, 3H, CH_3);

MS (ESI) m/z 403 ($[M+H]^+$);

Anal. calcd for $C_{20}H_{19}ClN_2O_3S$: C:59.62 H:4.75 N:6.95 Found: C:59.51 H:4.71 N:6.71.

EXAMPLE 69

Preparation of 4-chloro-2-(*H*-pyrrol-1-yl)aniline

[0145] The title compound was prepared from 5-chloro-2-nitro aniline according to the procedures of Example 1 and 2 to yield a dark yellow solid, mp 89-91 °C.

¹H NMR (DMSO-d₆): δ 7.16 (d, 1H, ArH), 7.07 (s, 1H, ArH), 6.91 (t, 2H, PyrH), 6.83 (d, 1H, ArH), 6.22 (t, 2H, PyrH), 4.96 (bs, 2H, NH₂);

MS (ESI) *m/z* 193 ([M+H]⁺);

Anal. calcd for C₁₀H₉ClN₂: C:62.35 H:4.71 N:14.54 Found: C:62.55 H:4.78 N:14.29.

EXAMPLE 70

Preparation of 4-[(8-chloro-4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenyl ethyl carbonate

[0146] The title compound was prepared starting from the product of Example 69 according to the procedure of Example 3 and the resulting product converted according to Example 6 to yield colorless crystals, mp 117-119 °C.

¹H NMR (DMSO-d₆): δ 7.72 (s, 1H, ArH), 7.64 (d, 1H, ArH), 7.32 (d, 1H, ArH), 7.22 (d, 2H, ArH), 7.10 (d, 2H, ArH), 7.03 (s, 1H, H₁), 5.98 (m, 1H, H₂), 5.93 (m, 1H, H₃), 5.20 (t, 1H, CH), 4.21 (q, 2H, OCH₂3), 1.38 (m, 2H, CH₂), 1.22 (t, 3H, CH₃), 0.88 (t, 3H, CH₃);

MS (ESI) *m/z* 461 ([M+H]⁺);

Anal. calcd for C₂₂H₂₁ClN₂O₅S: C:57.33 H:4.59 N:6.08 Found: C:57.03 H:4.50 N:5.99.

EXAMPLE 71

Preparation of 4-[(8-chloro-4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol

[0147] The title compound was prepared from the product of Example 70 using the procedure of Example 7 to yield colorless crystals, mp 192-194 °C.

¹H NMR (DMSO-d₆): δ 10.31 (bs, 1H, OH), 7.70 (s, 1H, ArH), 7.61 (d, 1H, ArH), 7.24 (d, 1H, ArH), 7.12 (s, 1H, H₁), 6.98 (d, 2H, ArH), 6.52 (d, 2H, ArH), 6.03 (s, 1H, H₂), 5.95 (s, 1H, H₃), 5.18 (t, 1H, CH), 1.38 (m, 2H, CH₂), 0.82 (t, 3H, CH₃);

MS (ESI) *m/z* 387 ([M-H]⁻);

Anal. calcd for $C_{19}H_{17}ClN_2O_3S$: C:58.69 H:4.41 N:7.20 Found: C:58.48 H:4.17 N:6.91.

EXAMPLE 72

Preparation of 4-fluoro-5-methoxy-2-nitroaniline

[0148] To an ice cooled 100 ml round bottom flask charged with 30 ml of methanol was added 0.40 g (17.4 mmol) of sodium. After the solution was homogeneous, 1g (5.71 mmol) of 4,5 difluoro, 2-nitro aniline was added. The solution turns a bright yellow and a precipitate slowly forms. After 1 hour the solution was concentrated and 2N HCl added to the residue. The mixture was extracted with ethyl acetate (3 X 30 ml) and the organic layers combined, dried ($MgSO_4$) and concentrated to yield a yellow solid.

^1H NMR ($CDCl_3$): δ 7.83 (d, 1H, ArH), 6.20 (d, 1H, ArH), 6.18 (bs, 2H, NH_2), 3.92 (s, 3H, CH_3);

MS (ESI) m/z 185 ($[M-H]^-$);

Anal. calcd for $C_7H_7FN_2O_3$: C:45.17 H:3.79 N:15.05 Found: C:45.77 H:3.92 N:14.05.

EXAMPLE 73

Preparation of 4-ethyl-7-fluoro-8-methoxy-5-[(4-methoxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline

Step 1: Preparation of Preparation of 4-ethyl-7-fluoro-8-methoxy-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0149] 4-Ethyl-7-trifluoromethyl -4,5-dihydropyrrolo[1,2-a]quinoxaline was prepared the product of Example 72 according to the sequence of Examples 1 and 2, and the resulting solid treated with propionaldehyde according to the procedure of Example 3 to yield a light orange oil, which was used in the next step without further characterization.

Step 2: Preparation of the title compound

[0150] The product from Step 1 was treated according to the procedure of Example 4 to yield the title product as light yellow crystals mp 130-132 °C.

¹H NMR (DMSO-d₆) δ 7.41 (d,1H,ArH), 7.22 (d,1H,ArH), 7.05 (s,1H, H1), 6.96 (dd,1H,ArH), 6.92 (s,1H,ArH), 6.69 (d,1H,ArH), 6.00 (t,1H,H2), 5.97 (s,1H, H3), 5.17 (t,1H, CH), 3.89 (s,3H,OCH₃), 3.72 (s,3H,OCH₃), 1.92 (2,3H,CH₃) 1.36 (m,2H,CH₂), 0.84 (t,3H,CH₃);

MS (ESI) *m/z* 431 ([M+H]⁺);

Anal. calcd for C₂₂H₂₃FN₂O₄S: C:61.38 H:5.39 N:6.51 Found: C:61.14 H:5.33 N:6.33.

EXAMPLE 74

Preparation of 4-ethyl-7-fluoro-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxalin-8-ol

[0151] The title compound was prepared from the product of Example 73 following the procedure of Example 5 but using 4 equivalents of boron trichloride to yield light tan crystals, mp 194-196 °C.

¹H NMR (DMSO-d₆) δ 10.24 and 10.20 (bs, 2H,OH), 7.36 (d,1H,ArH), 6.95 (d,1H,ArH), 6.83 (s,1H, H1), 6.81 (s,1H,H1), 6.78 (dd,1H,ArH), 6.49 (d,1H,ArH), 5.98 (t,1H,H2), 5.94 (s,1H, H3), 5.17 (t,1H, CH), 1.92 (s,3H,CH₃) 1.36 (m,2H,CH₂), 0.84 (t,3H,CH₃);

MS (ESI) *m/z* 403 ([M+H]⁺);

Anal. calcd for C₂₀H₁₉FN₂O₄S: C:59.69 H:4.76 N:6.96 Found: C:59.02 H:4.67 N:6.73.

EXAMPLE 75

Preparation of 4-[(4-ethyl-7-fluoro-8-methoxypyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol

[0152] The title compound was prepared from the product of Example 73, step 1 according to the procedure of Example 6 and the resulting product hydrolyzed according to the procedure of Example 7 to yield the title product, mp 203-205 °C.

¹H NMR (DMSO-d₆) δ 10.24 (bs, 1H, OH), 7.41 (d, 1H, ArH), 7.25 (d, 1H, ArH), 7.11 (s, 1H, H1), 6.98 (d, 2H, ArH), 6.51 (d, 2H, ArH), 5.99 (t, 1H, H2), 5.90 (s, 1H, H3), 5.10 (t, 1H, CH), 1.37 (m, 2H, CH₂), 0.84 (t, 3H, CH₃);

MS (ESI) *m/z* 403 ([M+H]⁺);

Anal. calcd for C₂₀H₁₉FN₂O₄S: C:59.69 H:4.76 N:6.96 Found: C:59.46 H:4.75

N:6.80.

EXAMPLE 76

Preparation of 4-[[[(4*S*)-7-bromo-4-ethylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl]phenyl ethyl carbonate and 4-[[[(4*R*)-7-bromo-4-ethylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl]phenyl ethyl carbonate

[0153] The enantiomeric mixture from Example 43 was separated on a Chiracel OJ column eluting with 9:1 hexane:isopropanol at 0.8 ml/min.

Fraction 1:

[0154] The solid so obtained was crystallized from ethyl acetate:hexane to give 4-[[[(4*S*)-7-bromo-4-ethylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl]phenyl ethyl carbonate, mp 137-139 °C;

[α]_D²⁵ = -83.16° (c = 1% SOLUTION, DMSO);

¹H NMR (DMSO-d₆): δ 7.80 (s, 1H, ArH), 7.61 (d, 1H, ArH), 7.52 (d, 1H, ArH), 7.23 (d, 2H, ArH), 7.20 (d, 2H, ArH), 6.97 (d, 1H, H1), 5.98 (m, 1H, H2), 5.93 (d, 1H, H3), 5.20 (t, 1H, CH), 4.21 (q, 2H, OCH₂), 1.37 (m, 2H, CH₂), 1.23 (t, 3H, CH₃), 0.86 (t, 3H, CH₃);

MS (ESI) *m/z* 505 ([M+H]⁺);

Anal. calcd for C₂₂H₂₁BrN₂O₅S: C:52.29 H:4.19 N:5.54 Found: C:52.54 H:4.15

N:5.43.

Fraction 2:

[0155] The solid so obtained was crystallized from ethyl acetate:hexane to give 4-{[(4*R*)-7-bromo-4-ethylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}phenyl ethyl carbonate, mp 137-139 °C;

$[\alpha]_D^{25} = +84.39^\circ$ (c = 1% SOLUTION, DMSO);

^1H NMR (DMSO- d_6): δ 7.80 (s, 1H, ArH), 7.61 (d, 1H, ArH), 7.52 (d, 1H, ArH), 7.23 (d, 2H, ArH), 7.20 (d, 2H, ArH), 6.97 (d, 1H, H1), 5.98 (m, 1H, H2), 5.93 (d, 1H, H3), 5.20 (t, 1H, CH), 4.21 (q, 2H, OCH₂3), 1.37 (m, 2H, CH₂), 1.23 (t, 3H, CH₃), 0.86 (t, 3H, CH₃);

MS (ESI) m/z 505 ([M+H]⁺);

Anal. calcd for C₂₂H₂₁BrN₂O₅S: C:52.29 H:4.19 N:5.54 Found: C:52.29 H:4.23

N:5.38.

EXAMPLE 77

Preparation of 4-{[(4*S*)-7-bromo-4-ethylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}phenol

[0156] The title compound was obtained from the product of Example 76, fraction 1 according to the procedure of Example 7 and crystallized from ethyl acetate:hexane to yield crystals mp 187-189 °C.

$[\alpha]_D^{25} = -81.21^\circ$ (c = 1% SOLUTION, DMSO);

^1H NMR (DMSO- d_6): δ 10.31 (bs, 1H, OH), 7.77 (s, 1H, ArH), 7.54 (d, 1H, ArH), 7.51 (d, 1H, ArH), 7.07 (m, 1H, H1), 7.00 (d, 2H, ArH), 6.51 (d, 2H, ArH), 6.02 (d, 1H, H3), 5.97 (m, 1H, H2), 5.18 (t, 1H, CH), 1.37 (m, 2H, CH₂), 0.86 (t, 3H, CH₃);

MS (ESI) m/z 433 ([M+H]⁺);

Anal. calcd for C₁₉H₁₇BrN₂O₃S: C:52.67 H:3.95 N:6.46 Found: C:52.63 H:3.90

N:6.29.

EXAMPLE 78

Preparation of 4-{[(4*R*)-7-bromo-4-ethylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}phenol

[0157] The title compound was obtained from the product of Example 76, fraction 2 according to the procedure of Example 7 and crystallized from ethyl acetate:hexane to yield crystals mp 187-189 °C.

$[\alpha]_D^{25} = +72.16^\circ$ (c = 1% SOLUTION, DMSO);

^1H NMR (DMSO- d_6): δ 10.31 (bs, 1H, OH), 7.77 (s, 1H, ArH), 7.54 (d, 1H, ArH), 7.51 (d, 1H, ArH), 7.07 (m, 1H, H1), 7.00 (d, 2H, ArH), 6.51 (d, 2H, ArH), 6.02 (d, 1H, H3), 5.97 (m, 1H, H2), 5.18 (t, 1H, CH), 1.37 (m, 2H, CH₂), 0.86 (t, 3H, CH₃);

MS (ESI) m/z 433 ([M+H]⁺);

Anal. calcd for C₁₉H₁₇BrN₂O₃S: C:52.67 H:3.95 N:6.46 Found: C:52.66 H:3.87 N:6.38.

EXAMPLE 79

Preparation of 4-[(7-bromo-1-cyano-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl]phenyl ethyl carbonate

[0158] The title compound was obtained from the product of Example 43 according to the procedure of Example 11 and crystallized from ethyl acetate:hexane to yield crystals mp 153-154 °C;

^1H NMR (400 MHz, DMSO- D_6) δ ppm 0.9 (t, $J=7.3$ Hz, 3 H) 1.3 (t, $J=7.2$ Hz, 4 H) 1.4 (s, 1 H) 2.5 (s, 4 H) 3.3 (s, 3 H) 4.2 (q, $J=7.0$ Hz, 2 H) 5.3 (s, 1 H) 6.2 (d, $J=4.4$ Hz, 1 H) 7.0 (d, $J=3.8$ Hz, 1 H) 7.2 (m, 2 H) 7.3 (m, 2 H) 7.7 (d, $J=8.7$ Hz, 1 H) 7.8 (m, 1 H) 7.9 (d, $J=2.3$ Hz, 1 H)

Anal. calcd for C₂₃H₂₀BrN₃O₅S: C:52.08 H:3.80 N:7.92 Found: C:52.20 H:3.60 N:7.80.

EXAMPLE 80

Preparation of 7-bromo-4-ethyl-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0159] The title compound was obtained from the product of Example 79 according to the procedure of Example 7 and crystallized from ethyl acetate:hexane to yield crystals mp 190-192 °C.

MS (ESI) m/z 456/458 ($[M-H]^-$);

Anal. calcd for $C_{20}H_{16}BrN_3O_3S$: C:52.41 H:3.52 N:9.17 Found: C:52.60 H:3.45 N:8.87.

EXAMPLE 81

Preparation of 7-bromo-4-ethyl-5-[(3-methoxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0160] The title compound was obtained from the product of Example 42 according to the procedure of Example 4 using 3-methoxy benzenesulfonyl chloride and crystallized from ethyl acetate:hexane to yield crystals mp 117-118 °C.

MS (ESI) m/z 447/449 ($[M+H]^+$);

Anal. calcd for $C_{20}H_{19}BrN_2O_3S$: C:53.70 H:4.28 N:6.26 Found: C:53.76 H:4.18 N:6.21.

EXAMPLE 82

Preparation of 3-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl]phenol

[0161] The title compound was obtained from the product of Example 81 according to the procedure of Example 5 and crystallized from ethyl acetate:hexane to yield crystals

mp 176-178 °C;

MS (ESI) m/z 433/435 ($[M+H]^+$);

Anal. calcd for $C_{19}H_{17}BrN_2O_3S$: C:52.67 H:3.95 N:6.46 Found: C:52.36 H:3.64 N:6.11.

EXAMPLE 83

Preparation of 4-ethyl-7,8-difluoro-5-[(3-methoxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0162] The title compound was obtained from the product of Example 3 according to the procedure of Example 4 using 3-methoxy benzenesulfonyl chloride and crystallized from ethyl acetate:hexane to yield crystals mp 87-89 °C; MS (ESI) m/z 405 ($[M+H]^+$); Anal. calcd for $C_{20}H_{18}F_2N_2O_3S$: C:59.40 H:4.49 N:6.93 Found: C:59.53 H:4.34 N:6.79.

EXAMPLE 84

Preparation of 4-ethyl-7,8-difluoro-5-[(3-methoxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0163] The title compound was obtained from the product of Example 83 according to the procedure of Example 11 and crystallized from ethyl acetate:hexane to yield crystals mp 139-141 °C. MS (ESI) m/z 430 ($[M+H]^+$); Anal. calcd for $C_{21}H_{17}F_2N_3O_3S$: C:58.73 H:3.99 N:9.78 Found: C:58.89 H:4.07 N:9.50.

EXAMPLE 85

Preparation of 4-ethyl-7,8-difluoro-5-[(3-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0164] The title compound was obtained from the product of Example 84 according to the procedure of Example 5 and crystallized from ethyl acetate:hexane to yield crystals, mp 179-182 °C; MS (ESI) m/z 414 ($[M-H]^-$); Anal. calcd for $C_{20}H_{15}F_2N_3O_3S$: C:57.83 H:3.64 N:10.12 Found: C:57.21 H:3.55 N:9.81.

EXAMPLE 86

Preparation of 4-ethyl-7-fluoro-5-[(3-methoxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0165] The title compound was obtained from the product of Example 17 according to the procedure of Example 4 using 3-methoxy benzenesulfonyl chloride and crystallized from ethyl acetate:hexane to yield crystals, mp 90-91 °C.

MS (ESI) m/z 387 ($[M+H]^+$);

Anal. calcd for $C_{20}H_{19}FN_2O_3S$: C:62.16 H:4.96 N:7.25 Found: C:61.87 H:4.54 N:6.93.

EXAMPLE 87

Preparation of 3-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl]phenol

[0166] The title compound was obtained from the product of Example 86 according to the procedure of Example 5 and crystallized from ethyl acetate:hexane to yield crystals, mp 153-154 °C.

MS (ESI) m/z 373 ($[M+H]^+$).

EXAMPLE 88

Preparation of 4-[(4S)-7-bromo-1-cyano-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl}phenyl ethyl carbonate

[0167] The title compound was obtained from the product of Example 76, fraction 1 according to the procedure of Example 11 and crystallized from ethyl acetate:hexane to yield crystals, mp 185-187 °C.

$[\alpha]_D^{25} = -146^\circ$ ($c = 0.005\text{G/ML}$, DMSO);

Anal. calcd for $C_{23}H_{20}BrN_3O_5S$: C:52.08 H:3.80 N:7.92 Found: C:52.22 H:3.77 N:7.65.

EXAMPLE 89

Preparation of (4S)-7-bromo-4-ethyl-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0168] The title compound was obtained from the product of Example 88 according to the procedure of Example 7 and crystallized from ethyl acetate:hexane to yield crystals, mp 189-191 °C.

$[\alpha]_D^{25} = -112^\circ$ (c = 0.005G/ML, DMSO);

MS (ESI) m/z [M-H]⁻ = (456/458);

Anal. calcd for C₂₀H₁₆BrN₃O₃S: C:52.41 H:3.52 N:9.17 Found: C:52.61 H:3.80 N:8.97.

EXAMPLE 90

Preparation of 4-([(4R)-7-bromo-1-cyano-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl}phenyl ethyl carbonate

[0169] The title compound was obtained from the product of Example 76, fraction 2 according to the procedure of Example 11 and crystallized from ethyl acetate:hexane to yield crystals, mp 182-184 °C.

$[\alpha]_D^{25} = +106^\circ$ (c = 0.005G/ML, DMSO);

MS (ESI) m/z [M+H]⁺ (530/532);

Anal. calcd for C₂₃H₂₀BrN₃O₅S: C:52.08 H:3.80 N:7.92 Found: C:52.12 H:3.68 N:7.74

EXAMPLE 91

Preparation of (4R)-7-bromo-4-ethyl-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0170] The title compound was obtained from the product of Example 90 according to the procedure of Example 7 and crystallized from ethyl acetate:hexane to yield crystals, mp 182-185 °C;

MS (ESI) m/z [M-H]⁻ (456/458);

Anal. calcd for C₂₀H₁₆BrN₃O₃S: C:52.41 H:3.52 N:9.17 Found: C:52.16 H:3.51 N:8.89

EXAMPLE 92**Preparation of 4-[(1-cyano-4-ethyl-7,8-difluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl]phenyl ethyl carbonate**

[0171] The title compound was obtained from the product of Example 6 according to the procedure of Example 11 and crystallized from ethyl acetate:hexane to yield crystals, mp 148-150 °C.

MS (ESI) m/z 488 ($[M+H]^+$);

Anal. calcd for $C_{23}H_{19}F_2N_3O_5S$: C:56.67 H:3.93 N:8.62 Found: C:56.10 H:4.25 N:9.05.

EXAMPLE 93**Preparation of 4-ethyl-7,8-difluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile**

[0172] The title compound was obtained from the product of Example 92 according to the procedure of Example 7 and crystallized from ethyl acetate:hexane to yield crystals, mp 205-205 °C.

MS (ESI) m/z 414 ($[M-H]^-$);

Anal. calcd for $C_{20}H_{15}F_2N_3O_3S$: C:57.83 H:3.64 N:10.12 Found: C:57.44 H:3.31 N:9.65

EXAMPLE 94**Preparation of 3,4,5-trifluoro-2-(1H-pyrrol-1-yl)aniline**

[0173] 3,4,5-Trifluoro-2-(1H-pyrrol-1-yl)aniline was prepared from 2,3,4-trifluoro-6-nitro aniline according to the procedure of Example 1, and the isolated solid converted to the title product according to the procedure of Example 2. The product was isolated as a light yellow solid, mp 102-104 °C.

MS (ESI) m/z 213;

Anal. Calcd for $C_{10}H_7F_3N_2$: C, 56.61; H, 3.33; N, 13.20. Found: C, 56.72; H, 3.15; N, 13.02.

EXAMPLE 95

Preparation of 4-ethyl-7,8,9-trifluoro-4,5-dihydropyrrolo[1,2-a]quinoxaline

[0174] The title compound was prepared from the product of Example 94 according to the procedure of Example 3, mp 69-70 °C.

MS (ESI) m/z 253;

Anal. Calcd for $C_{13}H_{11}F_3N_2$: C, 61.90; H, 4.40; N, 11.11. Found: C, 61.85; H, 4.48; N, 11.04.

EXAMPLE 96

Preparation of ethyl 4-[(4-ethyl-7,8,9-trifluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl]phenyl carbonate

[0175] The title compound was prepared from the product of Example 95 according to the procedure of Example 6 to yield light tan crystals, mp 131-132 °C.

MS (ESI) m/z 481;

Anal. Calcd for $C_{22}H_{19}F_3N_2O_5S$: C, 55.00; H, 3.99; N, 5.83. Found: C, 55.10; H, 4.04; N, 5.64

EXAMPLE 97

Isolation 4-[(4*R*)-4-ethyl-7,8,9-trifluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl)sulfonyl]phenol and 4-[(4*S*)-4-ethyl-7,8,9-trifluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl)sulfonyl]phenol

[0176] The enantiomeric mixture of carbonate intermediate from Example 96 was separated on a Chiracel OJ column eluting with 9:1 hexane:isopropanol at 0.8 ml/min. The resulting carbonates were hydrolyzed with 2N NaOH and crystallized as before to isolate the title products.

4-{[(4*R*)-4-ethyl-7,8,9-trifluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}phenol

mp 155-156 °C;

$[\alpha]_D^{25} = -100.5^\circ$ ($c = 0.0056\text{G/ML}$, DMSO);

MS (ESI) m/z 409 ($[M+H]^+$);

Anal. calcd for $C_{19}H_{15}F_3N_2O_3S$: C:55.88 H:3.70 N:6.86 Found: C:55.81 H:3.70 N:6.76.

4-{[(4*S*)-4-ethyl-7,8,9-trifluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}phenol

mp 155-156 °C;

$[\alpha]_D^{25} = +123^\circ$ ($c = 0.0064\text{G/ML}$, DMSO);

MS (ESI) m/z 409 ($[M+H]^+$);

Anal. calcd for $C_{19}H_{15}F_3N_2O_3S$: C:55.88 H:3.70 N:6.86 Found: C:55.71 H:3.70 N:6.70.

EXAMPLE 98

Preparation of 4-[(4-ethyl-7,8,9-trifluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl)sulfonyl]phenol

[0177] The title compound was obtained from the product of Example 96 according to the procedure of Example 7 and crystallized from ethyl acetate:hexane to yield crystals, mp 175-176 °C.

MS (ESI) m/z 409 ($[M+H]^+$);

Anal. calcd for $C_{19}H_{15}F_3N_2O_3S$: C:55.88 H:3.70 N:6.86 Found: C:55.90 H:3.74 N:6.68

EXAMPLE 99

Preparation of 4-ethyl-7,8,9-trifluoro-5-[(3-methoxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-*a*]quinoxaline

[0178] The title compound was obtained from the product of Example 95 according to the procedure of Example 4 using 3-methoxy benzenesulfonyl chloride

and crystallized from ethyl acetate:hexane to yield crystals, mp 91-92 °C.

MS (ESI) m/z 423 ($[M+H]^+$);

Anal. calcd for $C_{20}H_{17}F_3N_2O_3S$: C:56.87 H:4.06 N:6.63 Found: C:56.88 H:4.03 N:6.48.

EXAMPLE 100

Preparation of 3-[(4-ethyl-7,8,9-trifluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl]phenol

[0179] The title compound was obtained from the product of Example 99 according to the procedure of Example 5 and crystallized from ethyl acetate:hexane to yield crystals,
mp 143-145 °C.

MS (ESI) m/z 407 ($[M-H]^-$);

Anal. calcd for $C_{19}H_{15}F_3N_2O_3S$: C:55.88 H:3.70 N:6.86 Found: C:56.01 H:3.77 N:6.76.

EXAMPLE 101

Isolation of (4S)-4-ethyl-7,8-difluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile and (4R)-4-ethyl-7,8-difluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0180] The enantiomeric mixture of carbonate intermediate from Example 92 was separated on a Chiracel OJ column eluting with 9:1 hexane:isopropanol at 0.8 ml/min.

(4S)-4-ethyl-7,8-difluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

mp 191-192 °C;

$[\alpha]_D^{25} = +57^\circ$ ($c = 0.0052$ G/ML, DMSO);

MS (ESI) m/z 416 ($[M+H]^+$);

Anal. calcd for $C_{20}H_{15}F_2N_3O_3S$: C:57.83 H:3.64 N:10.12 Found: C:57.82 H:3.46 N:9.63.

(4*R*)-4-ethyl-7,8-difluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-*a*]quinoxaline-1-carbonitrile

mp 194-195 °C;

$[\alpha]_D^{25} = -40^\circ$ ($c = 0.005$ G/ML, DMSO);

MS (ESI) m/z 416 ($[M+H]^+$);

Anal. calcd for $C_{20}H_{15}F_2N_3O_3S$: C:57.83 H:3.64 N:10.12 Found: C:57.90 H:3.77 N:9.58.

EXAMPLE 102

Isolation of 4-{[(4*S*)-4-ethyl-7,8-difluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}-2-methylphenol and 4-{[(4*R*)-4-ethyl-7,8-difluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}-2-methylphenol

[0181] The enantiomeric mixture of carbonate intermediate from Example 5 was separated on a Chiracel OJ column eluting with 9:1 hexane:isopropanol at 0.8 ml/min.

4-{[(4*S*)-4-ethyl-7,8-difluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}-2-methylphenol

mp 161-163 °C;

$[\alpha]_D^{25} = +112^\circ$ ($c = 0.0084$ G/ML, MeOH);

MS (ESI) m/z 405 ($[M+H]^+$);

Anal. calcd for $C_{20}H_{18}F_2N_2O_3S$: C:59.40 H:4.49 N:6.93 Found: C:59.24 H:4.35 N:6.76;

4-{[(4*R*)-4-ethyl-7,8-difluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}-2-methylphenol

mp 160-162 °C;

$[\alpha]_D^{25} = -116^\circ$ ($c = 0.0091$ G/ML, MeOH);

MS (ESI) m/z 405 ($[M+H]^+$);

Anal. calcd for $C_{20}H_{18}F_2N_2O_3S$: C:59.40 H:4.49 N:6.93 Found: C:59.32 H:4.37 N:6.79.

EXAMPLE 103

Preparation of 4-{[(4*S*)-1-cyano-4-ethyl-7,8-difluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}-2-methylphenyl sulfamate

[0182] 0.25 g (0.58 mmol) of the product from Example 11B was stirred in 20 mL of dimethyl acetamide at 0 °C. 0.27 g (2.3 mmol) of freshly prepared $ClSO_2NC$ was added. The solution was warmed to room temperature and stirred for 2 days. The reaction was partitioned between ethyl acetate and water, and the organic layer separated and dried with $MgSO_4$ and concentrated. A small amount of methanol and water was added to the residue to induce precipitation. The solid was removed by filtration and dried to yield 0.21 g of product, mp 204-207 °C.

$[\alpha]_D^{25} = +35^\circ$ (c = 0.005G/ML, DMSO);

MS (ESI) m/z 509 ($[M+H]^+$);

Anal. calcd for $C_{21}H_{18}F_2N_4O_5S_2$: C:49.60 H:3.57 N:11.02 Found: C:49.78 H:3.46 N:10.87.

EXAMPLE 104

Preparation of 4-{[(4*S*)-1-cyano-4-ethyl-7,8-difluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]sulfonyl}phenyl sulfamate

[0183] The title compound was prepared from (4*S*)-4-ethyl-7,8-difluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-*a*]quinoxaline-1-carbonitrile (see Example 101) according to the procedure of Example 103 to yield colorless crystals, mp 196-201 °C.

$[\alpha]_D^{25} = +25^\circ$ (c = 0.0054G/ML, DMSO);

MS (ESI) m/z 493 ($[M-H]^-$);

Anal. calcd for $C_{20}H_{16}F_2N_4O_5S_2$: C:48.58 H:3.26 N:11.33 Found: C:48.69 H:3.31 N:10.99

EXAMPLE 105

Preparation of 4-{4-ethyl-7,8-difluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl}sulfonyl}phenyl sulfamate

[0184] The title compound was prepared from the product of Example 7 according to the procedure of Example 103 to yield colorless crystals, mp 150-151 °C.

MS (ESI) m/z 470 ($[M+H]^+$);

Anal. calcd for $C_{19}H_{17}F_2N_3O_5S_2$: C:48.61 H:3.65 N:8.95 Found: C:49.10 H:3.55 N:8.69

EXAMPLE 106

Preparation of 3-[(7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5(4*H*)-yl)carbonyl]phenol

[0185] Step 1: 7-Bromo-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline was prepared from 5-bromo-2-(1*H*-pyrrolo-1-yl)-aniline (See Example 39) and acetaldehyde according to the procedure of Example 3 to yield 7-bromo-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline as off-white crystals. HRMS: calcd for $C_{12}H_{11}BrN_2$, 262.0106; found (ESI+), 263.01735; Anal. Calcd for $C_{12}H_{11}BrN_2$: C, 54.77; H, 4.21; N, 10.65. Found: C, 54.65; H, 4.01; N, 10.62.

[0186] Step 2: A solution of 7-bromo-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline (225 mg, 0.86 mmol) in methylene chloride (4 mL), under nitrogen, was treated with *m*-anisoyl chloride (219 mg, 1.28 mmol) followed by triethyl amine (0.24 mL, 1.72 mmol). The reaction was stirred at 25 °C for 15 h, after which time the reaction was washed with a saturated aqueous solution of sodium bicarbonate, and the reaction mixture was concentrated *in vacuo*. The product was purified via Biotage Horizon® (25S, silica, gradient from 5 % EtOAc/hexane to 40% EtOAc/hexane) to yield 287 mg (84%) of 7-bromo-5-(3-methoxybenzoyl)-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline as a white foam. MS (ESI) *m/z* 397/399 ([M+H]⁺); HRMS: calcd for C₂₀H₁₇BrN₂O₂, 396.0473; found (ESI+), 397.05389.

[0187] Step 3: A solution of 7-bromo-5-(3-methoxybenzoyl)-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline (240 mg, 0.60 mmol) and tetrabutylammonium iodide (558 mg, 1.51 mmol) in methylene chloride (5 mL) at -78 °C, under nitrogen, was treated with a 1 M solution of boron trichloride in methylene chloride (1.51 mL, 1.51 mmol). The reaction was then warmed to 0 °C and was stirred for 4 h. Ice and water was added to the reaction which was stirred to 30 min. The reaction was then diluted with a saturated aqueous solution of sodium bicarbonate, and the product was extracted with methylene chloride (3 x 25 mL). The product was purified via Biotage Horizon® (25S, silica, gradient from 15 % EtOAc/hexane to 60% EtOAc/hexane) to yield 196 mg (85%) of 3-[(7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5(4*H*)-yl)carbonyl]phenol as a white foam. MS (ESI) *m/z* 383/385 ([M+H]⁺); MS (ESI) *m/z* 381/383 ([M-H]⁻); HRMS: calcd for C₁₉H₁₅BrN₂O₂, 382.0317; found (ESI+), 383.03805.

EXAMPLE 107

Isolation of 3-[(4*S*)-7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl]phenol and 3-[(4*R*)-7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl]phenol

[0188] The enantiomers of 3-[(7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5(4*H*)-yl)carbonyl]phenol were separated via chiral HPLC [Pirkle Covalent Column (S,S), 50% ethanol/hexane] to yield 3-[(4*S*)-7-bromo-4-methylpyrrolo[1,2-

3-[[[(4*R*)-7-bromo-4-methylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl]phenol, $[\alpha]_D^{25} = +111^\circ$ ($c = 0.0067\text{G/ML}$, CHCl_3); MS (ESI) m/z 383/385 ($[\text{M}+\text{H}]^+$); MS (ESI) m/z 381/383 ($[\text{M}-\text{H}]^-$); HRMS: calcd for $\text{C}_{19}\text{H}_{15}\text{BrN}_2\text{O}_2$, 382.0317; found (ESI+), 383.03822; and 3-[[[(4*R*)-7-bromo-4-methylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl]phenol, $[\alpha]_D^{25} = -146^\circ$ ($c = 0.0067\text{G/ML}$, CHCl_3); MS (ESI) m/z 383/385 ($[\text{M}+\text{H}]^+$); MS (ESI) m/z 381/383 ($[\text{M}-\text{H}]^-$); HRMS: calcd for $\text{C}_{19}\text{H}_{15}\text{BrN}_2\text{O}_2$, 382.0317; found (ESI+), 383.03814.

EXAMPLE 108

Preparation of 4-[(7-bromo-4-methylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl)carbonyl]phenol

[0189] 7-Bromo-5-(4-methoxybenzoyl)-4-methyl-4,5-dihydropyrrolo[1,2-*a*]quinoxaline was prepared from 7-bromo-4-methyl-4,5-dihydropyrrolo[1,2-*a*]quinoxaline (see Example 106, Step 1) and *p*-anisoyl chloride according to the procedure of Example 106, Step 2 and purified via Biotage Horizon® (25S, silica, gradient from 5 % EtOAc/hexane to 40% EtOAc/hexane). MS (ESI) m/z 397/399 ($[\text{M}+\text{H}]^+$); HRMS: calcd for $\text{C}_{20}\text{H}_{17}\text{BrN}_2\text{O}_2$, 396.0473; found (ESI+), 396.04740.

[0190] The title product was prepared from 7-bromo-5-(4-methoxybenzoyl)-4-methyl-4,5-dihydropyrrolo[1,2-*a*]quinoxaline according to the procedure of Example 106, Step 3 then purified via Biotage Horizon® (25S, silica, gradient from 15 % EtOAc/hexane to 60% EtOAc/hexane) and isolated a white foam. MS (ESI) m/z 383/385 ($[\text{M}+\text{H}]^+$); MS (ESI) m/z 381/383 ($[\text{M}-\text{H}]^-$); HRMS: calcd for $\text{C}_{19}\text{H}_{15}\text{BrN}_2\text{O}_2$, 382.0317; found (ESI+), 383.03884.

EXAMPLE 109

Preparation of 4-[(7-bromo-4-methylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl)carbonyl]benzene-1,3-diol

[0191] 7-Bromo-5-(2,4-dimethoxybenzoyl)-4-methyl-4,5-dihydropyrrolo[1,2-*a*]quinoxaline was prepared from 2,4-dimethoxybenzoyl chloride

and 7-bromo-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline (see Example 106, Step 1) according to the procedure of Example 106, Step 2. The product was purified via Biotage Horizon® (25S, silica, gradient from 5 % EtOAc/hexane to 40% EtOAc/hexane) and isolated as a white foam. MS (ESI) m/z 427/429 ($[M+H]^+$); HRMS: calcd for $C_{21}H_{19}BrN_2O_3$, 426.0579; found (ESI+), 427.0642.

[0192] The title compound was prepared from 7-bromo-5-(2,4-dimethoxybenzoyl)-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline according to the procedure of Example 106, Step 3 then purified via Biotage Horizon® (25S, silica, gradient from 20 % EtOAc/hexane to 70% EtOAc/hexane) and isolated as a whitefoam. MS (ESI) m/z 399/401 ($[M+H]^+$); MS (ESI) m/z 397/399 ($[M-H]^-$); HRMS: calcd for $C_{19}H_{15}BrN_2O_3$, 398.0266; found (ESI+), 399.03298.

EXAMPLE 110

Preparation of 4-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol

[0193] 7-Bromo-4-ethyl-5-(4-methoxybenzoyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline was prepared from 7-bromo-4-ethyl-4,5-dihydropyrrolo[1,2-a]quinoxaline (see Example 42) and *p*-anisoyl chloride according to the procedure of Example 106, Step 2. The product was purified via Biotage Horizon® (25S, silica, gradient from 5 % EtOAc/hexane to 40% EtOAc/hexane) and isolated as a white foam. MS (ESI) m/z 411/413 ($[M+H]^+$); HRMS: calcd for $C_{21}H_{19}BrN_2O_2$, 410.0630; found (ESI+), 411.06959.

[0194] The title compound was prepared from 7-bromo-4-ethyl-5-(4-methoxybenzoyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline according to the procedure of Example 106, Step 3 then purified via Biotage Horizon® (25S, silica, gradient from 15 % EtOAc/hexane to 60% EtOAc/hexane) and isolated as a white foam. MS (ESI) m/z 397/399 ($[M+H]^+$); MS (ESI) m/z 395/397 ($[M-H]^-$); HRMS: calcd for $C_{20}H_{17}BrN_2O_2$, 396.0473; found (ESI+), 397.05421.

EXAMPLE 111

Isolation of 4-{[(4S)-7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol and 4-{[(4R)-7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol

[0195] The enantiomers of 4-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol were separated via chiral HPLC [Pirkle Covalent Column (S,S), 50% ethanol/hexane] to yield 4-{[(4S)-7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol, $[\alpha]_D^{25} = +148^\circ$ ($c = 0.010\text{G/ML}$, CHCl_3); MS (ESI) m/z 397/399 ($[\text{M}+\text{H}]^+$); MS (ESI) m/z 395/397 ($[\text{M}-\text{H}]^-$); HRMS: calcd for $\text{C}_{20}\text{H}_{17}\text{BrN}_2\text{O}_2$, 396.0473; found (ESI+), 397.05413; and 4-{[(4R)-7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol, $[\alpha]_D^{25} = -135^\circ$ ($c = 0.010\text{G/ML}$, CHCl_3); MS (ESI) m/z 397/399 ($[\text{M}+\text{H}]^+$); MS (ESI) m/z 395/397 ($[\text{M}-\text{H}]^-$); HRMS: calcd for $\text{C}_{20}\text{H}_{17}\text{BrN}_2\text{O}_2$, 396.0473; found (ESI+), 397.05424.

EXAMPLE 112

Preparation of 3-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol

[0196] 7-Bromo-4-ethyl-5-(3-methoxybenzoyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline was prepared from 7-bromo-4-ethyl-4,5-dihydropyrrolo[1,2-a]quinoxaline (See Example 42) and *m*-anisoyl according to the procedure of Example 106, Step 2. The product was purified via Biotage Horizon® (25S, silica, gradient from 5 % EtOAc/hexane to 40% EtOAc/hexane) and isolated as a white foam. MS (ESI) m/z 411/413 ($[\text{M}+\text{H}]^+$).

[0197] The title compound was prepared from 7-bromo-4-ethyl-5-(3-methoxybenzoyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline according to the procedure of Example 106, Step 3 then purified via Biotage Horizon® (25S, silica, gradient from 15 % EtOAc/hexane to 60% EtOAc/hexane) and isolated as a white foam. MS (ESI) m/z 397/399 ($[\text{M}+\text{H}]^+$); MS (ESI) m/z 395/397 ($[\text{M}-\text{H}]^-$); HRMS: calcd for $\text{C}_{20}\text{H}_{17}\text{BrN}_2\text{O}_2$, 396.0473; found (ESI+), 397.05368.

EXAMPLE 113

Preparation of 7-bromo-5-(2,4-dimethoxybenzoyl)-4-ethyl-4,5-dihydropyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]benzene-1,3-diol

[0198] 7-Bromo-5-(2,4-dimethoxybenzoyl)-4-ethyl-4,5-dihydropyrrolo[1,2-a]quinoxaline was prepared from 7-bromo-4-ethyl-4,5-dihydropyrrolo[1,2-a]quinoxaline (see Example 42) and 2,4-dimethoxybenzoyl chloride according to the procedure of Example 106, Step 2. The product was purified via Biotage Horizon® (25S, silica, gradient from 5 % EtOAc/hexane to 40% EtOAc/hexane) and isolated as a white foam. MS (ESI) m/z 441/443 ($[M+H]^+$); HRMS: calcd for $C_{22}H_{21}BrN_2O_3$, 440.0736; found (ESI+), 441.08006.

[0199] The title compound was prepared from 7-bromo-5-(2,4-dimethoxybenzoyl)-4-ethyl-4,5-dihydropyrrolo[1,2-a]quinoxaline according to the procedure of Example 106, Step 3 then purified via Biotage Horizon® (25S, silica, gradient from 20 % EtOAc/hexane to 70% EtOAc/hexane) and isolated as a white foam. MS (ESI) m/z 413/415 ($[M+H]^+$); MS (ESI) m/z 411/413 ($[M-H]^-$); HRMS: calcd for $C_{20}H_{17}BrN_2O_3$, 412.0423; found (ESI+), 413.04881.

EXAMPLE 114

Preparation of 3-[(7-bromo-4-*tert*-butylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol

[0200] 7-Bromo-4-*tert*-butyl-4,5-dihydropyrrolo[1,2-a]quinoxaline was prepared from the product of Example 39 and trimethyl acetaldehyde according to the procedure of Example 3 as off-white crystals. MS (ESI) m/z 305/307 ($[M+H]^+$); HRMS: calcd for $C_{15}H_{17}BrN_2$, 304.0575; found (ESI+), 305.06413.

[0201] 7-Bromo-4-*tert*-butyl-5-(3-methoxybenzoyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline was prepared from 7-bromo-4-*tert*-butyl-4,5-dihydropyrrolo[1,2-a]quinoxaline and *m*-anisoyl chloride according to the procedure of Example 106, Step 2. The product was purified via Biotage Horizon® (25S, silica, gradient from 5 % EtOAc/hexane to 40% EtOAc/hexane) and isolated as a white foam. MS (ESI) m/z 439/441 ($[M+H]^+$); HRMS: calcd for $C_{23}H_{23}BrN_2O_2$, 438.0943; found (ESI+), 439.10084.

[0202] The title compound was prepared from 7-bromo-4-*tert*-butyl-5-(3-methoxybenzoyl)-4,5-dihydropyrrolo[1,2-*a*]quinoxaline according to the procedure of Example 106, Step 3 then was purified via Biotage Horizon® (25S, silica, gradient from 15 % EtOAc/hexane to 60% EtOAc/hexane) and isolated as a white foam. MS (ESI) m/z 425/427 ($[M+H]^+$); MS (ESI) m/z 423/425 ($[M-H]^-$); HRMS: calcd for $C_{22}H_{21}BrN_2O_2$, 424.0786; found (ESI+), 425.08532.

EXAMPLE 115

Isolation of 3-{[(4*S*)-7-bromo-4-*tert*-butylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol and 3-{[(4*R*)-7-bromo-4-*tert*-butylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol

[0203] The enantiomers of 3-[(7-bromo-4-*tert*-butylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl)carbonyl]phenol were separated via chiral HPLC [Pirkle Covalent Column (S,S), 100% ethanol] to yield 3-{[(4*S*)-7-bromo-4-*tert*-butylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol, $[\alpha]_D^{25} = +195^\circ$ ($c = 0.010\text{G/ML}$, CHCl_3); MS (ESI) m/z 425/427 ($[M+H]^+$); MS (ESI) m/z 423/425 ($[M-H]^-$); HRMS: calcd for $C_{22}H_{21}BrN_2O_2$, 424.0786; found (ESI+), 425.08561; and 3-{[(4*R*)-7-bromo-4-*tert*-butylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol, $[\alpha]_D^{25} = -231^\circ$ ($c = 0.010\text{G/ML}$, CHCl_3); MS (ESI) m/z 425/427 ($[M+H]^+$); MS (ESI) m/z 423/425 ($[M-H]^-$); HRMS: calcd for $C_{22}H_{21}BrN_2O_2$, 424.0786; found (ESI+), 425.0857.

EXAMPLE 116

Preparation of 4-[(7-bromo-4-*tert*-butylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol

[0204] 7-Bromo-4-*tert*-butyl-5-(4-methoxybenzoyl)-4,5-dihydropyrrolo[1,2-*a*]quinoxaline was prepared from 7-bromo-4-*tert*-butyl-4,5-dihydropyrrolo[1,2-*a*]quinoxaline (see Example 114, Step 1) and *p*-anisoyl chloride according to the procedure of Example 106, Step 2. The product was purified via Biotage Horizon® (25S, silica, gradient from 5 % EtOAc/hexane to 40% EtOAc/hexane) and isolated as

a white foam. MS (ESI) m/z 437/441 ($[M+H]^+$); HRMS: calcd for $C_{23}H_{23}BrN_2O_2$, 438.0943; found (ESI+), 439.1010.

[0205] The title compound was prepared from 7-bromo-4-*tert*-butyl-5-(4-methoxybenzoyl)-4,5-dihydropyrrolo[1,2-*a*]quinoxaline according to the procedure of Example 106, Step 3 then purified via Biotage Horizon® (25S, silica, gradient from 15 % EtOAc/hexane to 60% EtOAc/hexane) and isolated as a white foam. MS (ESI) m/z 425/427 ($[M+H]^+$); MS (ESI) m/z 423/425 ($[M-H]^-$); HRMS: calcd for $C_{22}H_{21}BrN_2O_2$, 424.0786; found (ESI+), 425.08573.

EXAMPLE 117

Preparation of 4-[(7-bromo-4-*tert*-butylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl)carbonyl]benzene-1,3-diol

[0206] 7-Bromo-4-*tert*-butyl-5-(2,4-dimethoxybenzoyl)-4,5-dihydropyrrolo[1,2-*a*]quinoxaline was prepared from 7-bromo-4-*tert*-butyl-4,5-dihydropyrrolo[1,2-*a*]quinoxaline (see Example 114, Step 1) and 2,4-dimethoxybenzoyl chloride according to the procedure of Example 106, Step 2. The product was purified via Biotage Horizon® (25S, silica, gradient from 5 % EtOAc/hexane to 40% EtOAc/hexane) and isolated as a white foam. MS (ESI) m/z 469/471 ($[M+H]^+$); HRMS: calcd for $C_{24}H_{25}BrN_2O_3$, 468.1049; found (ESI+), 469.11175.

[0207] The title compound was prepared from 7-bromo-4-*tert*-butyl-5-(2,4-dimethoxybenzoyl)-4,5-dihydropyrrolo[1,2-*a*]quinoxaline according to the procedure of Example 106, Step 3 then purified via Biotage Horizon® (25S, silica, gradient from 20 % EtOAc/hexane to 70% EtOAc/hexane) and isolated as a white foam. MS (ESI) m/z 413/415 ($[M+H]^+$); MS (ESI) m/z 411/413 ($[M-H]^-$); HRMS: calcd for $C_{20}H_{17}BrN_2O_3$, 412.0423; found (ESI+), 413.04881.

EXAMPLE 118

Preparation of 4-[(4-ethyl-7-fluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl)carbonyl]phenol

[0208] 4-Ethyl-7-fluoro-5-(4-methoxybenzoyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline was prepared from the product of Example 17 and *p*-anisoyl chloride according to the procedure of Example 106, Step 2, mp 39-42 °C. MS (ESI) *m/z* 351; Anal. Calcd for C₂₁H₁₉FN₂O₂: C, 71.99; H, 5.47; N, 7.99. Found: C, 70.90; H, 5.62; N, 7.65.

[0209] The title compound was prepared from 4-ethyl-7-fluoro-5-(4-methoxybenzoyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline according to the procedure of Example 106, Step 3, mp 165-167. MS (ESI) *m/z* 337; Anal. Calcd for C₂₀H₁₇FN₂O₂: C, 71.42; H, 5.09; N, 8.33. Found: C, 71.09; H, 5.40; N, 7.93.

EXAMPLE 119

Isolation of 4-{[(4*S*)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}phenol and 4-{[(4*R*)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}phenol

[0210] The enantiomers of 4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl)carbonyl]phenol (See Example 118) were separated via chiral HPLC [Pirkle Covalent Column (S,S), 100% ethanol] to yield 4-{[(4*S*)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}phenol [α]_D²⁵ = +428° (*c* = 0.0054 g/mL, DMSO); MS (ESI) *m/z* 337; MS (ESI) *m/z* 335; Anal. Calcd for C₂₀H₁₇FN₂O₂: C, 71.42; H, 5.09; N, 8.33. Found: C, 72.25; H, 5.75; N, 7.89 and 4-{[(4*R*)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}phenol [α]_D²⁵ = -440° (*c* = 0.005 g/mL, DMSO); MS (ESI) *m/z* 337; MS (ESI) *m/z* 335; Anal. Calcd for C₂₀H₁₇FN₂O₂: C, 71.42; H, 5.09; N, 8.33. Found: C, 70.22; H, 5.43; N, 7.49

EXAMPLE 120

Preparation of 4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl)carbonyl]benzene-1,3-diol

[0211] 5-(2,4-Dimethoxybenzoyl)-4-ethyl-7-fluoro-4,5-dihydropyrrolo[1,2-a]quinoxaline was prepared from the product of Example 17 and 2,4-dimethoxy benzoyl chloride according to the procedure of Example 106, Step 2, mp 131-132 °C.

MS (ESI) m/z 381; Anal. Calcd for $C_{22}H_{21}FN_2O_3$: C, 69.46; H, 5.56; N, 7.36. Found: C, 69.22; H, 5.63; N, 7.32.

[0212] The title compound was prepared from 5-(2,4-dimethoxybenzoyl)-4-ethyl-7-fluoro-4,5-dihydropyrrolo[1,2-a]quinoxaline according to the procedure of Example 106, Step 3, mp 153-155. MS (ESI) m/z 353; MS (ESI) m/z 351; Anal. Calcd for $C_{20}H_{17}FN_2O_3$: C, 68.17; H, 4.86; N, 7.95. Found: C, 65.62; H, 4.76; N, 6.93.

EXAMPLE 121

Isolation of 4-{[(4*R*)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}benzene-1,3-diol and 4-{[(4*S*)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}benzene-1,3-diol

[0213] The enantiomers of 4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl)carbonyl]benzene-1,3-diol (See Example 120) were separated via chiral HPLC [Pirkle Covalent Column (S,S), 100% ethanol] to yield 4-{[(4*R*)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}benzene-1,3-diol $[\alpha]_D^{25} = -385^\circ$ ($c = 0.0054$ g/mL, DMSO); MS (ESI) m/z 353; MS (ESI) m/z 351; Anal. Calcd for $C_{20}H_{17}FN_2O_3$: C, 68.17; H, 4.86; N, 7.95. Found: C, 67.86; H, 5.12; N, 7.42 and 4-{[(4*S*)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}benzene-1,3-diol $[\alpha]_D^{25} = +421^\circ$ ($c = 0.0051$ g/mL, DMSO); MS (ESI) m/z 353; MS (ESI) m/z 351; Anal. Calcd for $C_{20}H_{17}FN_2O_3$: C, 68.17; H, 4.86; N, 7.95. Found: C, 67.11; H, 4.86; N, 7.56.

EXAMPLE 122

Preparation of 4-[(4-methyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl)carbonyl]phenol

[0214] 7-Fluoro-5-(4-methoxybenzoyl)-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline was prepared from the product of Example 47 and *p*-anisoyl chloride according to the procedure of Example 106, Step 2. MS (ESI) m/z 337; Anal. Calcd for $C_{20}H_{17}FN_2O_2$: C, 71.42; H, 5.09; N, 8.33. Found: C, 70.89; H, 4.96; N, 8.01.

[0215] The title compound was prepared from 7-fluoro-5-(4-methoxybenzoyl)-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline according to the

procedure of Example 100, Step 3, and used in the next step without further purification or characterization.

EXAMPLE 123

Isolation of 4-{[(4*R*)-7-fluoro-4-methylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol and 4-{[(4*S*)-7-fluoro-4-methylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol

[0216] The enantiomers of 4-[(4-methyl-7-fluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol (See Example 122) were separated via chiral HPLC [Pirkle Covalent Column (S,S), 100% ethanol] to yield 4-{[(4*R*)-7-fluoro-4-methylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol, mp 125-129 °C. $[\alpha]_D^{25} = -258^\circ$ (c = 0.0052 g/mL, DMSO); MS (ESI) *m/z* 323; MS (ESI) *m/z* 321; Anal. Calcd for C₁₉H₁₅FN₂O₂: C, 70.80; H, 4.69; N, 8.69. Found: C, 68.82; H, 4.72; N, 7.38 and 4-{[(4*S*)-7-fluoro-4-methylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol mp 126-129 °C. $[\alpha]_D^{25} = +333^\circ$ (c = 0.0051 g/mL, DMSO); MS (ESI) *m/z* 323; MS (ESI) *m/z* 321; Anal. Calcd for C₁₉H₁₅FN₂O₂: C, 70.80; H, 4.69; N, 8.69. Found: C, 69.85; H, 5.25; N, 7.57

EXAMPLE 124

Preparation of 4-[(7-chloro-4-ethylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}benzene-1,3-diol

[0217] 7-Chloro-5-(2,4-dimethoxybenzoyl)-4-ethyl-4,5-dihydropyrrolo[1,2-*a*]quinoxaline was prepared from the intermediate of Example 68A and 2,4-dimethoxy benzoyl chloride according to the procedure of Example 106, Step 2 mp 70-74 °C. MS (ESI) *m/z* 397; Anal. Calcd for C₂₂H₂₁ClN₂O₃: C, 66.58; H, 5.33; N, 7.06. Found: C, 66.34; H, 5.59; N, 6.85

[0218] The title compound was prepared from 7-chloro-5-(2,4-dimethoxybenzoyl)-4-ethyl-4,5-dihydropyrrolo[1,2-a]quinoxaline according to the procedure of Example 106, Step 3, mp 198-201 °C. MS (ESI) m/z 367; MS (ESI) m/z 369

EXAMPLE 125

Isolation of 4-{[(4*R*)-7-chloro-4-ethylpyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}benzene-1,3-diol and 4-{[(4*S*)-7-chloro-4-ethylpyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}benzene-1,3-diol

[0219] The enantiomers of 4-[(7-chloro-4-ethylpyrrolo[1,2-a]quinoxalin-5(4*H*)-yl)carbonyl]benzene-1,3-diol (See Example 124) were separated via chiral HPLC [Pirkle Covalent Column (S,S), 100% ethanol] to yield 4-{[(4*R*)-7-chloro-4-ethylpyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}benzene-1,3-diol mp 213-214 °C, $[\alpha]_D^{25} = -167^\circ$ ($c = 0.0056$ g/mL, DMSO); MS (ESI) m/z 369; MS (ESI) m/z 367; Anal. Calcd for $C_{20}H_{17}ClN_2O_3$: C, 65.13; H, 4.65; N, 7.60. Found: C, 65.00; H, 4.79; N, 7.22 and 4-{[(4*S*)-7-chloro-4-ethylpyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}benzene-1,3-diol, mp 213-214 °C; $[\alpha]_D^{25} = -167^\circ$ ($c = 0.0056$ g/mL, DMSO); MS (ESI) m/z 369; MS (ESI) m/z 367; Anal. Calcd for $C_{20}H_{17}ClN_2O_3$: C, 65.13; H, 4.65; N, 7.60. Found: C, 65.00; H, 4.79; N, 7.22

EXAMPLE 126

Preparation of 3-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl)carbonyl]phenol

[0220] 4-Ethyl-7-fluoro-5-(3-methoxybenzoyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline was prepared from the product of Example 17 and *m*-anisoyl chloride according to the procedure of Example 106, Step 2 mp 70-74 °C. MS (ESI) m/z 351; Anal. Calcd for $C_{21}H_{19}FN_2O_2$: C, 71.99; H, 5.47; N, 7.99. Found: C, 70.08; H, 5.55; N, 7.14

[0221] The title compound was prepared from 4-ethyl-7-fluoro-5-(3-methoxybenzoyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline according to the procedure of Example 106, Step 3, mp 115-117 °C. MS (ESI) *m/z* 337; MS (ESI) *m/z* 335; Anal. Calcd for C₂₀H₁₇FN₂O₂: C, 71.42; H, 5.09; N, 8.33. Found: C, 71.19; H, 5.34; N, 8.32.

EXAMPLE 127

Isolation of 3-{[(4*R*)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}phenol and 3-{[(4*S*)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}phenol

[0222] The enantiomers of 3-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl)carbonyl]phenol (See Example 126) were separated via chiral HPLC [Pirkle Covalent Column (S,S), 100% ethanol] to yield 3-{[(4*R*)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}phenol, mp 115-116 °C; [α]_D²⁵ = -411° (c = 0.005 g/mL, DMSO); MS (ESI) *m/z* 337; MS (ESI) *m/z* 335; Anal. Calcd for C₂₀H₁₇FN₂O₂: C, 71.42; H, 5.09; N, 8.33. Found: C, 71.59; H, 5.25; N, 7.78 and 3-{[(4*S*)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}phenol, mp 116-117 °C; [α]_D²⁵ = +517° (c = 0.005 g/mL, DMSO); MS (ESI) *m/z* 337; MS (ESI) *m/z* 335; Anal. Calcd for C₂₀H₁₇FN₂O₂: C, 71.42; H, 5.09; N, 8.33. Found: C, 71.42; H, 5.40; N, 7.93

EXAMPLE 128

Preparation of (4*R*)-4-ethyl-7-fluoro-5-(4-hydroxybenzoyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0223] The title compound was prepared from the product of Example 122 according to the procedure of Example 11. MS (ESI) *m/z* 362; MS (ESI) *m/z* 360.

EXAMPLE 129

Preparation of (4*S*)-4-ethyl-7-fluoro-5-(4-hydroxybenzoyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile

[0224] The title compound was prepared from the product of Example 122 according to the procedure of Example 11. MS (ESI) *m/z* 362; MS (ESI) *m/z* 360.

EXAMPLE 130**Preparation of 3-[(4-methyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl)carbonyl]phenol**

[0225] 7-Fluoro-5-(3-methoxybenzoyl)-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline was prepared from the product of Example 47 and *m*-anisoyl chloride according to the procedure of Example 106, Step 2. MS (ESI) *m/z* 337.

[0226] The title compound was prepared from 7-fluoro-5-(3-methoxybenzoyl)-4-methyl-4,5-dihydropyrrolo[1,2-a]quinoxaline according to the procedure of Example 106, Step 3, and used in the next step without further purification or characterization.

EXAMPLE 131**Isolation of 3-{[(4*R*)-4-methyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}phenol and 3-{[(4*S*)-4-methyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}phenol**

[0227] The enantiomers of 3-[(4-methyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4*H*)-yl)carbonyl]phenol (See Example 130) were separated via chiral HPLC [Pirkle Covalent Column (S,S), 100% ethanol] to yield 3-{[(4*S*)-7-fluoro-4-methylpyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}phenol, MS (ESI) *m/z* 323; MS (ESI) *m/z* 321; Anal. Calcd for C₁₉H₁₅FN₂O₂: C, 70.80; H, 4.69; N, 8.69. Found: C, 69.44; H, 4.99; N, 8.91 and 3-{[(4*R*)-7-fluoro-4-methylpyrrolo[1,2-a]quinoxalin-5(4*H*)-yl]carbonyl}phenol MS (ESI) *m/z* 323; MS (ESI) *m/z* 321; Anal. Calcd for C₁₉H₁₅FN₂O₂: C, 70.80; H, 4.69; N, 8.69. Found: C, 70.58; H, 5.42; N, 8.76

Example 132**In vitro Methods****Cells**

[0228] T-175 flasks of 100% confluent HAECT-1 cells (immortalized human aortic endothelial cells) were washed with 8 ml of HBSS (HEPES buffered

same solution) and infected for four hours with 6 ml of a 1:10 dilution of Ad5-wt-hER α virus (an adenovirus transfection vector that mediates CMV promoter driven expression of human ER α) in phenol red free Endothelial Cell Basal medium (Clonetics, San Diego CA, Catalog # CC-3129) containing 0.25% bovine serum albumin (EBM-BSA). After four hours, cells were washed with EBM-BSA and incubated overnight in the same medium. Following overnight incubation, cells were washed with EBM-BSA and infected for 2 hours with 6 ml of a 1:10 dilution of Ad5-3x(NF κ B).Luc virus (Adenovirus luciferase expression vector driven by 3 repeats of the MHC NF κ B site 5' to the thymidine kinase promoter) in EBM-BSA. After two hours, cells were washed and incubated at 34°C for 1 hour. Cells were then washed, trypsinized, counted and resuspended in 95%FBS / 5% dimethylsulfoxide at a concentration of 4×10^6 cells/ml, frozen as 1 or 5 ml aliquots in cryo-vials and stored at -150°C. Control (no ER infection) cells were processed as above without Ad5-wt-hER α virus infection.

IL-6 and Creatine Kinase Assays

[0229] ER α infected HAECT-1 cells or control cells were thawed, diluted 42x in warm EBM-BSA, plated into 96-well plates at 0.1 ml/well and incubated for 4h at 34°C. Test compounds were added to the cells as 2x stocks in EBM-BSA containing 2 ng/ml IL-1 β (R&D Systems) and plates were returned to the incubator (34°C). After 15-20h, 100 μ l aliquots of media were removed from the cells and assayed for IL-6 content using a BioSource human IL-6 ELISA Kit. Cells were subsequently washed with 300 μ l of Dulbecco's phosphate buffered saline and lysed in 50 μ l of Cell Culture Lysis Reagent (Promega). Luciferase was determined on a Wallac Victor² Luminometer (Gaithersburg, MD) using 10 μ l of lysate and mixing with 100 μ l of Promega Luciferase Assay reagent. Creatine kinase was determined from the rate of increase in A₃₄₀ following addition of 100 μ l of CK assay reagent (Sigma, cat. No 47-10) to the remainder of the cell lysate.

Data Analyses

[0230] For IC₅₀ and EC₅₀ calculations, mean IL-6, luciferase or CK values versus log₁₀ of the compound concentration were fitted to a four

parameter logistic equation. The IC_{50} / EC_{50} value, 'Hill slope', upper and lower limits of the curve were iteratively estimated.

Mice

[0231] Ovariectomized C57BL/6 mice (16-20g) (Taconic) were separated into groups of 8. After 5-7 days of recuperation, the mice were fed a chow diet or an atherogenic diet (15.75% fat, 1.25% cholesterol and 0.5% sodium cholate) (Purina diet #21539). EE or test compound was administered once daily by gavage in a methylcellulose/tween vehicle (0.1 ml per mouse) for 5 weeks. At the end of the experimental period, the liver was collected and uterine wet weight was recorded.

RNA Analysis

[0232] Liver total RNA was prepared by using Trizol reagent (BRL). Estrogen and compound regulation of NF- κ B target genes were verified by real time RT-PCR using an ABI PRISM 7700 Sequence Detection System according to the manufacturer's protocol (Applied Biosystems). The data was analyzed using the Sequence Detector v1.7 software (Applied Biosystems) and normalized to GAPDH using the Applied Biosystems primer set.

In vitro Results

[0233] Table 1 summarizes the activities of E2 and several "anti-inflammatory estrogens" in the HAECT-1 NF- κ B, IL-6 and creatine kinase assays in Ad5-wt-ER infected cells. Table 2 lists the activities of the same compounds in the HAECT-1 NF- κ B and creatine kinase assays in uninfected cells.

Table 1. Effects of 17- β -estradiol on NF- κ B and CK expression in Ad5-wt-ER infected HAECT-1 cells

	ER/Nf- κ B		IL-6		CK	
Example	IC_{50} (nM)	Efficacy	IC_{50} (nM)	Efficacy	IC_{50} (nM)	Efficacy (%)
No.		(%)*		(%)*		

EZ	1.7	100	ND	ND	5.8	100
5	82	99	ND	ND	450	37
7	26	113	ND	ND	380	37
10	14	97	ND	ND	97	39
11B	332	96	ND	ND	830	96
12	1823	91	ND	ND	N/O	
13	20	104	ND	ND	N/O	
13A (+)-(S)	6	110	ND	ND	N/O	
13A (-)-R	1237	102	ND	ND	334	36
15	150	105	ND	ND	N/O	
19	34	94	ND	ND		52
21	71	97	ND	ND	287	38
23	ND	ND	6.6	162	40	52
28	52	105	ND	ND	106	45
29	587	100	ND	ND	327	28
31	364	104	ND	ND	N/O	
33	1321	208	ND	ND	N/O	
35	962	72	ND	ND	107	19
38	201	109	ND	ND	2019	38
41	217	109	ND	ND	36	35
44	42	97	ND	ND	171	51
45	12	95	ND	ND	45	53
46	62	108	ND	ND	444	43
49	67	85	ND	ND	1573	19
51	155	66	ND	ND	N/O	
52	11	100	ND	ND	N/O	
56	79	107	ND	ND	N/O	
58	85	132	ND	ND	83	42
59	9700	75	ND	ND	3000	-13
61	10000	69	ND	ND	1700	15

			ND	ND	N/O	
66	320	98	ND	ND	N/O	
68A	93	105	ND	ND	531	49
70	150	98	ND	ND	264	45
71	175	101	ND	ND	279	34
74	157	75	ND	ND	N/O	
75	36	84	ND	ND	375	46
77	11	186	ND	ND	212	39
78	ND	ND	1096	40	N/O	
80	ND	ND	444	103	ND	ND
82	ND	ND	51	114	ND	ND
85	ND	ND	696	112	ND	ND
87	ND	ND	41	112	205	33
89	ND	ND	150	188	9.9	7
91	ND	ND	1460	86		-4
93	ND	ND	299	105	N/O	
97 (S)	ND	ND	9	134	31	37
97 R	ND	ND	68	103	32	108
98	ND	ND	92	117	ND	ND
100	ND	ND	14	193	99	42
101 (S)	ND	ND	424	131	91	30
102 (S)	ND	ND	8.4	161	ND	ND
102 (R)	ND	ND	448	117	1772	31
103	ND	ND	101	93	34	-18
104	ND	ND	178	110	ND	ND
105	ND	ND	2	116	3.6	49
106	ND	ND	10	54	ND	ND
107 (S)	ND	ND	1062	66	ND	ND
107 (R)	ND	ND	39	89	38	113
108	ND	ND	53	118	18	7
109	ND	ND	42	128	398	40
110	ND	ND	369	78	N/O	

111 (S)	ND	ND	1008	65	ND	ND
111 (R)	ND	ND	46	87	117	40
112	ND	ND	152	88	207	21
113	ND	ND	9.5	101	25	28
114	ND	ND	441	38	ND	ND
115 (S)	ND	ND	455	94	ND	ND
115 (R)	ND	ND	647	82	ND	ND
116	ND	ND	207	90	N/O	
117	ND	ND	9	90	33	42
118	ND	ND	3	95	20	32
119 (S)	ND	ND	101	79	ND	ND
119 (R)	ND	ND	8	95	11	27
121 (S)	ND	ND	72	95	64	32
121 (R)	ND	ND	1.6	108	13	36
123 (S)	ND	ND	606	47	ND	ND
123 (R)	ND	ND	23	112	198	27
125 (S)	ND	ND	1099	81	68	15
125 (R)	ND	ND	0.4	120	ND	ND
127 (S)	ND	ND	1331	41	33	33
127 (R)	ND	ND	62	132	159	35
128	ND	ND	64	111	ND	ND
129	ND	ND	29	-77	636	-7
131 (R)	ND	ND	179	103	N/O	
131 (S)	ND	ND	1462	69	N/O	

*Efficacy values are relative to the maximal inhibition (IL-6 assay) or stimulation (CK assay) observed with E2

N/O - activity not observed at concentrations tested.

[0234] E2 inhibits NF- κ B expression in Ad5-wt-ER infected HAECT-1 cells with an IC₅₀ value of 1.7 nM and induces expression of creatine kinase in the same cells with similar potency (5.8 nM) (Table 1). In contrast, most of the example compounds potently and efficaciously inhibit NF- κ B expression in Ad5-wt-ER infected HAECT-1 cells but do not induce CK expression (Table 1).

All of the above compounds inhibit NF- κ B expression in an ER-dependent manner as indicated by their inactivity on IL-6 in HAECT-1 cells not infected with the Ad5-wt-ER virus (Table 2). The ability of the example compounds to inhibit IL-6 expression without inducing CK activity (Table 1) is consistent with an anti-inflammatory activity in the absence of classic estrogenic activity.

Evaluation of test compound using an ERE-reporter test procedure in MCF-7 breast cancer cells

[0235] Stock solutions of test compounds (usually 0.1 M) are prepared in DMSO and then diluted 10 to 100-fold with DMSO to make working solutions of 1 or 10 mM. The DMSO stocks are stored at either 4 °C (0.1 M) or -20 °C (< 0.1M). MCF-7 cells are passaged twice a week with growth medium [D-MEM/F-12 medium containing 10% (v/v) heat-inactivated fetal bovine serum, 1% (v/v) Penicillin-Streptomycin, and 2 mM glutaMax-1]. The cells are maintained in vented flasks at 37 °C inside a 5% CO₂/95% humidified air incubator. One day prior to treatment, the cells are plated with growth medium at 25,000 cells/well into 96 well plates and incubated at 37 °C overnight.

[0236] The cells are infected for 2 hr at 37 °C with 50 μ l/well of a 1:10 dilution of adenovirus 5-ERE-tk-luciferase in experimental medium [phenol red-free D-MEM/F-12 medium containing 10% (v/v) heat-inactivated charcoal-stripped fetal bovine serum, 1% (v/v) Penicillin-Streptomycin, 2 mM glutaMax-1, 1 mM sodium pyruvate]. The wells are then washed once with 150 μ l of experimental medium. Finally, the cells are treated for 24 hr at 37 °C in replicates of 8 wells/treatment with 150 μ l/well of vehicle ($\leq$ 0.1% v/v DMSO) or compound that is diluted $\geq$ 1000-fold into experimental medium.

[0237] Initial screening of test compounds is done at a single dose of 1 μ M that is tested alone (estrogen receptor agonist mode) or in combination with 0.1 nM 17 β -estradiol (EC₈₀; estrogen receptor antagonist mode). Each 96 well plate also includes a vehicle control group (0.1% v/v DMSO) and an estrogen receptor agonist control group (either 0.1 or 1 nM 17 β -estradiol). Dose-response experiments are performed in either the estrogen receptor agonist and/or estrogen receptor antagonist modes on active compounds in log increases from 10⁻¹⁴ to 10⁻⁵ M. From these dose-

response curves, EC₅₀ and IC₅₀ values, respectively, are generated. The final well in each treatment group contains 5 µl of 3×10^{-5} M ICI-182,780 (10^{-6} M final concentration) as an estrogen receptor antagonist control.

[0238] After treatment, the cells are lysed on a shaker for 15 min with 25 µl/well of 1X cell culture lysis reagent (Promega Corporation). The cell lysates (20 µl) are transferred to a 96 well luminometer plate, and luciferase activity is measured in a MicroLumat LB 96 P luminometer (EG & G Berthold) using 100 µl/well of luciferase substrate (Promega Corporation). Prior to the injection of substrate, a 1 second background measurement is made for each well. Following the injection of substrate, luciferase activity is measured for 10 seconds after a 1 second delay. The data are transferred from the luminometer to a Macintosh personal computer and analyzed using the JMP software (SAS Institute); this program subtracts the background reading from the luciferase measurement for each well and then determines the mean and standard deviation of each treatment.

[0239] The luciferase data are transformed by logarithms, and the Huber M-estimator is used to down-weight the outlying transformed observations. The JMP software is used to analyze the transformed and weighted data for one-way ANOVA (Dunnett's test). The compound treatments are compared to the vehicle control results in the estrogen receptor agonist mode, or the positive estrogen receptor agonist control results (0.1 nM 17β-estradiol) in the estrogen receptor antagonist mode. For the initial single dose experiment, if the compound treatment results are significantly different from the appropriate control ($p < 0.05$), then the results are reported as the percent relative to the 17β-estradiol control [i.e., $((\text{compound} - \text{vehicle control}) / (\text{17}\beta\text{-estradiol control} - \text{vehicle control})) \times 100$]. The JMP software is also used to determine the EC₅₀ and/or IC₅₀ values from the non-linear dose-response curves.

Evaluation of uterotrophic activity

[0240] Uterotrophic activity of a test compound can be measured according to the following standard pharmacological test procedures.

[0241] Procedure 1: Sexually immature (18 days of age) Sprague-Dawley rats are obtained from Taconic and provided unrestricted access to a casein-based diet (Purina Mills 5K96C) and water. On day 19, 20 and 21 the rats are dosed

subcutaneously with 17α -ethinyl- 17β -estradiol (0.06 μ g/rat/day), test compound or vehicle (50% DMSO/50% Dulbecco's PBS). To assess estrogen receptor antagonist, compounds are coadministered with 17α -ethinyl- 17β -estradiol (0.06 μ g/rat/day). There are six rats/group and they are euthanized approximately 24 hours after the last injection by CO₂ asphyxiation and pneumothorax. Uteri are removed and weighed after trimming associated fat and expressing any internal fluid. A tissue sample can also be snap frozen for analysis of gene expression (e.g. complement factor 3 mRNA).

[0242] Procedure 2: Sexually immature (18 days of age) 129 SvE mice are obtained from Taconic and provided unrestricted access to a casein-based diet (Purina Mills 5K96C) and water. On day 22, 23, 24 and 25 the mice are dosed subcutaneously with compound or vehicle (corn oil). There are six mice/group and they are euthanized approximately 6 hours after the last injection by CO₂ asphyxiation and pneumothorax. Uteri are removed and weighed after trimming associated fat and expressing any internal fluid.

Evaluation of osteoporosis and lipid modulation (cardioprotection)

[0243] Female Sprague-Dawley rats, ovariectomized or sham operated, are obtained 1 day after surgery from Taconic Farms (weight range 240 - 275 g). They are housed 3 or 4 rats/cage in a room on a 12/12 (light/dark) schedule and provided with food (Purina 5K96C rat chow) and water ad libitum. Treatment for all studies begin 1 day after arrival and rats are dosed 7 days per week as indicated for 6 weeks. A group of age matched sham operated rats not receiving any treatment serve as an intact, estrogen replete control group for each study.

[0244] All test compounds are prepared in a vehicle of 50% DMSO (JT Baker, Phillipsburg, NJ) / 1x Dulbecco's phosphate saline (GibcoBRL, Grand Island, NY) at defined concentrations so that the treatment volume is 0.1 mL/100 g body weight. 17β -estradiol is dissolved in corn oil (20 μ g/mL) and delivered subcutaneously, 0.1 mL/rat. All dosages are adjusted at three week intervals according to group mean body weight measurements, and given subcutaneously.

[0245] Five weeks after the initiation of treatment and one week prior to the termination of the study, each rat is evaluated for bone mineral density (BMD). The total and trabecular density of the proximal tibia are evaluated in anesthetized rats using an XCT-960M (pQCT; Stratec Medizintechnik, Pforzheim, Germany). The

measurements are performed as follows: Fifteen minutes prior to scanning, each rat is anesthetized with an intraperitoneal injection of 45 mg/kg ketamine, 8.5 mg/kg xylazine, and 1.5 mg/kg acepromazine.

[0246] The right hind limb is passed through a polycarbonate tube with a diameter of 25 mm and taped to an acrylic frame with the ankle joint at a 90° angle and the knee joint at 180°. The polycarbonate tube is affixed to a sliding platform that maintains it perpendicular to the aperture of the pQCT. The platform is adjusted so that the distal end of the femur and the proximal end of the tibia is in the scanning field. A two dimensional scout view is run for a length of 10 mm and a line resolution of 0.2 mm. After the scout view is displayed on the monitor, the proximal end of the tibia is located. The pQCT scan is initiated 3.4 mm distal from this point. The pQCT scan is 1 mm thick, has a voxel (three dimensional pixel) size of 0.140 mm, and consists of 145 projections through the slice.

[0247] After the pQCT scan is completed, the image is displayed on the monitor. A region of interest including the tibia but excluding the fibula is outlined. The soft tissue is mathematically removed using an iterative algorithm. The density of the remaining bone (total density) is reported in mg/cm^3 . The outer 55% of the bone is mathematically peeled away in a concentric spiral. The density of the remaining bone (Trabecular density) is reported in mg/cm^3 .

[0248] One week after BMD evaluation the rats are euthanized by CO_2 asphyxiation and pneumothorax, and blood is collected for cholesterol determination. The uteri are also removed and weighed after trimming associated fat and expressing any luminal fluid. Total cholesterol is determined using a Boehringer-Mannheim Hitachi 911 clinical analyzer using the Cholesterol/HP kit. Statistics were compared using one-way analysis of variance with Dunnet's test.

Evaluation of antioxidant activity

[0249] Porcine aortas are obtained from an abattoir, washed, transported in chilled PBS, and aortic endothelial cells are harvested. To harvest the cells, the intercostal vessels of the aorta are tied off and one end of the aorta clamped. Fresh, sterile filtered, 0.2% collagenase (Sigma Type I) is placed in the vessel and the other end of the vessel then clamped to form a closed system. The aorta is incubated at 37 °C for 15-20 minutes, after which the collagenase solution is collected and centrifuged

for 5 minutes at 2000 x g. Each pellet is suspended in 7 mL of endothelial cell culture medium consisting of phenol red free DMEM/Ham's F12 media supplemented with charcoal stripped FBS (5%), NuSerum (5%), L-glutamine (4 mM), penicillin-streptomycin (1000 U/ml, 100 µg/ml) and gentamycin (75 µg/ml), seeded in 100 mm petri dish and incubated at 37 °C in 5%CO₂. After 20 minutes, the cells are rinsed with PBS and fresh medium added, this was repeated again at 24 hours. The cells are confluent after approximately 1 week. The endothelial cells are routinely fed twice a week and, when confluent, trypsinized and seeded at a 1:7 ratio. Cell mediated oxidation of 12.5 µg/mL LDL is allowed to proceed in the presence of the compound to be evaluated (5 µM) for 4 hours at 37 °C. Results are expressed as the percent inhibition of the oxidative process as measured by the TBARS (thiobarbituric acid reactive substances) method for analysis of free aldehydes [Yagi, *Biochemical Medicine* 15: 212-6 (1976)].

Progesterone receptor mRNA regulation standard pharmacological test procedure

[0250] This test procedure can be used to evaluate the estrogenic or antiestrogenic activity of compounds from this invention [Shughrue, *et al.*, *Endocrinology* 138: 5476-5484 (1997)].

Rat Hot Flush Test Procedure

[0251] The effect of test compounds on hot flushes can be evaluated in a standard pharmacological test procedure which measures the ability of a test compound to blunt the increase in tail skin temperature which occurs as morphine-addicted rats are acutely withdrawn from the drug using naloxone [Merchenthaler, *et al.*, *Maturitas* 30: 307-16 (1998)]. It can also be used to detect estrogen receptor antagonist activity by co-dosing test compound with the reference estrogen.

Evaluation of vasomotor function in isolated rat aortic rings

[0252] Sprague-Dawley rats (240-260 grams) are divided into 4 groups:

1. Normal non-ovariectomized (intact)
2. Ovariectomized (ovex) vehicle treated
3. Ovariectomized 17β-estradiol treated (1 mg/kg/day)
4. Ovariectomized animals treated with test compound (various doses)

[0253] Animals are ovariectomized approximately 3 weeks prior to treatment. Each animal receives either 17- β estradiol sulfate (1 mg/kg/day) or test compound suspended in distilled, deionized water with 1% tween-80 by gastric gavage. Vehicle treated animals received an appropriate volume of the vehicle used in the drug treated groups.

[0254] Animals are euthanized by CO₂ inhalation and exsanguination. Thoracic aortae are rapidly removed and placed in 37 °C physiological solution with the following composition (mM): NaCl (54.7), KCl (5.0), NaHCO₃ (25.0), MgCl₂ 2H₂O (2.5), D-glucose (11.8) and CaCl₂ (0.2) gassed with CO₂-O₂, 95%/5% for a final pH of 7.4. The adventitia is removed from the outer surface and the vessel is cut into 2-3 mm wide rings. Rings are suspended in a 10 mL tissue bath with one end attached to the bottom of the bath and the other to a force transducer. A resting tension of 1 gram is placed on the rings. Rings are equilibrated for 1 hour, signals are acquired and analyzed.

[0255] After equilibration, the rings are exposed to increasing concentrations of phenylephrine (10⁻⁸ to 10⁻⁴ M) and the tension recorded. Baths are then rinsed 3 times with fresh buffer. After washout, 200 mM L-NAME is added to the tissue bath and equilibrated for 30 minutes. The phenylephrine concentration response curve is then repeated.

Evaluation of cardioprotective activity

[0256] Apolipoprotein E-deficient C57/B1J (apo E KO) mice are obtained from Taconic Farms. All animal procedures are performed under strict compliance to IACUC guidelines. Ovariectomized female apo E KO mice, 4-7 weeks of age, are housed in shoe-box cages and were allowed free access to food and water. The animals are randomized by weight into groups (n=12-15 mice per group). The animals are dosed with test compounds or estrogen (17 β -estradiol sulfate at 1 mg/kg/day) in the diet using a Precise-dosing Protocol, where the amount of diet consumed is measured weekly, and the dose adjusted accordingly, based on animal weight. The diet used is a Western-style diet (57U5) that is prepared by Purina and contains 0.50% cholesterol, 20% lard and 25 IU/KG Vitamin E. The animals are dosed/fed using this paradigm for a period of 12 weeks. Control animals are fed the Western-style diet and receive no compound. At the end of the study period, the

animals are euthanized and plasma samples obtained. The hearts are perfused in situ, first with saline and then with neutral buffered 10% formalin solution.

[0257] For the determination of plasma lipids and lipoproteins, total cholesterol and triglycerides are determined using enzymatic methods with commercially available kits from Boehringer Mannheim and Wako Biochemicals, respectively and analyzed using the Boehringer Mannheim Hitachi 911 Analyzer. Separation and quantification of plasma lipoproteins were performed using FPLC size fractionation. Briefly, 50-100 mL of serum is filtered and injected into Superose 12 and Superose 6 columns connected in series and eluted at a constant flow rate with 1 mM sodium EDTA and 0.15 M NaCl. Areas of each curve representing VLDL, LDL and HDL are integrated using Waters Millennium™ software, and each lipoprotein fraction is quantified by multiplying the Total Cholesterol value by the relative percent area of each respective chromatogram peak.

[0258] For the quantification of aortic atherosclerosis, the aortas are carefully isolated and placed in formalin fixative for 48-72 hours before handling. Atherosclerotic lesions are identified using Oil Red O staining. The vessels are briefly destained, and then imaged using a Nikon SMU800 microscope fitted with a Sony 3CCD video camera system in concert with IMAQ Configuration Utility (National Instrument) as the image capturing software. The lesions are quantified en face along the aortic arch using a custom threshold utility software package (Coleman Technologies). Automated lesion assessment is performed on the vessels using the threshold function of the program, specifically on the region contained within the aortic arch from the proximal edge of the brachio-cephalic trunk to the distal edge of the left subclavian artery. Aortic atherosclerosis data are expressed as percent lesion involvement strictly within this defined luminal area.

Evaluation of cognition enhancement

[0259] Ovariectomized rats (n=50) are habituated to an 8-arm radial arm maze for 10-min periods on each of 5 consecutive days. Animals are water-deprived prior to habituation and testing. A 100 µL aliquot of water placed at the ends of each arm serves as reinforcement. Acquisition of a win-shift task in the radial arm maze is accomplished by allowing the animal to have access to one baited arm. After drinking, the animal exits the arm and re-enters the central compartment, where it

now has access to the previously visited arm or to a novel arm. A correct response is recorded when the animal chooses to enter a novel arm. Each animal is given 5 trials per day for 3 days. After the last acquisition trial, the animals are assigned to one of the following 4 groups:

1. Negative controls: injected with 10% DMSO/ sesame oil vehicle once daily for 6 days (1 mL/kg, SC)
2. Positive controls: injected with 17 β -estradiol benzoate for 2 days and tested 4 days after the second injection (17 β -estradiol benzoate at 10 μ g/0.1 mL per rat)
3. Estradiol: 17 β -estradiol will be injected daily for 6 days (20 μ g/kg, SC)
4. Test compound: injected daily for 6 days (doses vary).

All injections will begin after testing on the last day of acquisition. The last injection for groups 1, 3, and 4 will take place 2 hours before testing for working memory.

[0260] The test for working memory is a delayed non-matching-to-sample task (DNMS) utilizing delays of 15, 30, or 60 seconds. This task is a variation of the acquisition task in which the rat is placed in the central arena and allowed to enter one arm as before. A second arm is opened once the rat traverses halfway down the first arm, and again the rat is required to choose this arm. When it has traveled halfway down this second arm, both doors are closed and the delay is instituted. Once the delay has expired, both of the original two doors, and a third novel door, are opened simultaneously. A correct response is recorded when the animal travels halfway down the third, novel arm. An incorrect response is recorded when the animal travels halfway down either the first or second arms. Each animal will receive 5 trials at each of the three delay intervals for a total of 15 trials per subject.

Evaluation of effect on pleurisy

[0261] The ability to reduce the symptoms of experimentally-induced pleurisy in rats can be evaluated according to the procedure of Cuzzocrea [Endocrinology 141: 1455-63 (2000)].

Evaluation of protection against glutamate-induced cytotoxicity (neuroprotection)

[0262] The neuroprotective activity of compounds of this invention can be evaluated in an in vitro standard pharmacological test procedure using glutamate challenge [Zaulyanov, *et al.*, *Cellular & Molecular Neurobiology* 19: 705-18 (1999); Prokai, *et al.*, *Journal of Medicinal Chemistry* 44: 110-4 (2001)].

Evaluation in the Mammary End Bud Test Procedure

[0263] Estrogens are required for full ductal elongation and branching of the mammary ducts, and the subsequent development of lobulo-alveolar end buds under the influence of progesterone. In this test procedure, the mammotrophic activity of selected compounds of the invention can be evaluated according to the following standard pharmacological test procedure. Twenty-eight day old Sprague-Dawley rats (Taconic Farms, Germantown, NY) are ovariectomized and rested for nine days. Animals are housed under a 12-hour light/dark cycle, fed a casein-based Purina Laboratory Rodent Diet 5K96 (Purina, Richmond, IN) and allowed free access to water. Rats were then dosed subcutaneously for six days with vehicle (50% DMSO (JT Baker, Phillipsburg, NJ) / 50% 1x Dulbecco's Phosphate buffered saline (GibcoBRL, Grand Island, NY), 17 β -estradiol (0.1 mg/kg) or test compound (20 mg/kg). For the final three days, rats are also dosed subcutaneously with progesterone (30 mg/kg). On the seventh day, rats are euthanised and a mammary fat pad excised. This fat pad is analyzed for casein kinase II mRNA as a marker of end bud proliferation. Casein kinase II mRNA is analyzed by real-time RT-PCR. Briefly, RNA is isolated following Trizol (GibcoBRL, Grand Island, NY) according to the manufacture's directions, Samples are treated with DNase I using DNA-free kit (Ambion), and casein kinase II mRNA levels are measured by real-time RT-PCR using the Taqman Gold procedure (PE Applied Biosystems). A total of 50 ng of RNA is analyzed in triplicate using casein kinase II specific primer pair (5' primer, CACACGGATGGCGCATACT (SEQ. ID NO. 1); 3' primer, CTCGGGATGCACCATGAAG (SEQ. ID NO. 2)) and customized probe (TAMRA-CGGCACTGGTTTCCCTCACATGCT-FAM (SEQ. ID NO. 3)). Casein kinase II mRNA levels are normalized to 18s ribosomal RNA contained within each sample reaction using primers and probe supplied by PE Applied Biosystems.

Evaluation in the HLA Rat Standard Pharmacological Test Procedure for inflammatory bowel disease

[0264] Representative compounds can be evaluated in the HLA rat standard pharmacological test procedure which emulates inflammatory bowel disease in humans. The following briefly describes the procedure used and results obtained. Male HLA-B27 rats are obtained from Taconic and provided unrestricted access to food (PMI Lab diet 5001) and water. Rats are dosed subcutaneously once per day with either vehicle (50% DMSO / 50% 1x Dulbecco's Phosphate Buffered Saline) or test compound (0.1 to 10 mg/kg) for at least one week. Stool quality is observed daily and graded according to the following scale: Diarrhea = 3; soft stool = 2; normal stool = 1. At the end of the study, serum is collected and stored at -70 °C. A section of colon is prepared for histological analysis and an additional segment is analyzed for myeloperoxidase activity.

[0265] For histological analysis, colonic tissue is immersed in 10% neutral buffered formalin. Each specimen of colon is separated into four samples for evaluation. The formalin-fixed tissues are processed in a Tissue Tek vacuum infiltration processor (Miles, Inc; West Haven, Connecticut) for paraffin embedding. The samples are sectioned at 5 µm and then stained with hematoxylin and eosin (H&E) for blinded histologic evaluations using a scale modified after Boughton-Smith. After the scores are completed the samples are unblinded, and data are tabulated and analyzed by ANOVA linear modeling with multiple mean comparisons. Sections of colonic tissue are evaluated for several disease indicators and given relative scores.

Evaluation in three models of arthritis

[0266] *Lewis rat assay of adjuvant-induced arthritis.* Sixty, female, 12 weeks old, Lewis rats are housed according to standard facility operating procedures. They receive a standard regimen of food and water ad libitum. Each animal is identified by a cage card indicating the project group and animal number. Each rat number is marked by indelible ink marker on the tail. At least 10-21 days before study they are anesthetized and ovariectomized by standard aseptic surgical techniques.

[0267] Freund's Adjuvant-Complete (Sigma Immuno Chemicals, St. Louis, MO) is used to induce arthritis, each mL containing 1 mg Mycobacterium

tuberculosis heat killed and dried, 0.85 mL mineral oil and 0.15 mL mannide monooleate Lot No. 084H8800.

[0268] The following are examples of two test procedures. Inhibition test procedure: Thirty rats are injected intradermally with 0.1 mL of Freund's Adjuvant-Complete at the base of the tail. The animals are randomized to four groups, each group containing six rats. Each day, the groups receive vehicle (50% DMSO (JT Baker, Phillipsburg, NJ) / 1x Dulbecco's phosphate saline (GibcoBRL, Grand Island, NY)) or test compound (0.1-10 mg/kg, administered subcutaneously). All rats begin treatment on Day 1.

[0269] Treatment test procedure: Thirty rats are injected intradermally with 0.1 mL of Freund's Adjuvant-Complete at the base of the tail. The animals are randomized to four groups, each group containing six rats. Each day, the groups receive vehicle (50% DMSO (JT Baker, Phillipsburg, NJ) / 1x Dulbecco's phosphate saline (GibcoBRL, Grand Island, NY)) or test compound (0.1-10 mg/kg, administered subcutaneously). All rats begin treatment on Day 8 after adjuvant injection.

[0270] Statistical analysis is performed using Abacus Concepts Super ANOVA. (Abacus Concepts, Inc., Berkeley, CA). All of the parameters of interest are subjected to Analysis of Variance with Duncan's new multiple range post hoc testing between groups. Data are expressed throughout as mean $\pm$ standard deviation (SD), and differences are deemed significant if $p < 0.05$.

[0271] The degree of arthritis severity is monitored daily in terms of the following disease indices: Hindpaw erythema, hindpaw swelling, tenderness of the joints, and movements and posture. An integer scale of 0 to 3 is used to quantify the level of erythema (0= normal paw, 1= mild erythema, 2= moderate erythema, 3= severe erythema) and swelling (0=normal paw, 1=mild swelling, 2= moderate swelling, 3= severe swelling of the hind paw). The maximal score per day is 12.

[0272] At the end of the study the rats are euthanized with CO₂, hindlimbs removed at necropsy and fixed in 10% buffered formalin, and the tarsal joints decalcified and embedded in paraffin. Histologic sections are stained with Hematoxylin and Eosin or Saffranin O - Fast Green stain.

[0273] Slides are coded so that the examiner is blinded to the treatment groups. Synovial tissue from tarsal joints is evaluated based on synovial hyperplasia, inflammatory cell infiltration, and pannus formation [Poole and Coombs,

International Archives of Allergy & Applied Immunology 54: 97-113 (1977)] as outlined below.

Category	Grade
1. Synovial lining cells	
a. No change	0
b. Cells enlarged, slightly thickened	1
c. Cells enlarged, increase in numbers, moderately thickened. No villus present	2
d. Cells enlarged, thickened. Villus present	3
2. Fibroplasia	
a. No change	0
b. Fibroplasia present under lining cells	1
c. Small areas of areolar tissue replaced by fibrous tissue	2
d. Replacement of areolar tissue by fibrous tissue	3
3. Inflammatory cells	
a. Occasionally seen, scattered throughout section	0
b. Cells present in small numbers in or just under lining cell layer and/or around blood vessels.	1
c. Small focal collection of cells may be present	2
d. Large numbers of cells present in capsule and in or under lining cell layers. Large foci often seen.	3
4. Pannus	
a. Not detectable	0
b. Detectable	1

[0274] In addition, articular cartilage and bone is evaluated using Mankin's histological grading system [Mankin, *et al.*, *Journal of Bone & Joint Surgery - American Volume* 53: 523-37 (1971)] as shown below.

Category	Grade
1. Structure	
a. Normal	0
b. Surface irregularity	1
c. Pannus and surface irregularity	2
d. Clefts to transitional zone	3
e. Clefts to radial zone	4
f. Clefts to calcified zone	5
g. Complete disorganization	6
2. Cells	
a. Normal	0
b. Diffuse hypercellularity	1
c. Cloning	2
d. Hypocellularity	3
3. Safranin-O staining	
a. Normal	0
b. Slight reduction	1
c. Modest reduction	2
d. Severe reduction	3
e. No dye noted	4
4. Tidemark integrity	
a. Intact	0
b. Crossed by blood vessels	1

Evaluation in the HLA-B27 Rat model of arthritis.

[0275] Representative compounds are evaluated in the HLA-B27 rat standard pharmacological test procedure which emulates arthritis in humans. The following briefly describes the procedure used. Male HLA-B27 rats are obtained from Taconic and provided unrestricted access to a food (PMI Lab diet 5001) and water. Rats are dosed subcutaneously once per day with either vehicle (50% DMSO / 50% 1x Dulbecco's Phosphate Buffered Saline) or test compound (0.1 to 10 mg/kg) for at least one week. Joint scores and histology are evaluated as described above for the Lewis rat model of adjuvant-induced arthritis.

Evaluation in the collagen induced arthritis models.

[0276] Compounds are evaluated in BALB/c mice, 6-8 weeks of age, in which arthritis is induced by monoclonal antibodies raised against type II collagen, plus lipopolysaccharide (LPS). The animals were administered intravenously with a combination of 4 different mAbs totalling 4 mg/mouse on day 0, and followed by intravenous 25 µg of LPS 72 hours later (day 3). From day 3, one hour after LPS application, tested compounds are give orally once daily for 15 days. For each

animal, increase in volume of both hind paws is measured using a plethysmometer with water cell (12 mm diameter) on days 0, 5, 7, 10, 14 and 17. Percent inhibition of increase in volume is calculated.

Evaluation in *in vivo* models of carcinogenesis

[0277] The ability of compounds of this invention to treat and inhibit various malignancies or hyperproliferic disorders can be evaluated in standard pharmacological test procedures that are readily available in the literature, and include the following two procedures.

[0278] *Breast cancer.* Athymic nu/nu (nude) mice are obtained ovariectomized from Charles River Laboratories (Wilmington, MA). One day prior to tumor cell injection, animals are implanted with time-release pellets containing 0.36-1.7 mg 17 β -estradiol (60 or 90 day release, Innovative Research of America, Sarasota, FL) or a placebo. The pellet is introduced subcutaneously into the intrascapular region using a 10-gauge precision trochar. Subsequently, mice are injected subcutaneously into the breast tissue with either 1x10⁷ MCF-7 cells or 1x10⁷ BG-1 cells. The cells are mixed with an equal volume of matrigel, a basement membrane matrix preparation to enhance tumor establishment. Test compounds can be evaluated either by dosing one day after tumor cell implantation (inhibition regimen) or after tumors have reached a certain size (treatment regimen). Compounds are administered either intraperitoneally or orally in a vehicle of 1% tween-80 in saline each day. Tumor size is evaluated every three or seven days.

[0279] *Colon cancer.* The ability to treat or inhibit colon cancer can be evaluated in the test procedure of Smirnoff [*Oncology Research* 11: 255-64 (1999)].

Evaluation of neuroprotection in two *in vivo* test procedures

[0280] *Transient global ischemia in the Mongolian gerbil.* The effect of test compounds on preventing or treating brain injury in response to oxygen deprivation/reperfusion can be measured using the following test procedure.

[0281] Female Mongolian gerbils (60-80 g; Charles River Laboratories, Kingston, NY) are housed in the Wyeth-Ayerst animal care facility (AAALAC certified) with a 12-hour light, 12-hour dark photoperiod and free access to tap water and a low-estrogen casein diet (Purina; Richmond, IN). After acclimation (3-5 days),

gerbils are anesthetized with isoflurane (2-3% mixture with O₂), ovariectomized (Day 0). Beginning the following morning (Day 1), gerbils are treated subcutaneously each day with either vehicle (10% ETOH/corn oil), 17 β -estradiol (1 mg/kg) or an experimental compound (0.1-20 mg/kg). On Day 6, gerbils (n=4-5/group) are anesthetized with isoflurane, the common carotid arteries visualized via a mid-line neck incision and both arteries simultaneously occluded for 5 minutes with non-traumatic micro aneurysm clips. After occlusion, the clips are removed to allow cerebral reperfusion and the neck incision closed with wound clips. All animals are fasted overnight prior to the global ischemia surgery, a step that facilitates consistent ischemic injury. On Day 12, gerbils are exposed to a lethal dose of CO₂, and the brains frozen on dry ice and stored at -80 °C.

[0282] The degree of neuronal protection is evaluated by in situ hybridization analysis of neurogranin mRNA. Briefly, 20 μ m coronal cryostat sections are collected on gelatin-coated slides, dried and stored at -80 °C. At the time of processing, the desiccated slide boxes are warmed to room temperature, the slides postfixed in 4% paraformaldehyde, treated with acetic anhydride and then delipidated and dehydrated with chloroform and ethanol. Processed section-mounted slides are then hybridized with 200 μ l (6x10⁶ DPM/ slide) of an antisense or sense (control) riboprobe for Neurogranin (³⁵S-UTP-labeled NG-241; bases 99-340). in a 50% formamide hybridization mix and incubated overnight at 55 °C in a humidified slide chamber without coverslipping. The following morning, the slides are collected in racks, immersed in 2xSSC (0.3 M NaCl, 0.03 M sodium citrate; pH 7.0) / 10 mM DTT, treated with RNase A (20 μ g/ml) and washed (2 x 30 min) at 67 °C in 0.1x SSC to remove nonspecific label. After dehydration, the slides are opposed to BioMax (BMR-1; Kodak) X-ray film overnight.

[0283] The level of neurogranin hybridization signal is used to quantitatively assess the degree of neuronal loss in the CA1 region after injury and to evaluate the efficacy of 17 β -estradiol and experimental compounds. Neurogranin mRNA is selected for these studies because it is highly expressed in the hippocampal neurons including CA1, but absent in glia and other cell types present in this brain region. Therefore, measurement of the amount of neurogranin mRNA present represents surviving neurons. Relative optical density measurements of neurogranin hybridization signal are obtained from film autoradiograms with a computer based

image analysis system (C-Imaging Inc., Pittsburgh, PA). The results from 6 sections (40 μ m apart) per animal are averaged and statistically evaluated. Numerical values are reported as the mean $\pm$ SEM. One-way analysis of variance is used to test for differences in the level of neurogranin mRNA and all statements of non-difference in the results section imply that $p > 0.05$.

[0284] *Middle cerebral artery occlusion in mice.* Neuroprotection can be evaluated according to the test procedures described by Dubal [see, Dubal, *et al.*, *Proceedings of the National Academy of Sciences of the United States of America* 98: 1952-1957 (2001), Dubal, *et al.*, *Journal of Neuroscience* 19: 6385-6393 (1999)].

Ovulation inhibition standard pharmacological test procedure

[0285] The test procedure is used to determine whether test compounds can inhibit or change the timing of ovulation. It can also be used to determine the number of oocytes ovulated [Lundeen, *et al.*, *J Steroid Biochem Mol Biol* 78: 137-143 (2001)].

Transplantation Rejection

[0286] To test the ability of the test compounds to prevent transplant rejection. Compounds can be tested in animal models of heart transplantation (Stetson *et al.*, *Circulation* 104:676-682 (2001) or transplant atherosclerosis (Deitrich *et al.*, *Arterioscler. Thromb. Vasc Biol.* 20:343-352 (2000), Lou *et al.*, *Circulation* 94:3355-3361 (1996).

Prevention of Restenosis

[0287] The test procedure is used to determine whether test compounds can inhibit vascular smooth muscle cell proliferation after carotid artery injury similar to what occurs after balloon angioplasty. The test compounds can be tested in animal models previously described (Karas, *et al.*, *Circ Res.* 89:534-539 (2001), Cerek, *et al.*, *Atherosclerosis* 131:59-66 (1997).

Treatment of Myocardial Infarction

[0288] Test compounds can be tested in animal models of ischemia/reperfusion to determine whether they would inhibit cell death occurring during a myocardial infarction. The compounds can be tested in models described previously (Delyani *et al.*, *J Mol & Cell Cardiology* 28:1001-1008 (1996), Izumi *et al.* *J Clin Invest.* 108:203-213 (2001) and Chandrasekar *et al.*, *Circulation* 103:2296-2302 (2001)).

Treatment for Myocarditis and Congestive Heart Failure

[0289] Test compounds can be tested in models of heart failure to determine whether compounds could be an effective therapy and improve cardiac function. Compounds can be tested in animals as described previously (Yokoseki *et al.*, *Circ Res.* 89:1-9 (2001), Wallen *et al.*, *Hypertension* 36:774-779 (2000) and Toshiaki *et al.*, *Circulation* 104:1094-1103 (2001)).

Treatment for Diabetes

[0290] Test compounds can be tested in models of diabetes to determine their effect on reversal of obesity and diet-induced insulin resistance. Compounds can be tested in animal models as previously described (Yuan *et al.* *Science* 293:1673-1677 (2001)).

Treatment for Asthma

[0291] *Pulmonary Inflammation Model* Sensitize mice with OVA emulsified in alum on days 0 and 14 (ip injection). On days 28 and 29, challenge with an aerosol of OVA for 20 min (1%-5% OVA) and then on Day 30 the animals are sacrificed and harvest BAL and/or lung tissue for analysis of pulmonary inflammation.

[0292] *Airway Hyperresponsiveness.* This model is similar to that described above however animals are challenged on 3 consecutive days with an aerosol of OVA and airway hyperresponsiveness is measured 48 h after the last challenge. BAL can also be taken at this stage if required.

[0293] To look more directly at the effects of mast cells in conjunction with ER, one may use a passive cutaneous anaphylaxis model in which IgE is injected into the ear and then 24 hours later inject DNP-HSA iv. Ear thickness is measured at early

and late phase reaction. Furthermore, tissues may be fixed in K2 and embed in Epoxy resin and cut 1um sections. These fixed tissues may be stained for mast cells in order to quantitate the degree of mast cell degranulation.

[0294] Based on the results obtained in the standard pharmacological test procedures, the compounds of this invention are selective anti-inflammatory compounds which as described herein useful for the treatment and prevention of chronic inflammatory diseases without stimulating uterine and breast cell proliferation as found with classic estrogens.

[0295] Accordingly, the compounds of this invention are useful in treating or inhibiting osteoporosis and in the inhibition of bone demineralization, which may result from an imbalance in a individual's formation of new bone tissues and the resorption of older tissues, leading to a net loss of bone. Such bone depletion results in a range of individuals, particularly in post-menopausal women, women who have undergone bilateral oophorectomy, those receiving or who have received extended corticosteroid therapies, those experiencing gonadal dysgenesis, and those suffering from Cushing's syndrome. Special needs for bone, including teeth and oral bone, replacement can also be addressed using these compounds in individuals with bone fractures, defective bone structures, and those receiving bone-related surgeries and/or the implantation of prosthesis. In addition to those problems described above, these compounds can be used in treatment or inhibition for osteoarthritis, hypocalcemia, hypercalcemia, Paget's disease, osteomalacia, osteomalacia, osteomalacia, multiple myeloma and other forms of cancer having deleterious effects on bone tissues.

[0296] The compounds of this invention are also active in the brain and are therefore useful for inhibiting or treating Alzheimer's disease, cognitive decline, decreased libido, senile dementia, neurodegenerative disorders, depression, anxiety, insomnia, schizophrenia, and infertility. The compounds of this invention are also useful in treating or inhibiting benign or malignant abnormal tissue growth including, glomerulosclerosis, prostatic hypertrophy, uterine leiomyomas, breast cancer, scleroderma, fibromatosis, endometriosis, endometrial cancer, polycystic ovary syndrome, endometrial polyps, benign breast disease, adenomyosis, ovarian cancer, melanoma, prostate cancer, cancers of the colon, CNS cancers, such as glioma or astioblastoma.

[0297] The compounds of this invention are cardioprotective and are antioxidants, and are useful in lowering cholesterol, triglycerides, Lp(a), and LDL levels; inhibiting or treating hypercholesteremia, hyperlipidemia, cardiovascular disease, atherosclerosis, peripheral vascular disease, restenosis, and vasospasm, and inhibiting vascular wall damage from cellular events leading toward immune mediated vascular damage.

[0298] The compounds of this invention are also useful in treating disorders associated with inflammation or autoimmune diseases, including inflammatory bowel disease (Crohn's disease, ulcerative colitis, indeterminate colitis), arthritis (rheumatoid arthritis, spondyloarthropathies, osteoarthritis), pleurisy, ischemia/reperfusion injury (e.g. stroke, transplant rejection, myocardial infarction, etc.), asthma, giant cell arteritis, prostatitis, uveitis, psoriasis, multiple sclerosis, systemic lupus erythematosus and sepsis.

[0299] The compounds of this invention are also useful in treating or inhibiting ocular disorders including cataracts, uveitis, and macular degeneration and in treating skin conditions such as aging, alopecia, and acne.


[0300] The compounds of this invention are also useful in treating or inhibiting metabolic disorders such as type-II diabetes, of lipid metabolism, appetite (e.g. anorexia nervosa and bulimia).

[0301] Compounds in this invention are also useful in treating or inhibiting bleeding disorders such as hereditary hemorrhagic telangiectasia, dysfunctional uterine bleeding, and combating hemorrhagic shock.

[0302] The compounds of this invention are useful in disease states where amenorrhea is advantageous, such as leukemia, endometrial ablations, chronic renal or hepatic disease or coagulation diseases or disorders.

what is claimed:

1. A compound of the formula:



Formula I

wherein:

G is SO₂ or CO

R₁, R₄, R₈, and R₉ are each, independently, H, Cl, Br, F, I, NO₂, alkyl, alkoxy, phenyl, OCF₃, CF₃, CN;

R₂, R₃, R₅, and R₆ are each, independently, hydrogen, hydroxy, alkyl, alkoxy, or halogen; or R₂ and R₅ may together form a ring, said ring being a 4 to 8 membered cycloalkane, cycloalkene, cycloalkyne, or aromatic ring optionally containing one or more heteroatoms;

R₇ is hydrogen, alkyl, -(C=O)R₁₆, -S(O)₂R₁₇, -S(O)₂N(R₁₈)(R₁₉), or D-glucuronidate;

R₁₀ and R₁₁ are each, independently, H, alkyl, cycloalkyl, or phenyl;

R₁₆ is alkyl, alkoxy, arylalkyl or aryl;

R₁₇ is alkyl, aryl, heteroaryl, cycloalkyl, alkenyl, cycloalkenyl, or alkynyl;


R₁₈ and R₁₉ are, independently, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, monofluoroalkyl, perfluoroalkyl, aryl, arylalkyl, cycloalkenyl, heteroaryl, heteroarylalkyl, hydroxy-(C₂-C₆)alkyl, alkoxyalkyl, alkylthioalkyl, carbonyl, acyl, alkoxycarbonyl, -C(O)NH₂, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminoalkyl, or dialkylaminoalkyl;

or R₁₈ and R₁₉ are taken together with the nitrogen atom to which they are attached to form a saturated, unsaturated or partially saturated C₄-C₆ carbon ring;

X is H, alkyl, CN, CHO, F, Br, Cl, CONR_xR_y, COOH, CO₂R_z or cycloalkyl;
and

R_x, R_y, and R_z are each, independently, H or alkyl;
or a pharmaceutically acceptable salt thereof or a prodrug thereof.

2. The compound of claim 1 wherein OR₇ is OH or O(C=O)R₁₆.
3. The compound of claim 1 or claim 2 wherein OR₇ is OH in the para position.
4. The compound of any one of claims 1 to 3 wherein R₃ is selected from H, alkyl, Cl, F, Br, CF₃, OH, or OMe.
5. The compound of any one of claims 1 to 4 wherein R₁₀ and R₁₁ are each, independently, H, alkyl or cycloalkyl
6. The compound of claim 1 that is of the formula:



wherein:

G is SO₂ or CO;

R₁₀ and R₁₁ are each, independently, H, alkyl or cycloalkyl;

Z is H, alkyl, Cl, F, Br, CF₃, OH, or OMe; and

X is H, alkyl, CN, CHO, F, Br, Cl, CONR_xR_y, COOH, CO₂R_z or cycloalkyl.

7. The compound of any one of claims 1 to 6 wherein R₂, R₅ and R₆ are each selected from hydrogen, halogen, hydroxyl and alkoxy.
8. The compound of any one of claims 1 to 7 wherein R₅ or R₆ is OH.

9. The compound of any one of claims 1 to 8 wherein R₂ is CH₃.
10. The compound of any one of claims 1 to 9 wherein R₁₀ is CH₃ or C₂H₅ and R₁₁ is H.
11. The compound of any one of claims 1 to 10 wherein R₉ is Br, F, Cl, or CF₃.
12. The compound of any one of claims 1 to 10 wherein R₉ is F.
13. The compound of claim 1 that is one of the following:
 - 4-[(4-ethyl-7,8-difluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
 - 4-[(4-ethyl-7,8-difluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
 - 4-[(7,8-difluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
 - (S)-4-ethyl-7,8-difluoro-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
 - 4-ethyl-7,8-difluoro-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
 - 4-[(1,7,8-trifluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
 - 4-{[(S)-1,7,8-trifluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl}phenol,
 - 4-{[(R)-1,7,8-trifluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl}phenol,
 - 4-[(7,8-difluoro-4,4-dimethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
 - 4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
 - 4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
 - 4-[(4-ethyl-1,7-difluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
 - 4-[(4-ethyl-1,7-difluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,

4-[(1-bromo-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
2-chloro-4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-ethyl-7-fluoro-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
4-ethyl-7-fluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2,6-dimethylphenol,
4-[(7-bromo-4,4-dimethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-[(7-bromo-4-ethyl-1-fluoropyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
4-[(7-fluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-[(7-fluoro-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
4-[(7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-{[4-ethyl-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl}phenol,
4-{[4-ethyl-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl}-2-methylphenol,
4-ethyl-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-7-(trifluoromethyl)-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
2-chloro-4-{[4-ethyl-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl}phenol,
4-[(4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
4-[(7-chloro-4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]-2-methylphenol,
4-[(8-chloro-4-ethylpyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,

4-ethyl-7-fluoro-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxalin-8-ol,
4-[(4-ethyl-7-fluoro-8-methoxypyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyl]phenol,
4-{[(4S)-7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl}phenol,
4-{[(4R)-7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl}phenol,
7-bromo-4-ethyl-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
3-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl]phenol,
4-ethyl-7,8-difluoro-5-[(3-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
3-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl]phenol,
(4S)-7-bromo-4-ethyl-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
(4R)-7-bromo-4-ethyl-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
4-ethyl-7,8-difluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
4-{[(4R)-4-ethyl-7,8,9-trifluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl}phenol,
4-{[(4S)-4-ethyl-7,8,9-trifluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl}phenol,
4-[(4-ethyl-7,8,9-trifluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl]phenol,
3-[(4-ethyl-7,8,9-trifluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl]phenol,
(4S)-4-ethyl-7,8-difluoro-5-[(4-hydroxyphenyl)sulfonyl]-4,5-dihydropyrrolo[1,2-a]quinoxaline-1-carbonitrile,
4-{[(4S)-4-ethyl-7,8-difluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl}-2-methylphenol,
4-{[(4R)-4-ethyl-7,8-difluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl}-2-methylphenol,
4-{[(4S)-1-cyano-4-ethyl-7,8-difluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl)sulfonyl}-2-methylphenyl sulfamate,

4-{[(4S)-1-cyano-4-ethyl-7,8-difluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl]sulfonyl}phenyl sulfamate,
4-{4-ethyl-7,8-difluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl]sulfonyl}phenyl sulfamate,
3-[(7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol,
3-{[(4S)-7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
3-{[(4R)-7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
4-[(7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol,
4-[(7-bromo-4-methylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]benzene-1,3-diol
4-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol,
4-{[(4S)-7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
4-{[(4R)-7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
3-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol,
4-[(7-bromo-4-ethylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]benzene-1,3-diol,
3-[(7-bromo-4-*tert*-butylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol,
3-{[(4S)-7-bromo-4-*tert*-butylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
3-{[(4R)-7-bromo-4-*tert*-butylpyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
4-[(7-bromo-4-*tert*-butylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol,
4-[(7-bromo-4-*tert*-butylpyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]benzene-1,3-diol,
4-[(4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl)carbonyl]phenol,
4-{[(4S)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
4-{[(4R)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}phenol,
4-{[(4R)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}benzene-1,3-diol,
4-{[(4S)-4-ethyl-7-fluoropyrrolo[1,2-a]quinoxalin-5(4H)-yl]carbonyl}benzene-1,3-diol,

4-{[(4*R*)-7-fluoro-4-methylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol,
 4-{[(4*S*)-7-fluoro-4-methylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol,
 4-{[(4*R*)-7-chloro-4-ethylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}benzene-1,3-diol,
 4-{[(4*S*)-7-chloro-4-ethylpyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}benzene-1,3-diol,
 3-{[(4*R*)-4-ethyl-7-fluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol,
 3-{[(4*S*)-4-ethyl-7-fluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol,
 (4*R*)-4-ethyl-7-fluoro-5-(4-hydroxybenzoyl)-4,5-dihydropyrrolo[1,2-*a*]quinoxaline-1-carbonitrile,
 (4*S*)-4-ethyl-7-fluoro-5-(4-hydroxybenzoyl)-4,5-dihydropyrrolo[1,2-*a*]quinoxaline-1-carbonitrile,
 3-{[(4*R*)-4-methyl-7-fluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol, or
 3-{[(4*S*)-4-methyl-7-fluoropyrrolo[1,2-*a*]quinoxalin-5(4*H*)-yl]carbonyl}phenol.

14. A pharmaceutical composition comprising a compound of any one of claims 1 to 13 and a pharmaceutical carrier.

15. A method of treating or inhibiting chronic inflammatory disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of any one of claims 1 to 13.

16. A method of treating or inhibiting rheumatoid arthritis, spondyloarthropathies, osteoarthritis, psoriatic arthritis, or juvenile arthritis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of any one of claims 1 to 13.

17. A method of treating or inhibiting inflammatory bowel disease, Crohn's disease, ulcerative colitis, or indeterminate colitis in a mammal in need thereof, which

comprises administering to said mammal an effective amount of a compound of any one of claims 1 to 13.

18. A method of treating or inhibiting psoriasis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of any one of claims 1 to 13.

19. A method of treating or inhibiting asthma or chronic obstructive pulmonary disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of any one of claims 1 to 13.

20. A method of treating or inhibiting stroke, ischemia, or reperfusion injury in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of any one of claims 1 to 13.

21. A method of lowering cholesterol, triglycerides, Lp(a), and LDL levels; inhibiting or treating hypercholesteremia, hyperlipidemia, cardiovascular disease, atherosclerosis, acute coronary syndrome, peripheral vascular disease, restenosis, or vasospasm in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of any one of claims 1 to 13.

22. A method of treating or inhibiting Alzheimer's disease, cognitive decline, or senile dementia in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of any one of claims 1 to 13.

23. A method of treating or inhibiting type II diabetes in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of any one of claims 1 to 13.

24. A method of treating or inhibiting sepsis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of any one of claims 1 to 13.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2005/045511

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D487/04 A61K31/495

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	US 5 536 718 A (ALBRIGHT ET AL) 16 July 1996 (1996-07-16) column 1, lines 44,54-56 column 13, lines 15-25 -----	1-24

☐ Further documents are listed in the continuation of Box C

☒ See patent family annex

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

18 May 2006

Date of mailing of the international search report

06/06/2006

Name and mailing address of the ISA/

European Patent Office, P B 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Jeanjean, F

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2005/045511

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5536718	A	16-07-1996	AT 320429 T 15-04-2006
		AU 707982 B2	22-07-1999
		AU 4769896 A	07-08-1996
		BR 9607182 A	11-11-1997
		CN 1198746 A	11-11-1998
		CZ 9702249 A3	17-12-1997
		EA 1143 B1	30-10-2000
		EP 0804438 A1	05-11-1997
		HU 9800646 A2	28-08-1998
		IL 116775 A	17-08-1999
		JP 11500106 T	06-01-1999
		NZ 302111 A	29-04-1999
		TW 403752 B	01-09-2000
		WO 9622293 A1	25-07-1996
		US 5610156 A	11-03-1997
		US 5612334 A	18-03-1997
		US 5700796 A	23-12-1997
		US 5753648 A	19-05-1998
		ZA 9600297 A	15-07-1997